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Tuberculosis
Tuberculosis is the number one cause of death in humans due to a single infectious 
agent1, with an estimated 10 million new cases and 1.6 million deaths in 20172. 
Tuberculosis is caused by infection with Mycobacterium tuberculosis, which is spread 
from a person with the respiratory form of the disease to another person via air 
droplets generated by coughing and sneezing. After exposure to M. tuberculosis, the 
outcome can vary (Figure 1.1). Following infection, the bacteria can be cleared through 
the action of the innate immune system (early clearance); the infection can rapidly 
progress to active tuberculosis disease, or it can be contained in a latent form with 
no clinical signs of disease2. One fourth of the world’s population has this latent form 
of tuberculosis infection, which may or may not reactivate up to several decades 
after initial exposure3. In addition, not only the outcome of M. tuberculosis infection 
is variable, the course of active disease can also vary. Pulmonary tuberculosis and 
various forms of extrapulmonary disease such as tuberculous meningitis and miliary 
tuberculosis are all presentations of active tuberculosis disease.
Various factors contribute to the heterogeneity of M. tuberculosis infection and 
tuberculosis disease. For example, weakened immunity, such as in human immuno-
deficiency virus (HIV)-positive individuals, is a strong risk factor for rapid progression 
from M. tuberculosis infection to active disease4. To date, most of the research efforts 
on tuberculosis have focused on host and environmental factors influencing transmission, 
drug resistance, and susceptibility to infection and disease5. However, it is becoming 
increasingly clear that bacterial factors are also important. Not only is the genetic 
diversity of M. tuberculosis higher than previously thought6, knowledge is also 
expanding that this genomic diversity translates into relevant disease phenotypic 
variation. Over the past decades, studies have shown that M. tuberculosis genotype 
families show differences in terms of their geographical spread7,8, immune responses 
in the patient9, and virulence6,10. Virulence in tuberculosis relates to the ability of 
the bacteria to survive in the face of the host immune responses, their capacity to 
cause lung damage, to survive in aerosols outside the host, and lastly to successfully 
transmit and infect a new host11,12. Altogether, this suggests that M. tuberculosis genetic 
variation may play an important role in the success of the pathogen, which has been 
coexisting with mankind since hunter-gatherer times for an estimated 70,000 years13.
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Human tuberculosis is mainly caused by M. tuberculosis and M. africanum. Both are 
human-adapted members of a bigger Mycobacterium tuberculosis complex (MTBC), 
which emerged as a professional pathogen from an environmental Mycobacterium 
through stepwise adaptation to an intracellular milieu. MTBC has little sequence 
variation compared with other bacteria and some of the genotyping tools applied to 
other bacterial pathogens are uninformative in MTBC14. Hence, classifying MTBC 
clinical strains requires analytical methods that capture genomic diversity in a more 
comprehensive manner. Whole genome sequencing, in contrast with other typing 
techniques, allows indexing of MTBC diversity across the whole genome, capturing as 
much variation as possible and enabling detailed analyses of the evolutionary forces 
driving this diversity.
Figure 1.1.  The different outcomes and disease manifestations after exposure to M. tuberculosis
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Today, based on whole genome sequence analyses, we know that the human-adapted 
members of MTBC can be further divided into seven phylogenetic lineages: Lineage 1 
to 4 and Lineage 7 belong to M. tuberculosis sensu stricto, whereas Linage 5 and 6 are 
traditionally known as M. africanum West Africa 1 and 2, respectively15. These lineages 
can be grouped into evolutionarily “ancient” and “modern” lineages, with a deletion in 
the TbD1 genomic region found exclusively in the evolutionarily “modern” lineages, 
serving as a genetic marker separating the two groups. The geographical spread of 
these lineages differs markedly, with the modern lineages (Lineage 2, 3 and 4) exhibiting 
a global distribution and the ancient lineages (Lineage 1, 5, 6 and 7) a strong 
geographical restriction6. Lineage 2 (also known as the East-Asian lineage) and 
Lineage 4 (Euro-American lineage) are the most widespread globally. Comparisons 
with M. canetti and other smooth tubercle bacilli, which are phylogenetically the 
closest relatives of MTBC16, have shown that many individual genomic features including 
point mutations in key genes, as well as epistatic interactions between these features 
might have contributed to the evolution of M. tuberculosis towards an obligate human 
pathogen16. This in contrast to many other bacterial pathogens in which pathogenicity 
results from the presence or absence of specific “virulence factors”.
Strains of MTBC differ genetically in their content of single nucleotide polymorphisms 
(SNPs), small insertions and deletions, mobile and repetitive elements, large genomic 
deletions, and large duplications. Whole genome sequencing can reveal all sources of 
genomic variation. The complete genome sequence of the best-characterized strain 
of M. tuberculosis, H37Rv (belonging to Lineage 4), has been determined and published 
for the first time by Cole and colleagues in 199817. The M. tuberculosis H37Rv genome 
comprises approximately 4.4 million base pairs and contains around 4,000 genes. 
M. tuberculosis differs from other bacteria in that a very large proportion of its coding 
potential accounts for the production of enzymes involved in lipogenesis and lipolysis, 
and for two families of glycine-rich proteins with characteristic Pro-Glu (PE) or 
Pro-Pro-Glu (PPE) motifs that may represent a source of antigenic variation17,18. Based 
on whole genome sequencing analyses of all MTBC lineages, we know that on average, 
two human-adapted MTBC strains differ by about 1,200 SNPs (0.03% of the genome 
when excluding repetitive elements)6. Strains from the same lineage show less genetic 
diversity than strains from different lineages, with the least diversity for strains 
belonging to Lineage 7 (on average 230 SNPs difference between any two strains 
belonging to this lineage), and largest for strains belonging to Lineage 1 (730 SNPs on 
average)6.
In addition to exploring and quantifying the genomic diversity in MTBC to get a better 
understanding of the evolution and molecular epidemiology, whole genome sequencing 
data can be used together with computational methods to predict the impact of this 
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variation on a range of clinical or immunological phenotypes. Ultimately, differences 
among MTBC strains are determined by their genomic differences. In this thesis I have 
used whole genome sequencing data to link M. tuberculosis genetic variation to three 
relevant phenotypes: drug resistance (Chapter 2, 3 and 4), disease localisation 
(Chapter 5) and transmission (Chapter 6), which I will discuss in the following sections.
Antituberculosis drug resistance
Drug-resistant M. tuberculosis was first documented in the late 1940s, shortly after the 
introduction of the first anti tuberculosis drug, streptomycin19. However, drug-resistant 
tuberculosis did not receive global attention until the 1990s when large outbreaks of 
multidrug-resistant tuberculosis were identified in the United States and Europe20-22. 
It has since become clear that drug-resistant tuberculosis, caused by rifampicin- 
resistant, multidrug-resistant or extensively drug-resistant strains (Box 1.1), is a growing 
concern and threatens global tuberculosis control. Treatment for patients with multidrug- 
resistant or extensively drug-resistant tuberculosis is prolonged and expensive, 
and associated with morbidity and mortality23,24. The drugs used are toxic and poorly 
tolerated, and adverse events are common and may be severe and irreversible25,26.
Patients can carry a drug-resistant M. tuberculosis strain as a result of two processes: 
acquisition or transmission of resistance. Noncompliance or misuse of antituberculo-
sis drugs, such as monotherapy or the addition of single drugs to failing regimens, can 
result in the emergence of resistant mutants (acquired resistance). Transmission of 
such resistant strains to another person may result in infection and eventually disease 
(primary or transmitted resistance)24. Outbreaks of highly fatal drug-resistant tuber - 
culosis have been documented in several settings, especially those in which the 
prevalence of HIV infection is high32-34.
Phenotypic testing is the standard for drug susceptibility testing despite its challenges, 
which are felt most acutely in resource-limited settings. These challenges include the 
slow growth rate of M. tuberculosis, the high-level biosafety infrastructure required 
and uncertainties around the proposed clinical breakpoints for some drugs35. The 
mechanism underlying drug resistance in M. tuberculosis differs from other bacterial 
species that often acquire resistance through horizontal gene transfer systems such as 
plasmid exchange. In M. tuberculosis, drug resistance is solely conferred by de novo 
mutations in genes coding for drug targets or for proteins involved in drug metabolic 
pathways, possibly preceded by efflux pump up-regulation. Changes in the DNA of M. 
tuberculosis usually result from point mutations, indels, or, more rarely, large 
deletions36. Together with M. tuberculosis’ low mutation rate of an estimated 0.3-0.5 
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substitutions per genome per year36, this makes whole genome sequencing a 
well-suited technique to study M. tuberculosis, creating a unique opportunity for 
genotypic drug susceptibility testing. Early results from an extensive study linking 
whole genome sequencing data to phenotypic drug susceptibility testing have 
provided information for a pilot of drug-susceptibility testing based on whole genome 
sequencing in the United Kingdom37.
Tuberculosis disease phenotype
The result of exposure to M. tuberculosis depends on the interplay between the innate 
and adaptive immune mechanisms of the human host on the one hand, and the 
bacterial mechanisms to evade or antagonize these immune responses on the other 
hand. Early clearance can be defined as the eradication of infecting M. tuberculosis by 
the innate immune system before an adaptive immune response develops, and was 
Box 1.1.  Definitions of drug-resistant tuberculosis
Drug-susceptible tuberculosis
Tuberculosis caused by M. tuberculosis strains that are susceptible to all first-line anti-
tuberculosis drugs. The first-line standard regimen that is currently recommended for the 
treatment of drug-susceptible tuberculosis is based on a 2-month intensive phase with 
four drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) followed by a 4-month 
 consolidation phase with two drugs (isoniazid and rifampicin)27.
Rifampicin-resistant tuberculosis
Tuberculosis caused by M. tuberculosis strains that are resistant to rifampicin.
Multidrug-resistant tuberculosis
Tuberculosis caused by M. tuberculosis strains that are resistant to at least isoniazid and 
rifampicin, the two most effective first-line antituberculosis drugs. Treatment is more costly 
and toxic and has lower cure rates than drug-susceptible tuberculosis28,29, although this 
has improved since the introduction of bedaquiline30.
Extensively drug-resistant tuberculosis
Tuberculosis caused by multidrug-resistant M. tuberculosis strains that are  additionally 
 resistant to any fluoroquinolone and any second-line injectable drug (i.e., kanamycin, 
 amikacin, or capreomycin). Cure and survival rates are worse for extensively drug-resistant 
tuberculosis than for multidrug-resistant tuberculosis31.
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recently found to occur in 25% of exposed individuals38. A persistent infection (latent 
tuberculosis) develops in those who fail to clear the infection, with an approximately 
10% lifetime risk of progression to active disease, highest in the first 18 months after 
infection39. Although active tuberculosis predominantly affects the lungs (pulmonary 
tuberculosis), it can cause disease in any other organ (extrapulmonary disease). 
The classic clinical features of pulmonary tuberculosis include cough, sputum production, 
haemoptysis, loss of appetite, weight loss, fever, and night sweats40. The wide variation 
in clinical manifestations, disease severity and outcome is one of the most intriguing 
aspects of tuberculosis and has been mainly attributed to host factors, among others 
HIV infection, diabetes, smoking, age, and malnutrition. However, host factors do not 
fully explain the observed variation and evidence is compiling that M. tuberculosis 
strain diversity is also important5,41.
M. tuberculosis strain differences have been characterized in vitro in macrophage 
infection models and in vivo in animals42 and differences have been defined by 
bacterial growth in cells or organs, the death of infected cells or animals, and 
differences in the histopathology of infected animal tissues43. Highly virulent M. 
tuberculosis isolates appeared to grow faster44, to cause more lung damage and 
mortality43,45, and were more capable to transmit46 than attenuated or low virulence 
strains. Differences between strains in clinical settings have been demonstrated with 
respect to their inflammatory response, the severity of the disease, transmission rate 
and disease presentation8. In addition, results from clinical and epidemiological 
studies suggested that strains from Lineage 5 and Lineage 6 are metabolically 
different, grow slower, and are less virulent than the other human-adapted MTBC 
lineages. Similarly, at least certain groups of Lineage 2 and Lineage 4 strains have 
been shown to be more virulent in terms of disease severity and human-to-human 
transmission, and strains belonging to the East-Asian/Beijing lineage were more likely 
to progress to active tuberculosis disease and were associated with extra-pulmonary 
tuberculosis, multidrug resistance, treatment failure, and relapse47-49.
These findings support that, next to human and environmental factors, M. tuberculosis 
strain diversity contributes to the variable outcome of infection and disease in human 
tuberculosis. However, the specific M. tuberculosis genetic factors determining the 
variation in disease phenotypes remain largely unknown, and differences between 
M. tuberculosis lineages do not explain the full spectrum of phenotypic variation 
observed. Whole genome sequencing offers the possibility to study M. tuberculosis 
genomic diversity at the highest possible resolution, at the level of individual nucleotide 
changes, therewith also capturing differences within M. tuberculosis lineages50. 
A better understanding of the genetic determinants of disease phenotypes, what I aim 
for in this thesis, would in turn aid in the understanding of tuberculosis’ pathogenesis.
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Mycobacterium tuberculosis transmission
Transmission from one person to another is crucial for M. tuberculosis’ survival. In 
order to be able to transmit, the bacterium needs to cause disease, leading to 
destruction of lung tissue and consequent expulsion of aerosolized M. tuberculosis 
bacilli. Disease development is a function of the host’s immunocompetence; 
individuals with HIV, for example, are at increased risk of progression to active disease. 
However, disease development is also a reflection of the evolutionary strategy of M. 
tuberculosis as a pathogen, which during human existence has needed to ensure 
transmission to the next host. M. tuberculosis has to undertake a delicate balancing 
act: cause enough disease to ensure transmission but not so much that patients 
rapidly die, taking the pathogen’s progeny with them27.
Preventing tuberculosis transmission is one of the spear points of tuberculosis control, 
but has proven to be extremely difficult. One of the reasons is the absence of an 
effective vaccine against tuberculosis. The bacillus Calmette-Guérin (BCG) vaccine has 
been widely used and is effective at preventing severe childhood forms of tuberculosis, 
but protection wanes by adolescence and the protective efficacy in adults is highly 
variable. The elimination of tuberculosis cannot reasonably be achieved by treatment 
of individual patients; hence an improved vaccine is required. The main challenge in 
developing an improved vaccine against tuberculosis has been the lack of under -
standing of correlates of a protective immune response. So far, vaccine development 
in tuberculosis has focused on inducing protective adaptive immunity to prevent 
progression to active tuberculosis disease, but the observation that some individuals 
do not develop M. tuberculosis infection even after heavy exposure to tuberculosis, 
suggests that the innate immune system is important for preventing initial infection 
with M. tuberculosis. Recent evidence suggests that BCG vaccination also plays a role 
in the natural protection or early clearance of M. tuberculosis. Alternative approaches 
aimed at boosting innate immunity could improve vaccine development to protect 
against M. tuberculosis infection, so contributing to tuberculosis prevention.
Transmission of tuberculosis is currently measured by genotyping of the isolates, 
 epidemiological contact investigation, or a combination of the two51. However, epidemio-
logical data are often challenging to obtain, and genotyping data are difficult to interpret 
without them. Whole genome sequencing facilitates identifying likely transmission 
events among patients without the requirement of epidemiological data; based on 
the principle that patients infected with genetically similar strains are considered to be 
part of the same transmission cluster52,53. Using this ‘DNA fingerprinting’ technique, 
many studies to date have investigated the association between M. tuberculosis genetic 
variation and transmission. However, two processes are involved in transmission; 
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initial infection of a contact, followed by progression of latent tuberculosis infection to 
active disease, and these cannot be distinguished by studying genetic clustering. 
This distinction is important when examining early clearance, which relates to direct 
transmission: passing infection from index case to contact persons54. M. tuberculosis 
could promote transmission by evading early clearance in the contacts, and the extent 
to which this evasion is successful is possibly genetically determined. Understanding 
which M. tuberculosis strain variation is associated with a more, or less successful 
innate immune response in the host will aid the identification of new vaccine targets 
and is topic of one of the studies in this thesis. 
Aim and scope of the thesis
This thesis aims at better understanding of the M. tuberculosis genetic factors determining 
drug resistance, disease presentation and transmission of tuberculosis. We examined 
the genomes of M. tuberculosis strains isolated from more than 1,000 patients from 
Indonesia, Peru and Romania, and linked genomic data with clinical metadata. The thesis 
consists of two parts. The first part focuses on antituberculosis drug resistance, 
combining M. tuberculosis genetic data with phenotypic drug susceptibility testing results, 
as well as information on patient-related risk factors for drug resistance. The second 
part addresses the effect of M. tuberculosis genetic variation on tuberculosis disease 
presentation and on transmission within households (Figure 1.2).
Drug resistance
The first part of this thesis describes the use of M. tuberculosis whole genome 
sequencing data to predict antituberculosis drug resistance in high-burden, low- 
resource countries. In Indonesia, which has the third-highest tuberculosis burden in 
the world, diagnosis of drug-resistant tuberculosis is difficult as M. tuberculosis culture 
is not routinely performed and phenotypic drug susceptibility testing is only available 
in reference laboratories. In Chapter 2, we examined for the first time the resistance- 
c onferring mutations to first- and second-line drugs in Indonesia using whole genome 
sequencing, and assessed the level of agreement between genotypic and phenotypic 
drug susceptibility testing.
Although whole genome sequencing can identify mutations associated with antituber-
culosis drug resistance, the impact of the many resistance mutations on the minimum 
inhibitory concentration remains unclear55. The level of resistance that a single 
nucleotide polymorphism causes, reflected by the minimum inhibitory concentration, 
is important for clinicians treating patients in order to determine whether to increase 
the dosage or change the regimen. Therefore, in Chapter 3 we examined the genomes 
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 17
General introduction | 17
1
of phenotypically drug-resistant M. tuberculosis isolates from Romanian patients for 
drug resistance mutations, and linked these to the measured minimum inhibitory 
concentrations. 
Phenotypic antituberculosis drug resistance has been associated with diabetes mellitus 
comorbidity56 and this may contribute to the poor treatment outcomes among tuberculosis 
patients with diabetes, but a basic understanding of the molecular mechanism behind 
this association is lacking. As opposed to phenotypic drug susceptibility testing, 
whole genome sequencing has the potential to unlock valuable information on the 
specific mutations underlying resistance, transmission clusters and on the phylogenetic 
background of drug-resistant M. tuberculosis strains. In Chapter 4, we used whole 
genome sequencing to assess genotypic drug resistance in M. tuberculosis isolates 
from Indonesian and Peruvian patients with and without diabetes. We examined if 
drug resistance mutations were more frequently found in isolates from patients with 
diabetes, compared to those without, after adjusting for other risk factors for drug 
resistance.
Figure 1.2.  The M. tuberculosis genotype was linked to multiple tuberculosis phenotypes in my thesis
M. tuberculosis genotype Phenotype
Part 1: drug resistance
(Chapters 2, 3 and 4)
Part 2: disease localisation
(Chapter 5)
Part 2: transmission 
(Chapter 6)
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Tuberculosis disease phenotype and transmission
Many studies have attempted to link host or environmental factors to various 
tuberculosis disease phenotypes, but together they do not fully explain the observed 
spectrum. In this part of the thesis we studied the effect of bacterial factors, using 
whole genome sequencing. Animal studies have shown that M. tuberculosis strains 
differ in their ability to disseminate to and survive in the central nervous system57,58, 
and in vitro studies have identified M. tuberculosis genes that were crucial for invading 
an artificial blood-brain barrier59. Much less is known about the role of M. tuberculosis 
genotype on the disease phenotype in humans. In Chapter 5, we therefore examined 
the effect of the infecting M. tuberculosis genotype on the susceptibility to tuberculous 
meningitis, compared to pulmonary tuberculosis. We used a novel approach of counting 
homoplasy events to detect genetic variants associated with either the pulmonary or 
meningeal tuberculosis presentation.
In addition to disease phenotype, M. tuberculosis genetic variation could also influence 
the risk of M. tuberculosis transmission. M. tuberculosis factors can increase the risk 
of transmission in two ways: first; through the index case, by inducing a disease 
phenotype that favours transmission. A higher bacillary load with more immuno-
pathology and worse cavitary disease results in increased spread of M. tuberculosis41. 
Second; through the contact, by resistance to the contact’s innate immune system60. 
Understanding these pathogen factors is essential to understanding on the one hand 
the virulence of M. tuberculosis in the index case, related to outgrowth and cavities, 
and on the other hand the virulence of M. tuberculosis in the contact, related to 
resistance to innate immunity. However, epidemiological evidence for M. tuberculosis 
genotype influencing risk of infection is scarce. Therefore, in Chapter 6, we investigated 
whether M. tuberculosis genotype influences the disease phenotype in the contact, 
or the success with which it can escape the innate immune defence of the contact, 
using a household-based case-contact study in Bandung, Indonesia.
Lastly, in Chapter 7, the findings of this thesis are summarized and discussed, and 
future challenges and opportunities of whole genome sequencing of M. tuberculosis 
are delineated.
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Abstract
Objectives
Whole-genome sequencing (WGS) is rarely used for drug resistance testing of 
Mycobacterium tuberculosis in high-endemic settings. Here we present the first study 
from Indonesia, which has the third highest tuberculosis (TB) burden worldwide, 
with <50% of drug-resistant cases currently detected.
Methods
WGS was applied for strains from 322 human immunodeficiency virus (HIV)-negative 
adult TB patients. Phenotypic drug susceptibility testing (DST) was performed for a 
proportion of the patients.
Results
Using WGS, mutations associated with drug resistance to any TB drug were identified 
in 51 (15.8%) of the 322 patients, including 42 patients (13.0%) with no prior TB 
treatment (primary resistance). Eight isolates (2.5%) were multidrug-resistant (MDR) 
and one was extensively drug-resistant (XDR). Most mutations were found in katG 
(n = 18), pncA (n = 18), rpoB (n = 10), fabG1 (n = 9) and embB (n = 9). Agreement of 
WGS-based resistance and phenotypic DST to first-line drugs was high for isoniazid 
and rifampicin but was lower for ethambutol and streptomycin. Drug resistance was 
more common in Indo- Oceanic lineage strains (37.5%) compared with Euro-American 
(18.2%) and East-Asian lineage strains (10.3%) (P = 0.044), but combinations of 
multiple mutations were most common among East-Asian lineage strains (P = 0.054).
Conclusions
These data support the potential use of WGS for more rapid and comprehensive 
prediction of drug-resistant TB in Indonesia. Future studies should address potential 
barriers to implementing WGS, the distribution of specific resistance mutations, and 
the association of particular mutations with endemic M. tuberculosis lineages in 
Indonesia.
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Introduction
Drug-resistant tuberculosis (TB) threatens the global control of TB in many parts of the 
world. There were an estimated 580 000 cases of multidrug-resistant TB (MDR-TB) in 
2015, with <50% being detected and even fewer receiving appropriate treatment1,2. 
Culture-based drug susceptibility testing (DST), the gold standard to diagnose 
drug-resistant TB, is technically difficult and takes about 4-6 weeks after the isolation 
of Mycobacterium tuberculosis. Furthermore, inconsistencies in DST results are widely 
reported, especially for ethambutol (EMB) and second-line drugs3,4, whilst phenotypic 
DST for pyrazinamide (PZA) requires different protocols5. Molecular-based DST testing 
using the Xpert MTB/ RIF assay can rapidly detect most rifampicin (RIF) resistance6, 
but this assay has incomplete sensitivity for RIF, does not examine resistance for other 
TB drugs and may fail to detect heteroresistance7,8.
Whole-genome sequencing (WGS) has been shown to be a potential tool for reliable 
prediction of the drug susceptibility phenotype of M. tuberculosis isolates within a 
clinically relevant timeframe9. However, so far WGS is mostly applied in well-resourced, 
low TB burden settings. Because of rapid advances in WGS technology and its decreasing 
cost and turnaround time, WGS is now becoming accessible in limited- resourced, high 
TB burden countries10. In the current study, WGS was applied to predict drug resistance 
in a selection of M. tuberculosis isolates from Indonesia, which has the third-highest TB 
burden in the world. In Indonesia, diagnosis of drug-resistant TB is challenging as 
M. tuberculosis culture is not routinely performed and DST is only available in certain 
reference laboratories. To date, the contribution and concordance of phenotypic and 
genotypic DST in Indonesia is unknown. This study aimed to describe resistance- 
conferring mutations to first- and second-line TB drugs in Indonesia using WGS and to 
examine their concordance with phenotypic DST and their distribution among different 
M. tuberculosis lineages.
Materials and Methods
Selection of M. tuberculosis isolates and drug susceptibility testing
WGS was performed on a random sample of archived M. tuberculosis isolates from 
322 human immunodeficiency virus (HIV)-negative adult patients (216 with pulmonary 
TB and 106 with meningeal TB) with complete medical information. Pulmonary TB 
patients had been diagnosed in Hasan Sadikin Hospital (Bandung, Indonesia) between 
2012–2013 and in the TB-HIV Research Centre of Universitas Padjadjaran (Bandung, 
Indonesia) between 2013–2015. TB meningitis patients had been diagnosed at Hasan 
Sadikin Hospital between 2006–201311. Specimens from each patient were processed 
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accordingly and were inoculated on solid Ogawa medium or in MODS (Microscopic 
Observation of Drug Susceptibility) liquid medium12. Positive cultures from each 
method were subcultured and aliquots were archived at  -80  °C prior to DNA extraction.
Xpert MTB/RIF was available in the study setting only after 2012 and was accessible 
only for patients with suspected MDR-TB according to Indonesian national guidelines. 
Phenotypic DST was not performed routinely for all patients but only when requested 
by treating physicians. DST was performed in the provincial referral laboratory using 
the proportion method on Löwenstein–Jensen (LJ) medium at concentrations of 40.0 
μg/mL for RIF, 0.2 μg / mL for isoniazid (INH), 2.0 μg /mL for EMB and 4.0 μg /mL for 
streptomycin (STR). Briefly, a 1.0 McFarland standard isolate suspension was serially 
diluted 10-fold (from 10 -1 to 10 -5) in sterile distilled water. Dilutions 10 -3 and 10 -5 were 
inoculated, respectively, onto LJ slants with and without drugs, and were incubated at 
37  °C. The results were read at 28 days and up to 42 days, depending on the control 
growth. An isolate was considered resistant to a given drug when growth of ≥1% above 
the control was observed in drug-containing medium. DST for second-line drugs was 
not available during patient inclusion for this study. Phenotypic DST was repeated for 
several isolates that had tested INH-susceptible but that harboured mutations 
conferring resistance to INH in the katG315 gene. In these cases, M. tuberculosis was 
subcultured from frozen isolates onto Ogawa slopes prior to DST. The study protocols 
for the inclusion of patients and for bioanalysis were approved by the Ethical Committee 
of the Faculty of Medicine of Universitas Padjadjaran.
Whole genome sequencing and analysis
Frozen isolates were subcultured on Ogawa slopes and mycobacterial DNA was 
extracted for sequencing using Ultra- Clean1 Microbial DNA Isolation Kit (MO BIO 
Laboratories, Carlsbad, CA) following the manufacturer’s protocol, or using the cetyl-
trimethylammonium bromide (CTAB) method of DNA purification. The concentration 
and purity of extracted DNA were measured using a NanoDropTM 2000 spectropho-
tometer (Thermo Fisher Scientific, Waltham, MA) and the intactness of DNA was 
checked by agarose gel electrophoresis.
M. tuberculosis DNA was sequenced on an Illumina HiSeq 2000 instrument (Illumina 
Inc., San Diego, CA) using 2 x 100-bp paired-end reads. Sequencing was performed at 
BGI (Hong Kong). After sequencing, the raw FASTQ sequence reads were filtered, 
including removal of adapter sequences, contamination, and low-quality reads that 
had more than 10% N base calls or had a quality score ≤4 in more than 40% of the 
bases. Five TB meningitis strains and four pulmonary TB strains were contaminated, 
based on a low GC content and were excluded from further analyses. Sequencing 
coverage was determined using the FastQC v.0.10.1 (http://www.bioinformatics.
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babraham.ac.uk/projects/fastqc/) quality control tool. The proportion of bases 
sequenced with a sequencing error rate of ≤1% per base ranged from 93% to 97% per 
genome. The average depth of coverage for the remaining 322 sequenced strains was 
121.1, and the average percentage of bases covered by at least one read was 98.9%. 
The sequence reads were aligned to reference strain M. tuberculosis H37Rv (GenBank 
accession no. NC_000962.3) and variants were called using Breseq software v.0.27.113. 
Mutations with low-quality evidence (i.e. possible mixed read alignment) were not 
included.
In silico determination of drug resistance
Raw FASTQ sequencing files were uploaded to TB Profiler, an online tool to determine 
drug resistance in silico10. It uses raw sequence data as input and compares identified 
single nucleotide polymorphisms (SNPs) and indels to a curated list of 1,325 drug 
resistance mutations and displays related output. The precision of TB Profiler’s curated 
mutation catalogue for predicting resistance had been assessed using six 
geographically distinct data sets from China, Pakistan, Malawi, Portugal, Russia and 
Canada10, and its accuracy compared with other in silico drug resistance prediction 
tools has been proven recently14.
Phylogeny construction
A phylogenetic tree was constructed to determine the evolutionary relationship of the 
isolates. All 29,199 variable positions identified by breseq across the 322 M. 
tuberculosis sequences were extracted and concatenated into a single alignment. 
Solely for the purpose of creating the phylogenetic tree, SNPs occurring in PE/PPE 
genes and genes related to mobile elements (listed in Table S2.1) were excluded to 
avoid any concern about inaccuracies in the read alignment in these parts of the 
genome. In addition, SNPs in an additional 40 genes previously associated with drug 
resistance10 were also removed to exclude the possibility that homoplasy of drug 
resistance mutations would significantly affect the phylogeny15. After applying these 
filters to the initial set of 29,199 SNPs, the 28,544 remaining SNPs were used to 
construct the phylogenetic tree using PhyML v.3.016 using the HKY85 model with four 
categories for the gamma model of rate distributions and 100 bootstraps.
To examine possible associations between M. tuberculosis lineage and drug susceptibility, 
the lineage was determined for each of the 322 strains using a 62-SNP barcode17. 
The resulting classification in the main M. tuberculosis lineages also served as a quality 
check for the generated maximum-likelihood phylogenetic tree, as it enabled us to 
validate that isolates belonging to the same lineage clustered together in the tree.
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Statistical analysis
The χ2 test was used to statistically test the association between M. tuberculosis 
lineage and drug susceptibility. Cohen’s k was used to determine the level of agreement 
between WGS and phenotypic DST for first-line drugs. In addition, enrichment values 
were calculated for drug resistance per lineage based on the ratio of lineage-specific 
observed and expected occurrence of drug resistance. The ratios were visualized in a 
heat map as a measure of association between M. tuberculosis lineage and drug 
susceptibility.
Results
Patient characteristics
Patients were mostly young (median age 33 years, interquartile range 23.5–45.0 years), 
51.9% were male and 16.1% reported a history of TB treatment. Using WGS, mutations 
associated with drug resistance to any TB drug were identified in 51 (15.8%) of the 
322 patients; 42 (13.0%) were identified to have primary resistance, MDR-TB was 
present in 8 patients (2.5%), including primary MDR-TB in 5 patients (1.6%) and primary 
extensively drug-resistant TB (XDR-TB) in 1 patient (0.3%) (Table 2.1, Table S2.2).
Mutations associated with drug resistance
Genetic variants in multiple genes associated with drug resistance in M. tuberculosis 
were identified by WGS (Table 2.2). A total of 29 isolates (9.0%) had mutations in genes 
associated with resistance to INH, including katG (n = 18), kasA (n = 3) and the promoter 
region of fabG1 C-15T (n = 9). Nine isolates with mutations at the fabG1 promoter site 
were predicted to have co-resistance to INH and ethionamide. The most common 
mutation in katG was Ser315Thr (n = 14), but the uncommon mutation katG Ser315Met 
was also found in two isolates, and katG Trp191Arg and katG Ala106Val were found in 
one isolate each. The katG Ser315Thr mutation was found in seven of eight MDR-TB 
isolates (Table 2.2). RIF resistance-conferring mutations were identified in ten isolates 
(3.1%), all in the rpoB gene. Six common mutations distributed over codons 435, 
445 and 450 were found, mostly as single mutations at one of these positions. 
Rare mutations at codon 432 and 441 were found together in one isolate. One MDR-TB 
isolate with rpoB Ser450Leu also harboured the well-known compensatory mutation 
at rpoC Leu527Val.
For EMB, nine isolates (2.8%) showed mutations in the embB gene, with the mutation 
Met 306Val being most common (n = 4), and rare mutations at codon 406 and codon 
497 in three MDR isolates. PZA resistance-conferring mutations were identified in 18 
isolates (5.6%). All mutations occurred as a single mutation in five codons in the pncA 
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gene. For fluoroquinolones (FQs), mutations in gyrA codon 90 and 94 were identified 
in 4 isolates (1.2%), three with FQ monoresistance and one XDR-TB isolate. With regard 
to resistance to STR and injectable agents, mutations were found in the rpsL and rrs 
loci in nine isolates (2.8%). Mutations at rrs codon 492 were only found in STR-mon-
oresistant strains. The XDR-TB isolate harboured a mutation at the eis promoter linked 
to kanamycin resistance.
Table 2.1.   Presence of drug resistance mutations in 322 clinical M. tuberculosis 
isolates detected by whole genome sequencing
Resistance pattern Number (%)
of strains
Susceptible to all drugs 271 (84.3)
Resistant to any drug 51 (15.8)
Resistant to first-line drugs
Any first-line drug 48 (14.9)
Isoniazid 29 (9.0)
Rifampicin 10 (3.1)
Ethambutol 8 (2.5)
Pyrazinamide 18 (5.6)
Streptomycin 9 (2.8)
Resistant to second-line drugs
Ethionamide 9 (2.8)
Fluoroquinolones 4 (1.2)
Amikacin 1 (0.3)
Kanamycin 1 (0.3)
Monoresistance
Isoniazid 10 (3.1)
Rifampicin 1 (0.3)
Pyrazinamide 15 (4.7)
Streptomycin 3 (0.9)
Fluoroquinolones 3 (0.9)
Resistance to multiple drugs
Multidrug resistance (MDR) 8 (2.5)
Extensively drug resistance (XDR) 1 (0.3)
Polyresistance* 10 (3.1)
*Defined as resistance to multiple drugs but not M/XDR
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Table 2.2.  Distribution of drug resistance-associated mutations in 51 M. tuberculosis 
isolates with any drug resistance identified by whole genome sequencing
Drug Gene Amino acid change No. of 
isolates
No. of  
MDR-TB isolates 
INH katG
fabG1
kasA
Double loci fabG1 + katG
Ser315Thr
Ser315Met
Trp191Arg 
C-15T promoter 
Gly312Ser 
C-15T promoter + Ala106Val
14
2
1
8
3
1
7a
0
0
1
0
1
RIF rpoB
Double loci rpoB + rpoC
His445Tyr 
His445Asp 
Asp435Val 
Asp435Tyr 
Ser450Leu 
His445Cys
Gln432Lys + Ser441Leu
Ser450Leu + Leu527Val
1
1
1
2
2
1
1
1
1
1
1
2
2a
1
0
1
EMB embB Met306Ile 
Met306Val 
Gly406Asp 
Gln497Lys
Met306Val + Gly406Asp
2
4
1
1
1
1a
1
1
1
1
STR rrs
rpsL
C492T
A514C
Lys43Arg
3
1
5
0
1
3a
PZA pncA His82Arg 
Thr87Met 
Ser66Pro 
Pro62Leu 
Ala171Val
6
9
1
1
1
0
1
1
0
1a
ETO fabG1 C-15T promoter 9 2
FLQ gyrA Asp94Gly 
Ala90Val 
Asp94Asn 
Asp94Ala
1
1
1
1
0
0
0
1a
AMK rrs A514C 1 1
KAN eis G-14A promoter 1 1a
*Abbreviations: INH: isoniazid; RIF: rifampicin; EMB: ethambutol; STR: streptomycin; PZA: pyrazinamide; 
ETO: ethionamide; FLQ: fluoroquinolones; AMK: amikacin; KAN: kanamycin; MDR-TB: multidrug-resistant.
aMutation occurred in the extensively drug-resistant (XDR) isolate.
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Agreement of phenotypic and genotypic drug susceptibility testing to 
first-line drugs
Overall, there was considerable agreement between genotypic and phenotypic DST. 
Phenotypic DST for the first-line drugs RIF, EMB and STR was available for 103 isolates 
with WGS data and for INH it was available for 102 isolates, with resistance found to 
INH (n = 17), RIF (n = 7), EMB (n = 6) and STR (n = 7). Concordance between WGS and 
phenotypic DST was high for RIF (k = 0.865; P < 0.001) and INH (k = 0.814; P < 0.001) 
but was low for EMB (k = 0.712; P < 0.001) and STR (k = 0.136; P = 0.148). Agreement of 
genotypic and phenotypic DST for each drug is shown in Figure 2.1.
The common mutations katG Ser315Thr and fabG1 C-15T were highly predictive of 
phenotypic INH resistance in this setting (89.5% of the isolates with either one of these 
mutations were phenotypically resistant). Similarly, mutations in the RIF resistance- 
determining region (RRDR) of rpoB were highly predictive of resistance to RIF (100% of 
the isolates with a mutation were phenotypically resistant). Nine isolates showed drug 
resistance-associated mutations but were susceptible by phenotypic DST. In those 
isolates, mutations were found for STR at rrs C492T (n = 3) and A514C (n = 1) and rpsL 
Lys43Arg (n = 1); for INH at katG Ser315Thr (n = 1), katG Trp191Arg (n = 1), fabG1 C-15T 
(n = 1) and kasA Gly312Ser (n = 3); and for EMB at embB Met306Val (n = 1) and 
Met306Ile (n = 1). Conversely, nine other isolates that were drug-resistant according to 
phenotypic DST (n = 7 for STR, n = 2 for RIF and n = 1 for EMB) showed no known drug 
resistance mutations using WGS. However, one isolate with phenotypic RIF resistance 
but without well-known drug resistance mutations harboured other mutations in rpoB 
(rpoB Cys681Gly and rpoB Pro1014Ser).
Phylogenetic distribution of drug resistance
Drug resistance rates and patterns differed significantly between different M. tuberculosis 
lineages (Figure 2.2; Table S2.3). Among 116 isolates belonging to the East-Asian 
lineage, 12 (10.3%) were genotypically drug-resistant compared with 36 (18.2%) of 198 
Euro-American strains and 3 (37.5%) of 8 Indo-Oceanic strains (χ2 = 6.258; P = 0.044). 
Although fewer strains belonging to the East-Asian lineage had drug resistance 
mutations, they more often had multiple drug resistance mutations (χ2 = 5.844; P = 0.054). 
From the phylogeny, it was observed that most of the pncA mutations in isolates 
harbouring PZA resistance clustered together. The nine isolates with a pncA Thr87Met 
mutation were adjacent in the tree, and the same goes for the six isolates carrying 
the pncA His82Arg mutation, suggesting transmitted resistance. However, the isolates 
differed by more than 12 SNPs, the commonly used threshold for (recent) transmission 
[18]. The other three mutations occurred only once and in genetically distant strains.
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Figure 2.1. Comparison of phenotypic drug susceptibility testing (DST) and DST by whole- 
genome sequencing (WGS) for Mycobacterium tuberculosis isolates to (A) any first-line drug, 
(B) isoniazid (INH), (C) rifampicin (RIF), (D) ethambutol (EMB) and (E) streptomycin (STR). 
Light grey, drug resistance determined by WGS; dark grey, drug resistance determined by 
phenotypic DST. Data are presented as number of strains. N = 103 for RIF, EMB and STR and 
N = 102 for INH.
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Discussion
This is the first study to report the use of WGS on clinical M. tuberculosis isolates from 
Indonesia, showing its potential for clinical management and TB control in Indonesia. 
Indonesia has a huge gap between MDR-TB incidence and MDR-TB treatment. Together 
with China, India, Nigeria and the Russian Federation, it accounted for >60% of this gap 
on a global scale in 20152. Of the 10,000 estimated MDR- or RIF-resistant notified 
pulmonary TB cases in Indonesia in 2015, only an estimated 15% were started on 
treatment2. A large part of this gap can be explained by poor detection of drug 
resistance. Phenotypic DST is poorly accessible in remote parts of the country. WGS 
could offer a rapid and comprehensive diagnostic solution, especially with the 
introduction of portable platforms and the decreasing price and turnaround time of 
WGS18, leading to quicker and more appropriate treatment.
Figure 2.2. Phylogenetic tree of 322 Mycobacterium tuberculosis isolates indicating drug 
resistance profiles and main lineages based on single nucleotide polymorphism (SNP) barcoding. 
INH, isoniazid; RIF rifampicin; EMB, ethambutol; PZA, pyrazinamide; STR, streptomycin; ETH, 
ethionamide; FQS, fluoroquinolones; AMK, amikacin; KAN, kanamycin.
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In a random collection of patient isolates, it was found that 15.8% carried mutations 
associated with drug resistance to any TB drug, often in patients without a history of 
TB treatment. This is much lower than reported in an earlier study in Indonesia where 
resistance to first-line drugs was reported in 38.2% of 262 culture-positive samples, 
although these samples were collected over the whole country and resistance was 
determined by phenotypic DST19. In the current study, resistance mutations to all 
first-line drugs, FQs and second-line injectable drugs were found. MDR-TB was present 
in eight isolates (2.5%), which is lower than expected based on recent survey data2, 
and XDR-TB was present in one isolate (0.3%).
In contrast to the findings from previous studies19–21, in the current study drug 
resistance was observed to occur more often in strains belonging to the Indo-Oceanic 
lineage compared with the Euro-American and East-Asian lineages. On the other hand, 
strains belonging to the East-Asian lineage more often harboured multiple mutations. 
One possible explanation is that the East-Asian lineage, which includes Beijing strains, 
appears to have a higher mutation rate that could lead to accelerated acquisition of 
drug resistance mutations. It may be one of the reasons why this lineage has been 
repeatedly associated with drug resistance22,23. However, this would also lead to more 
resistance against a single drug.
Published studies from Indonesia have clearly shown disparities in the relative 
distribution of M. tuberculosis genotypes across the archipelago. In this article, we 
reported resistance mutations in a urban setting in Java where modern lineage 2 
(East-Asian) and lineage 4 (Euro-American) are highly prevalent. These findings should 
be confirmed in other regions, especially eastern Indonesia, where lineage 1 
(Indo-Oceanic) occurs at a substantially higher frequency24–26. Current catalogues of 
drug resistance mutations rely predominantly on data from modern lineages 2 and 
410,27. A recent study from India, where lineage 1 and 3 predominate, reported putative 
novel resistance-conferring mutations in lineage 1 that had not previously been 
implicated in resistance27, suggesting that the mutations underlying genotypic drug 
resistance differ by lineage.
WGS offers the possibility to learn more about the influence of the genetic background 
of strains on all aspects of drug resistance evolution in M. tuberculosis. WGS could 
provide insight into secondary compensatory mutations, not conferring resistance but 
reducing the fitness cost of the resistance mutation by interacting epistatically with it. 
The rate of acquiring new drug resistance mutations and the fitness costs of these 
mutations may vary as a function of the strain genetic background27,28.
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Most mutations associated with INH resistance were found in katG (62.1%) and the 
promoter region of fabG1 (31.0%). Testing only for katG and fabG1 promoter mutations 
would detect INH resistance in 89.6% of the INH-resistant isolates. All mutations 
associated with RIF resistance were found only in the RRDR of rpoB. This therefore 
confirms the usefulness of these three specific regions for prediction of INH and RIF 
resistance29. Conversely, kasA Gly312Ser and katG Trp191Arg mutations were found in 
phenotypically INH-susceptible isolates. KasA (β-ketoacyl ACP synthase), coded by 
the kasA gene, is an enzyme involved in mycolic acid synthesis. Mutations in the kasA 
gene have been associated with low-level INH resistance30,31 but the role of these 
mutations in INH resistance remains unclear. Therefore, the significance of this gene in 
conferring drug resistance in Indonesia should be carefully assessed. Two isolates 
were phenotypically RIF-resistant but harboured mutations in rpoB that have not been 
associated with drug resistance before (Cys681Gly and Pro1014Ser), therefore their 
possible role in RIF resistance should be confirmed in other studies.
Regarding EMB, three loci of the embB gene (loci 306, 406 and 497) were identified, 
with mutations at locus 306 being the most frequent. Mutations in embB were present 
only in combination with other drug resistance mutations, in line with several studies 
that have demonstrated a strong association between embB306 mutations and INH-, 
RIF- or multidrug-resistant TB32. This finding suggests that embB306 mutations may 
have a selective advantage upon treatment with multiple drugs33. Regarding STR, 
isolates carried mutations in rpsL (n = 5) and rrs (n = 4). A common variant in rpsL 
(Lys43Arg) has been associated with high-level STR resistance32 and this variant was 
indeed the most common in this study. Phenotypic STR resistance was only confirmed 
in two of seven genotypically STR-resistant isolates with DST results available. Three 
isolates had a single mutation in rrs codon 492; their relevance should be carefully 
interpreted since this mutation has been reported as a marker for the LAM3 genetic 
lineage of M. tuberculosis rather than for STR resistance34.
In line with previous studies, concordance between WGS and phenotypic DST was 
good for INH and RIF29 but had low agreement for EMB and STR35,36. There are several 
possible explanations for this finding. First, discordance was mainly found with 
uncommon genotypic mutations, which may be associated with low-level resistance 
that can be missed by conventional phenotypic DST. Second, the difference between 
the epidemiological breakpoint and the minimum inhibitory concentration (MIC) for 
EMB and STR is relatively small35,36, which complicates phenotypic DST. Third, 
detection of phenotypic STR resistance in the absence of known mutations for STR 
resistance suggests the existence of other resistance mechanisms such as efflux 
pumps36. Finally, we cannot exclude errors in phenotypic DST despite good quality 
control in the laboratory. In this regard, the fact that one isolate was phenotypically 
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drug-susceptible with a high confidence katG Ser315Thr mutation for INH in WGS is a 
matter of concern since this mutation is associated with high-level resistance29,37. 
Given this high specificity, mutations at katG315 might even be used to assess 
laboratory quality for DST.
Second-line drug resistance was observed in a number of isolates. At present, there is 
no standard phenotypic DST for PZA and the second-line drugs in Indonesia, and 
evidence is limited on the performance of DST for these drugs38, indicating once more 
the potential added value of WGS in this setting. Also, reported prior treatment for TB 
poorly corresponded with genotypic drug resistance, and primary drug resistance was 
common in this study population of Indonesian patients. Of concern, the only XDR-TB 
strain was found in a patient who had reported no prior TB treatment. This suggests 
that selective use of genotypic or phenotypic DST, targeting only those with previous 
treatment or other factors presumed to be associated with drug resistance, will result 
in many undetected resistant cases and ongoing transmission of drug-resistant strains39. 
This is further supported by the observation that 10 of 51 isolates with mutations 
associated with resistance to any drug were not phenotypically tested for drug 
susceptibility because they did not have these risk factors. WGS could help in early 
identification of resistance in these patients, limiting the spread of drug-resistant TB.
Molecular drug resistance for PZA mostly involves mutations in the pncA gene. There 
is no predominant drug resistance mutation in pncA but a range of diverse mutations 
across the gene, each associated with a different MIC5. Five different mutations in pncA 
were found in the isolates in this study, almost all in PZA-monoresistant strains. Most 
previous studies reported that PZA resistance is common in MDR-TB strains40 although 
significant rates of PZA monoresistance have been reported in some settings40–42. 
A study in China showed that PZA monoresistance contributes to delay in the resolution 
of lung cavitation without affecting the sputum conversion and lesion elimination 
rates41. The non-essential nature of the pncA gene, such that it can accumulate various 
mutations without affecting the viability of the organism, might explain the spread of 
PZA-monoresistant strains. Two pncA mutations exclusively occurred in strains 
adjacent in the phylogenetic tree, suggesting possible transmission. However, the 
genetic difference between these strains was too large to conclude that this was 
indeed the case.
This study has several limitations. First, WGS was performed on a random sample of 
archived M. tuberculosis isolates so we cannot conclude that the proportions of drug 
resistance shown in this study are representative. This was a convenience sample 
collected from patients with pulmonary and meningeal TB. We estimate that several 
thousands of patients are treated for TB each year in Bandung. However, culture is not 
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routinely performed and isolates are not archived. Therefore, our sampling fraction is 
likely to be <10%. Second, phenotypic DST was available for most genotypically 
resistant strains but only for a fraction of isolates without resistance mutations. As a 
consequence, specificity estimation for genotypic resistance was not possible. Third, 
sequencing was performed retrospectively on archived isolates; therefore it was not 
possible to evaluate time to diagnosis of drug resistance using WGS. Nevertheless, we 
for the first time highlight the potential benefit of using WGS to generate an in silico 
drug susceptibility profile in Indonesia and show that mutations associated with drug 
resistance are highly predictive for phenotypic resistance to RIF and INH in the region. 
Larger studies are needed to confirm the clinical relevance of several uncommon 
mutations found in this strain collection. Given the fact that phenotypic DST is complex 
and slow and is poorly accessible in large parts of Indonesia, WGS could offer a rapid 
and comprehensive diagnostic solution. This technology is now more accessible with 
the introduction of portable platforms and an automatic bioinformatic pipeline as well 
as the decreasing price and turnaround time of WGS43. It could lead to quicker and 
more appropriate treatment in low-income settings where many still rely on empirical 
treatment regimens. This pilot study offers a good starting point to further evaluate the 
impact of WGS in the diagnosis, treatment, surveillance and control of drug-resistant 
TB in Indonesia.
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Supplementary tables
Table S2.1.  PE/PPE genes and drug resistance genes excluded for the phylogeny 
construction
PE/PPE genes and genes in repetitive regions Known drug 
resistance 
genes
Rv0031 Rv0922 Rv1575 Rv2107 Rv2741 Rv3381c
Rv0096 Rv0977 Rv1576c Rv2108 Rv2768c Rv3386
Rv0109 Rv0978c Rv1577c Rv2123 Rv2769c Rv3387 accD6
Rv0124 Rv0980c Rv1578c Rv2126c Rv2770c Rv3388 ahpC
Rv0151c Rv1034c Rv1579c Rv2162c Rv2791c Rv3425 efpA
Rv0152c Rv1035c Rv1580c Rv2167c Rv2810c Rv3426 embA
Rv0159c Rv1036c Rv1581c Rv2168c Rv2812 Rv3427c embB
Rv0160c Rv1039c Rv1582c Rv2177c Rv2814c Rv3428c embC
Rv0256c Rv1040c Rv1583c Rv2278 Rv2815c Rv3429 embR
Rv0278c Rv1041c Rv1584c Rv2279 Rv2853 Rv3430c ethA
Rv0279c Rv1042c Rv1585c Rv2328 Rv2885c Rv3474 fabD
Rv0280 Rv1047 Rv1586c Rv2340c Rv2892c Rv3475 fadE24
Rv0285 Rv1054 Rv1646 Rv2352c Rv2943 Rv3477 fbpC
Rv0286 Rv1067c Rv1651c Rv2353c Rv2943A Rv3478 furA
Rv0297 Rv1068c Rv1705c Rv2354 Rv2944 Rv3507 gid
Rv0304c Rv1087 Rv1706c Rv2355 Rv2961 Rv3508 gyrA
Rv0305c Rv1088 Rv1753c Rv2356c Rv2978c Rv3511 gyrB
Rv0335c Rv1089 Rv1756c Rv2371 Rv3018A Rv3512 inhA
Rv0354c Rv1091 Rv1757c Rv2396 Rv3018c Rv3514 iniA
Rv0355c Rv1135c Rv1763 Rv2408 Rv3021c Rv3532 iniB
Rv0387c Rv1149 Rv1764 Rv2424c Rv3022A Rv3533c iniC
Rv0388c Rv1168c Rv1765A Rv2430c Rv3022c Rv3539 kasA
Rv0442c Rv1169c Rv1768 Rv2431c Rv3023c Rv3558 katG
Rv0453 Rv1172c Rv1787 Rv2479c Rv3115 Rv3590c fabG1
Rv0532 Rv1195 Rv1788 Rv2480c Rv3125c Rv3595c manB
Rv0578c Rv1196 Rv1789 Rv2487c Rv3135 Rv3621c ndh
Rv0741 Rv1199c Rv1790 Rv2490c Rv3136 Rv3622c nat
Rv0742 Rv1214c Rv1791 Rv2512c Rv3144c Rv3636 oxyR
Rv0746 Rv1243c Rv1800 Rv2519 Rv3159c Rv3637 pncA
Rv0747 Rv1313c Rv1801 Rv2591 Rv3184 Rv3638 rmlD
Rv0754 Rv1325c Rv1802 Rv2608 Rv3185 Rv3640c rpoB
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Table S2.1.  Continued
PE/PPE genes and genes in repetitive regions Known drug 
resistance 
genes
Rv0755A Rv1361c Rv1803c Rv2615c Rv3186 Rv3650
Rv0755c Rv1369c Rv1806 Rv2634c Rv3187 Rv3652
Rv0795 Rv1370c Rv1807 Rv2646 Rv3191c Rv3653 rpsL
Rv0796 Rv1386 Rv1808 Rv2648 Rv3325 Rv3738c rrs
Rv0797 Rv1387 Rv1809 Rv2649 Rv3326 Rv3739c Rv0340
Rv0832 Rv1396c Rv1818c Rv2650c Rv3327 Rv3746c Rv1592c
Rv0833 Rv1430 Rv1840c Rv2651c Rv3343c Rv3751 Rv1772
Rv0834c Rv1441c Rv1917c Rv2652c Rv3344c Rv3798 Rv2242
Rv0850 Rv1450c Rv1918c Rv2653c Rv3345c Rv3812 Rv3124
Rv0872c Rv1452c Rv1983 Rv2654c Rv3347c Rv3827c Rv3125c
Rv0878c Rv1468c Rv2013 Rv2655c Rv3348 Rv3844 Rv3126c
Rv0915c Rv1548c Rv2014 Rv2656c Rv3349c Rv3872 thyA
Rv0916c Rv1573 Rv2105 Rv2657c Rv3350c Rv3873 tlyA
Rv0920c Rv1574 Rv2106 Rv2659c Rv3367 Rv3892c accD6
Rv2666 Rv3380c Rv3893c
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Table S2.3.  Heatmap of observed vs. expected genotypic drug resistance ratios  
per lineage and gene
East-Asian Euro-American Indo-Oceanic
katG 1,23 0,90 0,00
fabG1 0,62 1,26 0,00
kasA 0,00 0,00 40,25
rpoB 1,51 0,74 0,00
rpoC 2,78 0,00 0,00
embB 1,54 0,54 4,47
pncA 0,46 1,36 0,00
rrs 0,69 1,22 0,00
rpsL 2,22 0,33 0,00
gyrA 1,39 0,81 0,00
eis 2,78 0,00 0,00
Colours range from green (<1, observed drug resistance lower than expected drug resistance) to red 
(>1, observed drug resistance higher than expected drug resistance).
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Abstract
Objectives
Mycobacterium tuberculosis drug resistance poses a major threat to tuberculosis 
control. Current phenotypic tests for drug susceptibility are time-consuming, technically 
complex, and expensive. Whole genome sequencing is a promising alternative, though 
the impact of different drug resistance mutations on the minimum inhibitory concentration 
(MIC) remains to be investigated.
Methods
We examined the genomes of 72 phenotypically drug-resistant Mycobacterium 
tuberculosis isolates from 72 Romanian patients for drug resistance mutations. MICs 
for first- and second-line drugs were determined using the MycoTB microdilution 
method. These MICs were compared to macrodilution critical concentration testing by 
the Mycobacterium Growth Indicator Tube (MGIT) platform and correlated to drug 
resistance mutations.
Results
Sixty-three (87.5%) isolates harboured drug resistance mutations; 48 (66.7%) were 
genotypically multidrug-resistant. Different drug resistance mutations were associated 
with different MIC ranges; katG S315T for isoniazid, and rpoB S450L for rifampicin were 
associated with high MICs. However, several mutations such as in rpoB, rrs and rpsL, 
or embB were associated with MIC ranges including the critical concentration for 
rifampicin, aminoglycosides or ethambutol, respectively.
Conclusions
Different resistance mutations lead to distinct MICs, some of which may still be 
overcome by increased dosing. Whole genome sequencing can aid in the timely 
diagnosis of Mycobacterium tuberculosis drug resistance and guide clinical deci-
sion-making.
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Introduction
Drug-resistance poses a major threat to tuberculosis (TB) control. Global surveillance 
data suggest that in 2015, there were an estimated 480.000 new cases of multi-
drug-resistant TB (MDR-TB), i.e. resistant to at least isoniazid (INH) and rifampicin 
(RIF), and that 9.5% of these cases were extensively drug-resistant (XDR), i.e. also 
resistant to amikacin (AMI), kanamycin (KAN), or capreomycin (CAP), and at least one 
fluoroquinolone (FLQ)1. It is estimated that less than half of these cases are detected, 
and an even smaller proportion receive appropriate treatment1. One of the main 
problems in the control of drug-resistant TB (DR-TB) is the lack of laboratory capacity to 
diagnose resistance2. Conventional culture-based drug susceptibility testing (DST) is 
expensive, time-consuming and requires a specialized biosafety laboratory. Methods 
for DST for many of the second-line drugs have not yet been fully standardized3. 
In addition, these phenotypic methods often rely on growth of mycobacterial cultures 
in the presence of a single ‘critical’ drug concentration to distinguish resistant and 
susceptible strains based on epidemiological breakpoints, which are near the wild 
type minimum inhibitory concentration (MIC) distribution for some drugs4.
Molecular assays are now available and can overcome some of the disadvantages of 
phenotypic methods to diagnose DR-TB. Yet, these assays are expensive and cannot 
identify all of the genetic loci associated with drug resistance5,6. Whole genome 
sequencing (WGS) of M. tuberculosis, tackles this problem and could enable the 
reliable prediction of the drug susceptibility phenotype within a clinically relevant 
timeframe. A fundamental issue in the application of WGS to predict drug resistance is 
how to interpret mutations in relation to phenotypic antibiotic resistance. The level of 
resistance, reflected by the MIC, a single nucleotide polymorphism (SNP) causes is 
most important for clinicians treating patients, in order to determine whether to 
increase the dosage or change the regimen.
Therefore, in the current study we provide this missing link by comparing MICs to drug 
resistance mutations determined by WGS. For this purpose we used a collection of 
drug-resistant strains from Romania, which had 20,000 new TB cases, and 800 new 
MDR-TB cases in 2012, making it one of the 18 high-priority countries for TB control in 
the World Health Organization (WHO) European Region7.
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Methods
Selection of M. tuberculosis isolates
We used M. tuberculosis isolates from the bio-archive established at the TB laboratory 
of the Clinical Hospital of Infectious Diseases and Pneumophtisiology “Victor Babes”, 
Craiova, between 2014 and 2016. The laboratory runs approximately 7,000 sputum 
samples per year, covering much of the TB epidemic in Dolj county. Routine diagnostics 
as indicated by the National Control Programme include sputum microscopy and 
culture on Löwenstein-Jensen medium (liquid media introduced in May 2015). After 
primary culture on Löwenstein-Jensen medium, screening for INH and RIF-resistance is 
performed using INH 0.2 mg/l and RIF 40 mg/l-supplemented Löwenstein-Jensen slants.
All 73 isolates that were phenotypically resistant to INH and/or RIF were selected for 
the purpose of the present study. The 73 isolates were from different patients, and no 
serial isolates were included. Isolates stored in trypticase soy broth supplemented 
with glycerol were sub-cultured on Löwenstein-Jensen medium. Sub-cultured colonies 
were used for DNA extraction, and susceptibility testing.
Phenotypic drug susceptibility testing
All isolates were simultaneously subjected to MIC determinations of rifampicin, 
rifabutin, ethambutol, streptomycin, amikacin, kanamycin, ofloxacin, moxifloxacin, 
para-aminosalicylic acid (PAS), ethionamide and cycloserine by broth microdilution 
in Middlebrook 7H9 broth (SensiTitre MycoTB assay; Trek Diagnostics/ThermoFisher, 
Landsmeer, the Netherlands). Every isolate was tested once, unless contamination 
or no growth was observed; then the isolate was re-cultured and once more subjected 
to MIC testing. The MycoTB assay is a new method for susceptibility testing of 
M. tuberculosis complex8,9. The plate uses a 96-well microtiter broth format and 
contains 12 lyophilized first- and second-line antimycobacterial drugs. In contrast to 
other M. tuberculosis complex susceptibility methods, which test one or two critical 
concentrations of a drug, the MycoTB assay examines a range of drug concentrations 
and produces an MIC result. In addition, critical concentration testing for streptomycin, 
isoniazid, rifampicin and ethambutol (SIRE assay; BD BioScience, Erembodegem, 
Belgium) was performed using the Mycobacterium Growth Indicator Tube (MGIT) 
macrodilution platform (BD BioScience, Erembodegem, Belgium). The critical 
concentrations used for MGIT testing were 0.10 μg/ml for INH, 1.00 μg/ml for RIF, 5.00 
μg/ml for EMB, and 1.00 μg/ml for STR. Technicians performing susceptibility tests 
were blinded to the sequencing results.
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Whole genome sequencing and in silico determination of drug resistance
DNA isolation using UltraClean® Microbial DNA Isolation Kit (MO BIO Laboratories 
Inc., Carlsbad, CA) was followed by quantitative (Qubit v3.0) and qualitative assessment 
of the DNA (gel electrophoresis). We used the Nextera XT DNA Library Preparation Kit 
(Illumina, San Diego, CA) for library preparation. M. tuberculosis DNA was sequenced 
on an Illumina NextSeq500 instrument using 2 x 150 bp paired-end reads. One isolate 
was excluded due to failed library preparation, resulting in a total set of 72 isolates. No 
internal control was performed for WGS. After sequencing, the raw FASTQ sequence 
reads were filtered using Trim Galore (http://www.bioinformatics.babraham.ac.uk/ 
projects/trim_galore), including removing of adapter sequences. Sequencing coverage 
was determined using the FASTQC quality control tool version 0.10.1, and the Genome 
Analysis Toolkit10. The average proportion of bases sequenced with a sequencing 
error rate of 0.1% or less per base was 77.8% per genome. The average coverage depth 
for the 72 sequenced strains was 165.1, and the average percentage of bases covered 
by at least one read was 99.5%. Quality control statistics are shown in Table S3.1.
Raw FASTQ sequencing files were uploaded to TB Profiler version 0.2.1, an online tool 
to determine drug resistance in silico11. It uses raw sequence data as input, aligns 
these to the M. tuberculosis H37Rv reference genome, and compares identified single 
nucleotide polymorphisms (SNPs) and indels to a curated list of 1,325 drug resistance 
mutations. Although it allows examining heteroresistance, we focused on majority 
variants. In addition, it determines the M. tuberculosis lineage based on a 62-SNP 
barcode12. The TB Profiler-predicted resistance mutations were validated using 
PhyResSE, version 1.013, another online tool that maps raw sequencing reads to the M. 
tuberculosis H37Rv reference strain to report drug resistance and phylogenetic SNPs. 
We used the M. tuberculosis complex numbering system, based on the sequence of 
the reference strain: H37Rv14.
Phylogeny construction
A phylogeny was constructed to examine clustering of the isolates. The sequence 
reads were aligned to reference strain M. tuberculosis H37Rv, accession number 
NC_000962.3, and variants were called using Breseq software, version 0.27.115. We 
extracted all 5,980 variable positions across the 72 M. tuberculosis sequences and 
concatenated them into a single alignment. Solely for the purpose of creating the 
phylogenetic tree, SNPs occurring in PE/PPE genes, genes related to mobile elements, 
as well as genes previously associated with drug resistance11 were removed. The 
remaining 5,794 SNPs were used to construct the phylogenetic tree using PhyML, 
version 3.016 using the HKY85 model with four categories for the gamma distribution, 
and using a hundred bootstraps.
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Comparison of MGIT, minimum inhibitory concentrations  
and whole genome sequencing
For each isolate, susceptibility to STR, INH, RIF, and EMB as determined by MGIT was 
compared to the MICs determined by MycoTB. If MycoTB MICs were higher than the 
critical concentration (>0.25 μg/ml for INH, >1.0 μg/ml for RIF, >4.0 μg/ml for EMB, and 
>2.0 μg/ml for STR17, the isolate was considered resistant to the respective drug. 
Cohen’s kappa statistic was calculated for each drug to determine the level of agreement 
between MycoTB- and MGIT-determined resistance. In addition, drug resistance mutations 
identified by TB Profiler and/or PhyResSE were correlated to MGIT results and MICs. 
We visualized the MIC for each drug in histograms, and subsequently determined 
the frequencies of the individual resistance-determining mutations and plotted their 
distributions against the MGIT results for INH, RIF, EMB, and STR, and against the MICs 
for first- and second-line drugs. For isolates with discrepant susceptibility results for 
INH or RIF between WGS and MGIT, we compared the MGIT to the DST performed on 
Löwenstein-Jensen and in case of genotypically resistant, phenotypically susceptible 
isolates we examined the quality of the variant call (Table S3.2). All analyses were 
performed in R, version 3.3.1 (http://www.R-project.org).
Data availability
The raw sequence files (FASTQ) were archived on the NCBI Sequence Read Archive 
and are available at: http://www.ncbi.nlm.nih.gov/bioproject/475771. The individual 
isolates can be accessed under the following Biosample accession numbers: 
SAMN09402650-SAMN09402721. The Bioproject accession number is: PRJNA475771.
Results
Phenotypic drug susceptibility testing
MGIT results for INH, STR, and EMB were available for 68 out of 72 isolates (four 
cultures being contaminated); RIF MGIT results were available for 69 isolates, with 
three cultures contaminated. Fifty-seven isolates were phenotypically resistant to INH, 
34 to RIF, 24 to STR, and three to EMB. Using the MycoTB microdilution method, MICs 
for INH, RIF, STR, EMB, ETO, OFL, MXF, PAS, cycloserine, AMK, and KAN were successfully 
determined for 64 isolates; six samples were contaminated, and two repeatedly failed 
to grow in the MycoTB plate. By MycoTB, 51 isolates were resistant to INH, 31 to RIF, 
nine to STR, four to EMB, 40 to ETO, four to OFL, one to MXF, one to PAS, one to 
cycloserine, two to AMK, and three were resistant to KAN (Figure S3.1). Poly-drug 
resistance was observed in 47, and MDR-TB in 28 isolates, no isolates were XDR-TB 
according to MycoTB. The agreement between MGIT and MycoTB for INH, RIF, STR and 
EMB was greater than to be expected by chance (Table S3.3). Cohen’s kappa indicated 
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excellent agreement for INH (κ = 0.794; p < 0.001) and RIF (κ = 0.905; p < 0.001), and 
little agreement for STR (κ = 0.289; p = 0.006) and EMB (κ = 0.246; p = 0.045).
Whole genome sequencing and in silico determination of drug resistance
Sixty-three (87.5%) isolates harboured drug resistance-conferring mutations, and 
48 (66.7%) had INH and RIF resistance-conferring mutations and were genotypically 
multidrug-resistant. The identified drug resistance mutations are listed in Table 3.1. 
Resistance-conferring mutations to INH were identified in 61 (84.7%) isolates.
The most common INH resistance mutation was katG S315T, which was present in 
38 (52.8%) isolates as a single mutation, and in 16 (22.2%) together with a mutation in 
the fabG1 promotor region (synonym: inhA promotor region). Resistance-conferring 
mutations to RIF were found in 50 (69.4%) isolates. The most prevalent RIF resis-
tance-conferring mutation was rpoB S450L, observed in 17 (23.6%) isolates as a single 
mutation, and in one isolate as a combined mutation. Mutations in genes related to 
EMB susceptibility were identified in 39 (54.2%) isolates; embB M306I was observed 
in 25 (34.7%) isolates, and in 14 of these as a single mutation. Resistance to STR due 
to mutations in the rpsL and rrs loci was found in 19 (26.4%) isolates; with rrs A1401G 
in 13 isolates being the most frequent. This mutation however is not considered 
causative of STR resistance according to expert knowledge18,19. Mutations in the pncA 
gene, encoding the target of PZA were found in 23 (31.9%) isolates, 14 of which had a 
single pncA A146V mutation. Mutations to second-line drugs were less frequently 
observed, the rrs A1401G mutation associated with resistance to AMK, CAP, and KAN 
was most common, together with the C15T mutation in the promotor region of fabG1 
conferring resistance to ETO that was found in 20 (27.8%) isolates. The latter mutation 
is also associated with INH resistance. Only five isolates had one of four different 
mutations conferring resistance to FLQs.
Phylogenetic relatedness of the isolates
A phylogenetic tree was constructed based on 5,794 variable common nucleotide 
positions among the 72 M. tuberculosis isolates. Seventy-one isolates belonged to the 
Euro-American lineage and one belonged to the East-Asian lineage. The phylogeny 
showed that several isolates were closely related, but did not all harbour the same 
resistance-conferring mutations (Figure S3.2). Fourteen isolates within the same clade 
carried the fabG1 (C-15T promotor), katG (S315T), rpoB (S450L), embB (M306I), and 
pncA (A146V) mutations, but they also harboured different mutations. Another 21 
isolates clustered together in the tree and carried the S315T katG mutation, twenty of 
which had the H445N rpoB mutation, but apart from that their resistance profile 
differed. In addition, there were five pairs of neighbouring isolates that had similar 
resistance mutations.
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Table 3.1.  Frequency of M. tuberculosis resistance-conferring mutations
Drug Gene Mutation Frequency 
(%)
MGIT- 
resistant#
MIC > CC#
INH katG
katG + ahpC
katG + fabG1
fabG1
fabG1 + inhA
ahpC
Ser315Thr
Asp311Gly + G-48A promoter
Ser315Thr + C-15T promoter
C-15T promoter
C-15T promoter + Ile21Val
C-52T promoter
38 (52.8)
1 (1.4)
16 (22.2)
4 (5.6)
1 (1.4)
1 (1.4)
35/35
1/1
15/15
4/4
1/1
1/1
30/30
1/1
16/16
2/4
0/1
1/1
RIF rpoB Asp435Val
Gln432Pro
His445Asn
His445Asp
His445Tyr
Leu430Pro
Ser450Leu
Ser450Trp
Asp435Gly + His445Asn
Asp435Val + His445Asn
His445Asn + Pro454Leu
Leu430Pro + His445Asn
Met434Ile + His445Asn
Phe424Leu + His445Asn
His445Asn + Ser450Leu + Pro-
454Leu
4 (5.6)
1 (1.4)
12 (16.7)
1 (1.4)
4 (5.6)
2 (2.8)
17 (23.6)
1 (1.4)
1 (1.4)
1 (1.4)
2 (2.8)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)
3/4
1/1
2/11
1/1
4/4
0/1
15/15
1/1
1/1
1/1
0/2
1/1
1/1
1/1
1/1
3/4
1/1
1/7
1/1
4/4
0/1
16/16
1/1
1/1
NA
1/2
NA
1/1
0/1
0/1
EMB embA
embA + embB
embB
C-12T promoter
C-12T promoter + Asp354Ala
C-12T promoter + Glu504Asp
C-12T promoter + Met306Ile
C-12T promoter + Met306Leu + 
Asp354Ala
Asp354Ala
Gly406Asp
Met306Ile
Met306Leu
Met306Val
Met306Ile + Gly406Asp
Met306Val + Asp328Tyr
Met306Ile + Tyr319Ser + As-
p354Ala
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)
1 (1.4)
5 (6.9)
14 (19.4)
1 (1.4)
2 (2.8)
9 (12.5)
1 (1.4)
1 (1.4)
0/1
0/1
0/1
0/1
0/1
0/1
0/5
0/12
0/1
0/2
3/9
0/1
0/1
0/1
0/1
0/1
0/1
0/1
0/1
0/1
0/14
0/1
0/1
4/8
0/1
0/1
STR rpsL
rpsL + rrs
rrs
Lys43Arg
Lys88Arg
Lys43Arg + A1401G
A1401G*
A514C
C1402T*
C517T
1 (1.4)
1 (1.4)
2 (2.8)
11 (15.3)
2 (2.8)
1 (1.4)
1 (1.4)
1/1
1/1
2/2
6/10
2/2
1/1
NA
1/1
1/1
2/2
1/10
2/2
0/1
0/1
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Comparison of MGIT, minimum inhibitory concentrations  
and whole genome sequencing
First, whole genome sequencing was compared with phenotypic DST by MGIT. Figure S3.3 
and Table 3.1 show the comparison of MGIT and WGS resistance prediction. For MGIT, 
all isolates with well-known INH resistance-conferring mutations were phenotypically 
resistant to INH, and all isolates without these mutations were susceptible to INH. For 
RIF, 13/69 (19%) discrepancies were observed between MGIT and WGS; all concerned 
WGS-resistant, MGIT-susceptible isolates. Eleven of these had a H445N rpoB mutation; 
eleven were susceptible according to DST performed on Löwenstein-Jensen medium, 
and variant call qualities were good (Table S3.2). For STR, WGS and MGIT did not match 
for 15/68 (22%) isolates; four had an A1401G rrs mutation but were susceptible 
Table 3.1.  Continued
Drug Gene Mutation Frequency 
(%)
MGIT- 
resistant#
MIC > CC#
PZA pncA Ala146Val
Gln10Arg
Gln10Stop
Gly17Asp
Tyr34Stop
Tyr34Stop + Gly17Asp
14 (19.4)
1 (1.4)
4 (5.6)
2 (2.8)
1 (1.4)
1 (1.4)
NA NA
ETO ethA
fabG1
fabG1 + inhA
Thr61Met
C-15T promoter
C-15T promoter + Ile21Val
1 (1.4)
20 (27.8)
1 (1.4)
NA
1/1
19/19
1/1
FQ gyrA
gyrB
Ala90Val
Asp94Gly
Ser91Pro
Asp461Asn
1 (1.4)
2 (2.8)
1 (1.4)
1 (1.4)
NA
NA
1/2 (OFL); 
0/2 (MXF)
0/1 (OFL); 
0/1 (MXF)
1/1 (OFL); 
0/1 (MXF)
AMK rrs A1401G
A514C*
C1402T
C517T*
13 (18.1)
2 (2.8)
1 (1.4)
1 (1.4)
NA
2/12
0/2
0/1
0/1
CAP rrs A1401G
C1402T
13 (18.1)
1 (1.4) NA NA
KAN eis
rrs
G-14A promoter
A1401G
C1402T
2 (2.8)
13 (18.1)
1 (1.4)
NA
1/2
1/12
0/1
*These mutations possibly have no causative role in conferring drug resistance to the respective drug (18, 19). 
#Presented as N/N tested, because not all isolates with genotypic DST results had phenotypic DST results. 
The most frequently observed drug resistance mutations per drug are shown in bold. MGIT: Mycobacterium 
Growth Indicator Tube; MIC: minimum inhibitory concentration; CC: critical concentration; NA: not assessed.
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according to MGIT, and 11 were MGIT-resistant, but had no STR resistance-conferring 
mutations. For EMB, we observed 34/69 (49%) discrepancies; all isolates without an 
EMB resistance-conferring mutation were susceptible, but 34 isolates with an EMB 
resistance mutation were also susceptible. Only isolates with the combination of two 
embB mutations (M306I and G406D) were MGIT EMB-resistant, and this was only the 
case for three out of nine isolates with this combined mutation.
We next compared WGS with the MycoTB assay, which yields MICs (Figure 3.1 and 
Table 3.1). Different resistance mutations were associated with different MIC ranges. 
For INH, the katG S315T mutation was associated with clearly elevated MICs, as was 
the ahpC C52T promotor mutation although it only occurred in one isolate. Other 
mutations in ahpC, fabG1, and inhA were associated with MICs around or just above 
the critical concentration. For RIF, the rpoB S450L mutation was associated with 
elevated MICs, but other rpoB mutations were associated with a range of MICs 
including the critical concentration. Mutations in rpsL were all associated with MICs 
above the critical concentration for STR and the same applies to the rrs A514C mutation. 
However, other rrs mutations were associated with MICs around or below the critical 
concentration for STR. All found mutations in embA or embB were associated with 
elevated EMB MICs; their ranges included the critical concentration.
All isolates with resistance-conferring mutations to ETO had elevated MICs. The fabG1 
C15T promotor mutation was associated with a bimodal MIC distribution for ETO; some 
isolates had an MIC of twice the critical concentration; most others with the mutation 
had an eight times higher MIC than the critical concentration. For AMK and KAN, all 
observed mutations were associated with an MIC range below or including the critical 
concentration. OFL or MXF resistance mutations were uncommon, and these mutations 
were associated with an MIC above the critical concentration in only two isolates, and 
only for OFL. For STR and OFL, but especially for ETO, we observed isolates with no 
mutations conferring resistance to the respective drug, but with MICs above the critical 
concentration.
Discussion
In this study, we demonstrate that MIC determination using SensiTitre MycoTB is an 
excellent alternative to conventional DST methods; it is relatively rapid, straightfor-
ward, and it provides quantitative data on susceptibility to first- and second-line drugs, 
thus facilitating therapeutic decision-making and therapeutic drug monitoring to 
optimize regimen efficacy and minimize toxicity20. Whole genome sequencing has 
been shown to be a sensitive, accurate, rapid, and financially feasible method for M. 
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tuberculosis drug susceptibility testing21. Here we show that WGS has additional 
added value in terms of predicting the level of resistance to different drugs. For key anti- 
tuberculosis drugs including rifampicin, isoniazid, ethambutol and fluoroquinolones, 
distinct genomic mutations are associated with particular MIC ranges, some including 
the critical concentration.
The MycoTB microdilution method is a commercially available method for MIC testing 
in M. tuberculosis and the first for second-line drugs. Previous studies have tested its 
performance compared to currently available methods for drug susceptibility testing, 
such as the BACTEC MGIT 96022, the indirect agar proportion method8,9,23, the Löwen-
stein-Jensen proportion method24, genotypic tests25, or a combination of these17, and 
it has proven a rapid, convenient, quantitative, and accurate method for testing both 
first- and second-line antituberculosis drug susceptibility. We found discrepancies 
with WHO-endorsed phenotypic tests for first line drugs, especially STR and EMB, 
but phenotypic DST has been proven to be difficult for these drugs and the value of 
these tests as ‘gold standard’ is questionable. Compared to previous studies 
comparing MycoTB with MGIT, the MycoTB in the present study performed slightly 
better for INH and RIF, comparable for EMB, and slightly worse for STR17,22. Furthermore, 
the microwell plate format without the need for equipment will allow its use in 
resource-pour settings, where it is most needed, provided that culture-based DST is 
possible, and proper biosafety measures are taken. Moreover, the visual reading of the 
plates requires some operator experience.
Whole genome sequencing is revolutionizing drug susceptibility testing in tuberculosis 
and has great potential in public health interventions. However, the various platforms 
used, as well as the shortcomings of critical concentrations for phenotypic DST hinder 
the comparison of genotypic and phenotypic DST, hence the validation of WGS-based 
susceptibility testing26. The current critical concentrations have a limited evidence 
base and stem largely from observations on wild type MIC distributions, not from 
clinical or pharmacokinetics/pharmacodynamics studies27. Data from several studies 
indicate that these critical concentrations need to be revised because they either 
bisect the wild-type distribution, or are substantially higher than the MICs of wild-type 
organisms resulting in potential false reporting of susceptibility28. Indeed, in the 
current study, we observed that isolates with mutations associated with decreased 
susceptibility to RIF, STR, and EMB were reported susceptible according to MGIT, and 
MICs for these drugs were often around the critical concentration. These data support 
the notion of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
that critical concentrations should be defined by combining MIC distributions, 
preferably combined with clinical outcomes and pharmacokinetics/pharmacodynam-
ics data28,29. Even though WGS has already been successfully implemented in routine 
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diagnostic practice in some settings and has been shown to achieve generally high 
agreement with phenotypic first-line DST21,30,31, MIC testing may help in more 
accurately assessing the performance of WGS for drug resistance detection and the 
role of this method in TB laboratory diagnosis.
The discrepancies between MGIT and MICs observed in our study support the current 
dogma that inconsistencies between phenotypic and genotypic DST found in important 
studies investigating the use of WGS for predicting M. tuberculosis drug susceptibility 
are partly attributed to shortcomings with currently endorsed methods of phenotypic 
DST, which essentially provide only qualitative results (sensitive or resistant), 
especially where mutations conferring low-level drug resistance are involved32. 
However, it is important to appreciate that unknown resistance mechanisms, 
inadequate limits of detection or artefacts of sequencing, random errors, and false 
associations between genotype and phenotype due to epistatic interactions could all 
play a role33–35. The clinical impact of these discrepancies, and the effect of treatment 
regimen based on different DST methods are not clear yet, and clinical validation of the 
influence of MICs of single drugs on treatment outcome is warranted. The analysis of 
embB mutations has long been considered futile because they did not match well with 
phenotypic DST results36, our data however show that these mutations do have an 
effect on MICs thus potentially influence treatment efficacy37,38 as has been shown 
previously in a mouse model of aerogenic tuberculosis39.
Similar to what has been shown in a recent study by Heyckendorf et al.32, we observed 
that WGS did not miss phenotypically confirmed resistances to first-line drugs, except 
for STR. We discovered that the MIC-range for isolates without STR resistance-confer-
ring mutations was wide and included the critical concentration. Unknown mutations 
in these isolates could have caused resistance. Critical concentration artefacts could 
also explain the discrepancies; 16 isolates were MGIT-resistant for STR, but had an MIC 
below the critical concentration. In addition, WGS predicted resistance in a number of 
phenotypically susceptible isolates. Especially rpoB H445N, embB G406D and M306I, 
as well as the rrs mutations did not correlate well with phenotypic resistance, in line 
with previous findings19,26,40–42. We found that these mutations increased the MIC 
only slightly, or were associated with wide MIC-ranges. However, previous studies 
have shown that these mutations may still be clinically relevant37,39,41,43,44.
This is the first study to investigate drug resistance in M. tuberculosis isolates from the 
greater Craiova area, Romania. In this selection of phenotypically drug-resistant 
isolates we observed low frequencies of resistance to second-line drugs, possibly as 
a result of limited availability of second-line antituberculosis drugs7. Surprising was 
the observation that all-but-one of the isolates belonged to the Euro-American lineage, 
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because there has been an extremely large cluster of MDR/XDR-TB M. tuberculosis 
strains in the EU, especially in the eastern part, which is significantly related to the 
spread of one strain or clone of the Beijing genotype45.
The relatively small number of isolates does not permit drawing solid conclusions on 
the effect of most drug resistance mutations on drug susceptibility and the interrelat-
edness of different mutations, or their combined effects on the level of resistance. 
However, the findings we present are an important contribution to the field because of 
a lack of data correlating M. tuberculosis genotype and MICs46. In addition, the 
phylogeny showed one clade of genetically closely related isolates. This could have 
affected the MIC distribution of the drugs these isolates are resistant to. However, the 
drug resistance mutations found in these isolates differed to an extent that makes it 
unlikely that these isolates represent the same strain. Also, we could not associate 
drug resistance mutations with the corresponding MICs for two strains that failed to 
grow on the MycoTB microtiter plate and six that were contaminated. Lastly, 
pyrazinamide is not included in the MycoTB plate, and we could not assess the MICs 
related to pyrazinamide resistance-associated mutations, which were discovered in 23 
(32%) isolates.
In summary, we have shown that, especially for RIF, STR, and EMB, MICs near the 
critical concentration are common. Consequently, phenotypic DST based on critical 
concentration testing, e.g. the MGIT method, may provide inaccurate results, possibly 
leading to suboptimal treatment regimens. We compared WGS-predicted drug 
resistance mutations directly with MICs and found that different mutations lead to 
different levels of resistance; knowing the underlying mutations can guide clinical de-
cision-making and facilitate therapeutic drug monitoring, ultimately leading to better 
treatment outcome.
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Figure S3.2. Phylogenetic tree showing the genetic relatedness of 72 M. tuberculosis strains 
isolated from 72 Romanian patients.
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Supplementary tables
Table S3.1. Description of sequencing quality control parameters and statistics
Study number Clean reads Q20% Total bases Mean 
coverage
Median 
coverage
Percentage  
bases >1
MTB0083 5010168 98,8 729245204 155,8 160 99,6
MTB0085 9244564 98,9 1331280683 292,3 299 99,4
MTB0153 4980076 98,8 720076577 157,9 161 99,5
MTB0159 4326888 98,8 628038812 138,1 142 99,6
MTB0167 5439392 98,9 792319455 174,2 178 99,6
MTB0210 5880320 98,9 852347773 187,4 192 99,5
MTB0269 4613254 98,8 671851858 147,7 151 99,7
MTB0326 5072238 98,8 730714611 160,2 164 99,5
MTB0373 4397414 98,8 639876834 139,8 143 99,5
MTB0397 2668762 98,8 388958930 82,6 85 99,8
MTB0398 3282760 98,7 479249813 103,1 105 99,5
MTB0421 5498680 98,8 797711420 174,6 179 99,5
MTB0455 2581286 98,8 377936416 79,3 78 99,5
MTB0472 6458404 98,8 937346421 204,5 210 99,5
MTB0477 5466848 98,8 793482681 173,6 178 99,5
MTB0498 3500310 98,7 509420826 108,6 112 99,5
MTB0565 6226184 98,8 907091707 198,6 204 99,5
MTB0598 5334456 98,7 776163802 169,7 173 99,3
MTB0621 1315430 98,7 192150033 40,4 41 99,4
MTB0670 1723318 98,7 252717866 51,7 53 99,5
MTB0679 5047768 98,8 735251932 160,7 164 99,7
MTB0681 2592134 98,3 374789416 81,0 82 99,5
MTB0690 2788926 98,7 407670628 88,0 90 99,5
MTB0704 4512874 98,8 655016172 143,0 146 99,4
MTB0717 5180780 98,8 753070029 164,8 169 99,5
MTB0731 6910880 98,8 995135438 218,9 225 99,7
MTB0750 16678804 98,8 2289895133 501,3 500 99,6
MTB0751 5024722 98,8 725893624 159,6 160 99,6
MTB0777 6829294 98,8 984893721 216,8 222 99,6
MTB0805 6349612 98,9 920541812 202,5 208 99,8
MTB0808 13982680 98,9 1992277055 438,3 450 99,6
MTB0819 7285102 98,8 1045110908 228,2 233 99,3
MTB0820 6437616 98,8 928788036 203,9 209 99,6
MTB0822 10553814 98,8 1498369699 329,4 335 99,6
MTB0835 13273726 98,9 1867111990 410,9 422 99,5
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Table S3.1. Continued
Study number Clean reads Q20% Total bases Mean 
coverage
Median 
coverage
Percentage  
bases >1
MTB0838 11449646 98,9 1631527546 358,9 368 99,6
MTB0844 7042508 98,8 1014627854 223,5 229 99,6
MTB0869 9514364 98,8 1348716932 296,8 304 99,6
MTB0890 9986614 98,8 1426980119 312,9 321 99,5
MTB0898 2673806 98,8 389093509 78,8 80 99,5
MTB0899 3748466 98,8 543659909 110,8 111 99,6
MTB0902 5105332 98,8 738012399 161,6 166 99,5
MTB0935 4166006 98,8 600850392 131,6 134 99,9
MTB0940 6345710 98,9 912105253 200,3 205 99,8
MTB0954 5182548 98,9 749833435 164,1 169 99,3
MTB0955 6342280 98,9 912264427 200,4 206 99,4
MTB0968 5597674 98,8 808331240 177,3 182 99,6
MTB0971 4810290 98,8 697511432 153,1 158 99,5
MTB0998 6125292 98,8 882233413 193,8 200 99,5
MTB1063 3131132 98,8 452357038 99,1 102 99,5
MTB1085 4055568 98,8 586012462 127,2 131 99,5
MTB1091 4496052 98,8 651171048 143,0 147 99,5
MTB1094 5037192 98,8 726608727 159,5 164 99,5
MTB1105 2766362 98,8 403334631 86,0 88 99,5
MTB1114 7021708 98,8 1005915329 221,2 227 99,7
MTB1119 4133620 98,7 598668119 131,1 134 99,5
MTB1122 5510106 98,8 800687586 175,7 179 99,5
MTB1132 2041418 98,7 297936222 64,9 66 99,2
MTB1134 2636480 98,8 384682814 84,1 86 99,3
MTB1153 2592910 98,8 377531940 82,8 85 99,5
MTB1181 3687154 98,8 536107686 117,5 121 99,5
MTB1183 4231256 98,8 614868223 135,1 138 99,5
MTB1184 1520090 98,8 222159082 47,7 49 99,5
MTB1186 2331846 98,7 339340987 74,3 76 99,5
MTB1195 5434990 98,7 786889583 172,7 177 99,6
MTB1201 3044342 98,7 439656581 96,5 99 99,5
MTB1209 3420894 98,7 494659829 108,5 111 99,5
MTB1221 2829856 98,8 411306820 89,8 91 99,5
MTB1364 3977738 98,7 576100368 125,7 128 99,5
MTB1466 2388624 98,7 347922516 75,6 77 99,6
MTB1509 3914664 98,6 568644763 124,2 126 99,5
MTB1523 2993102 98,8 435834604 95,7 98 99,5
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Table S3.2.  Discrepant drug susceptibility test results according to whole genome 
sequencing and Mycobacterium Growth Indicator Tube.
Isolate
Discrepant 
WGS result
Discrepant 
MGIT result LJ result
Sequencing statistics
Un
de
rly
in
g 
m
ut
at
io
n
Se
qu
en
ci
ng
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ov
er
ag
e 
de
pt
h 
(n
o.
 o
f r
ea
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)
%
 o
f r
ea
ds
 s
up
po
rt
in
g 
th
e 
va
ria
nt
 
MTB0159 RIF-resistant RIF-susceptible RIF-susceptible rpoB (H445N) 147 100%
MTB0498 RIF-resistant RIF-susceptible RIF-susceptible rpoB (H445N) 115 96.5%
MTB0598 RIF-resistant RIF-susceptible Rif-resistant rpoB (D435V) 161 97.5%
MTB0621 RIF-resistant RIF-susceptible Rif-resistant rpoB (H445N)
rpoB (P454L)
37
48
100%
100%
MTB0681 RIF-resistant RIF-susceptible RIF-susceptible rpoB (H445N) 123 97.6%
MTB0819 RIF-resistant RIF-susceptible RIF-susceptible rpoB (L430P) 234 99.6%
MTB0838 RIF-resistant RIF-susceptible RIF-susceptible rpoB (H445N) 383 98.4%
MTB0898 RIF-resistant RIF-susceptible RIF-susceptible rpoB (H445N) 78 97.4%
MTB0899 RIF-resistant RIF-susceptible RIF-susceptible rpoB (H445N) 122 99.2%
MTB1085 RIF-resistant RIF-susceptible RIF-susceptible rpoB (H445N) 130 99.2%
MTB1091 RIF-resistant RIF-susceptible RIF-susceptible rpoB (H445N) 136 99.3%
MTB1153 RIF-resistant RIF-susceptible RIF-susceptible rpoB (H445N) 79 100%
MTB1195 RIF-resistant RIF-susceptible RIF-susceptible rpoB (H445N) 183 99.5%
Table S3.3. Concordance between Mycobacterium Growth Indicator Tube and MycoTB
MycoTB
% Categorical 
agreement
Cohen’s kappa 
(p-value)
MIC above 
breakpoint 
(resistant)
MIC below 
breakpoint 
(susceptible)
MGIT INH Resistant
Susceptible
48
1
3
10
93.5 0.794 (p<0.001)
RIF Resistant
Susceptible
29
1
2
31
95.2 0.905 (p<0.001)
STR Resistant
Susceptible
7
2
16
37
71.0 0.289 (p=0.006)
EMB Resistant
Susceptible
1
3
2
59
92.3 0.246 (p=0.045)
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Abstract
Background
Many tuberculosis (TB) patients with diabetes have poor treatment outcomes, but it 
is unclear whether this results from genotypic drug resistance of the infecting myco -
bacteria.
Methods
In this observational study we used whole genome sequencing to examine 1,365 
known drug resistance mutations in 896 Mycobacterium tuberculosis isolates from TB 
patients from Indonesia and Peru with (n=159) and without (n=737) diabetes, 19% and 
24% of whom respectively had been previously treated for TB. We used multilevel 
logistic regression to examine the relationship between diabetes and resistance 
mutations.
Results
In Indonesia, drug resistance mutations were found in M. tuberculosis isolates of 21 / 
115 (18%) patients with and 43 / 292 (15%) patients without diabetes, respectively. 
In Peru, mutations were found in 18 / 44 (41%) patients with, compared to 149 / 445 
(33%) without diabetes. Diabetes was independently associated with genotypic drug 
resistance (odds ratio (OR) = 1.69; 95% confidence interval (CI) = 1.04-2.77), 
in particular to rifampicin (OR = 2.52 (95% CI 1.19-5.34)). The association was stronger 
for those not previously treated for TB. Mutations in Rv1482c-fabG1, conferring resistance 
to isoniazid and ethionamide, and gyrA, conferring fluoroquinolone resistance, 
were overrepresented in isolates from Peruvian patients with diabetes (p<0.01 and 
p<0.05, respectively).
Conclusions
Diabetes is associated with genotypic drug resistance in M. tuberculosis, and this is 
not explained by prior TB treatment. Our findings support the importance of routine 
drug-susceptibility testing for TB patients with diabetes, and highlight the need for 
further study to understand the mechanism underlying the association.
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Introduction
The convergence of the tuberculosis (TB) and type 2 diabetes epidemics1 poses a 
great threat to global TB control. People with diabetes are three times more likely to 
develop active TB than people without diabetes, and diabetes is associated with 
increased death, TB treatment failure and recurrent TB2-5. A higher prevalence of 
drug-resistant TB among those with diabetes may be one contributing factor to their 
adverse clinical outcomes during and after TB treatment. Two recent meta-analyses 
examining the association between diabetes and multidrug-resistant TB (MDR-TB), 
including more than twenty-two thousand individuals with TB, showed that diabetes 
is an independent risk factor for MDR-TB3,6. Drug-resistant TB is associated with 
increased morbidity and mortality and has emerged as a major threat to TB control 
worldwide7. However, the genetic characteristics of resistant M. tuberculosis strains 
causing disease in diabetes patients remain to be discovered.
In the current study we used whole genome sequencing to investigate genetic 
differences of M. tuberculosis isolates causing disease in two cohorts of TB patients 
with and without diabetes, focusing on the presence of drug resistance-associated 
mutations. As opposed to phenotypic drug susceptibility testing (DST), whole genome 
sequencing has the potential to unlock valuable information on the specific mutations 
underlying resistance, transmission clusters and the phylogenetic background of 
drug-resistant M. tuberculosis strains8, thereby increasing our understanding of the 
molecular basis of resistance of M. tuberculosis in these patients.
Methods
Subjects and isolates
We used M. tuberculosis isolates from two established TB cohorts of Indonesian and 
Peruvian patients who were screened for diabetes. Both cohorts were part of TANDEM, 
a multi-centre study focussing on the relationship between TB and diabetes9-11. All 
participants underwent laboratory glycated hemoglobin (HbA1c) testing (using the 
high-performance liquid chromatography method), as recommended by WHO for 
diabetes screening12, regardless of their previous diabetes status. Further details on 
TB and diabetes case definitions are published elsewhere10,13 and are freely available 
in online appendices14. In Peru we selected all available M. tuberculosis isolates; in 
Indonesia we selected all available isolates from TB patients with diabetes plus a 
subset of isolates from patients without diabetes from the same clinics, during the 
same time period, frequency-matched by age. A single isolate from each patient, 
obtained at time of diagnosis, was selected for sequencing. Ethical approval was 
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received from the Observational/Interventions Research Ethics Committee, London 
School of Hygiene and Tropical Medicine on 18 December 2013 (LSHTM ethics ref: 6449, 
LSHTM amendment no: A473) and institutional review boards in Indonesia and Peru.
Cultured M. tuberculosis isolates underwent whole genome sequencing as described 
in the Supplementary methods. We used TB Profiler version 0.3.815 to determine 
M. tuberculosis lineage and drug resistance, comparing identified single nucleotide 
polymorphisms (SNPs) and indels to a curated list of drug resistance mutations. All 
non-synonymous SNPs in rpoA, rpoB outside the rifampicin resistance-determining 
region (RRDR), rpoC, ahpC promoter region and ubiA were considered as mutations 
possibly compensating for the loss of fitness caused by drug resistance mutations16-18.
A phylogeny was constructed using PhyML version 3.019. Based on the phylogeny, 
we calculated the distance to the genetically closest other isolate (minimum pairwise 
distance) for isolates from TB patients with and without diabetes separately. 
We compared the distribution of these distances using the Mann-Whitney U test, 
for Indonesia and Peru separately.
Statistical analysis
We compared patient- and isolate-related characteristics of TB patients with and 
without diabetes, stratified by country (Indonesia or Peru). We assessed the association 
between diabetes and genotypic drug resistance using multilevel logistic regression, 
correcting for age, gender, HIV-infection, previous TB treatment, and M. tuberculosis 
lineage. We expanded the analysis by examining differences in resistance to individual 
drugs and combined mutations accounting for MDR-TB, again using multilevel multi- 
variable logistic regression. To examine country-specific associations between diabetes 
and individual and multi-drug resistance, we used logistic regression stratified by country. 
We performed a sensitivity analysis to examine the effect of possible  misclassification of 
patients with newly diagnosed diabetes on the association with any drug resistance. 
Furthermore, we investigated whether HbA1c was associated with drug resistance and 
also analysed the data after excluding all patients with HIV.
We investigated whether resistance mutations in certain genes occurred more frequently 
in TB patients with diabetes. Per resistance gene, we summed the number of isolates 
with at least one known resistance mutation in the respective gene and compared 
these between patients with and without diabetes, for Indonesia and Peru separately.
Lastly, we examined if a possible association between diabetes and drug resistance 
could be explained by differences in potential compensatory mutations, hypothesizing 
that resistant isolates from patients with diabetes, who are thought to have a lower 
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host immune defence against M. tuberculosis20, would need fewer mutations compensating 
for loss of fitness associated with drug resistance. We determined the association 
between isoniazid and rifampicin resistance mutations and the presence of previously 
proposed accompanying compensatory mutations16,18,21, stratified for diabetes 
comorbidity, for Indonesian and Peruvian isolates separately.
Results
Patient and isolate characteristics
Diabetes was more common among the Indonesian (28%) compared to the Peruvian 
patients (9%), but genotypic drug resistance was more often observed in isolates from 
Peruvian (34%) compared to Indonesian patients (16%, Table 4.1). In both countries, 
TB patients with diabetes were older, more often female, and slightly heavier than TB 
patients without diabetes. Only 21% of the Indonesian and 14% of the Peruvian 
diabetes patients had been previously treated for TB, compared to 27% and 22% of 
the non-diabetes patients, respectively (Table 4.1).
A phylogenetic tree, based on 56,654 variable common nucleotide positions among 
896 M. tuberculosis isolates, showed that isolates from TB patients with diabetes 
were spread evenly across the phylogeny, i.e. they were not clustered (Figure 4.1). 
The M. tuberculosis lineage distribution for isolates from patients with diabetes 
was significantly different from those without (Chi-square = 11.559; p=0.009), with 
East-Asian strains being more common (30% vs. 20%) and Euro-American strains less 
common among the TB patients with diabetes (67% vs. 77%). However, this difference 
was no longer apparent after stratifying by country (Chi-square = 4.692; p=0.196 for 
Indonesia and Chi-square = 0.241; p=0.624 for Peru); lineage was indeed highly 
associated with country (Chi-square = 90.383; p<0.001). With respect to clonality: 
for isolates from Indonesian TB patients with diabetes, the median minimum pairwise 
distance was 161 SNPs; for patients without diabetes this amounted to 164 SNPs 
(p=0.867). For isolates from Peruvian TB patients with diabetes, the median minimum 
pairwise distance was 98 SNPs, compared to 67 SNPs in patients without diabetes 
(p=0.021, Supplementary figure S4.1).
Genotypic drug resistance in TB patients with and without diabetes
In Indonesia and Peru, respectively 18% and 39% of the patients with diabetes were 
infected with M. tuberculosis with at least one drug resistance-conferring mutation, 
compared to 15% and 20%, respectively, of the patients without diabetes (Fisher’s 
exact p=0.454 and p=0.006 respectively; Table 4.1). In multilevel logistic regression, 
genotypic drug resistance was significantly associated with diabetes, both in 
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univariable (odds ratio (OR) 1.6; 95% confidence interval (CI) 1.1-2.5), and multivariable 
analysis (OR 1.8; 95% CI 1.1-2.9). No other factors were independently associated with 
genotypic resistance (Table 4.2).
Combining both countries and accounting for the country effect using multilevel 
multivariable regression, diabetes was significantly associated with rifampicin resistance 
(OR 2.5; 95% CI 1.2-5.3), also among those not previously treated for TB (OR 3.1; 95% 
CI 1.2-8.3). In addition, we found a trend towards more fluoroquinolone resistance in 
TB patients with diabetes compared to those without, which reached significance for 
Peru (OR 6.69; 95% CI 1.37-32.68). Moreover, although this association did not reach 
statistical significance, the odds of MDR-TB was twice as high in patients with diabetes, 
compared to patients without (OR 2.09; 95% CI 0.92-4.77).
Table 4.1.   Baseline characteristics of tuberculosis patients with and without 
diabetes mellitus type 2
Indonesia Peru
Diabetes 
(N=115)
No diabetes 
(N=292)
Diabetes 
(N=44)
No diabetes 
(N=445)
Male gender 52 (45%) 168 (58%) 25 (57%) 268 (60%)
Age (years) – median (IQR) 50 (45-58) 39 (33-48) 52 (42-59) 28 (22-39)
BMI 21 (18-25) 18 (16-20) 24 (22-28) 22 (20-24)
History of previous TB 
treatment
24 (21%) 79 (27%) 6 (14%) 96 (22%)
BCG scar 51 (65%) 108 (60%) 38 (86%) 342 (77%)
HIV-positive 0 0 1 (3%) 18 (5%)
M. tuberculosis lineage
East-Asian
Euro-American
Indo-Oceanic
M. bovis
40 (35%)
69 (60%)
5 (4%)
1 (1%)
90 (31%)
178 (61%)
24 (8%)
0
7 (16%)
37 (84%)
0
0
59 (13%)
386 (87%)
0
0
Any resistance predicted 
by WGS
Treatment-naïve
Previously treated
21 (18%)
13 (11%)
8 (7%)
44 (15%)
31 (11%)
12 (4%)
17 (39%)
14 (32%)
3 (7%)
88 (20%)
67 (15%)
21 (5%)
MDR predicted by WGS 6 (5%) 8 (3%) 6 (14%) 38 (9%)
Data are presented as N (%) unless indicated otherwise.
Data are missing for BMI (Indonesia: n = 149), History of previous TB treatment (Indonesia: n = 3), BCG scar 
(Indonesia: n = 149), HIV-status (Indonesia: n = 1; Peru: n = 75).
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In both countries, regardless of diabetes comorbidity, genotypic resistance was most 
common for isoniazid, followed by rifampicin (Table 4.3). In Peru, Rv1482c-fabG1 (inhA-
promoter) mutations that confer resistance to isoniazid and ethionamide, and gyrA 
mutations that confer resistance to fluoroquinolones, were significantly more common 
in diabetes compared to non-diabetes TB patients (Table 4.3). In Indonesia, drug 
resistance rates were lower and no significant differences in specific resistance 
mutations were observed between isolates from patients with and without diabetes, 
although a trend towards more frequent rpoB mutations was observed among TB 
patients with diabetes (p=0.069).
Figure 4.1. Phylogenetic tree of 896 M. tuberculosis isolates from TB patients with and without 
diabetes, showing that isolates from TB patients with diabetes were not clustered. Branch 
colours indicate whether isolates belong to the Indo-Oceanic (pink), East-Asian (blue), 
Euro-American (red) M. tuberculosis lineage, or to the M. bovis (green) lineage. The inner circle 
surrounding the phylogenetic tree indicates whether isolates originate from diabetes (red) or 
non-diabetes (grey) TB patients. The outer circle indicates isolates from Indonesian (yellow) 
and Peruvian (blue) patients. The bars outside the circles represent the drug resistance profile 
of the respective isolate.
Sample_site
Indonesia
Peru
Drug_resistance
INH
RIF
EMB
PZA
STR
ETH
FQS
AMK
KAN
CAP
PAS
Phenotype
DM
No-DM
Tree scale: 0.01
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Potential compensatory mutations
In Indonesia, three out of 37 (8%) isolates with isoniazid resistance mutations carried 
at least one potential isoniazid resistance-compensating mutation, compared to 
39 out of 370 (11%) isolates without isoniazid resistance mutations (OR 0.7; 
95% CI 0.2-2.6). In Peru, this was six out of 77 (8%) compared to nine out of 412 
(2%) isolates, respectively (OR 3.8; 95% CI 1.3-11.0). Regarding rifampicin, ten out 
of 19 (53%) Indonesian isolates with rifampicin resistance mutations had at least 
one potential compensatory mutation in rpoA, rpoC and rpoB outside the RRDR, 
compared to118 out of 388 (30%) isolates without rifampicin resistance mutations 
Table 4.2.   Multilevel logistic regression model determining the association between 
diabetes and drug resistance, including a random intercept for site
Any drug  
resistance 
(N=169)
No drug 
resistance 
(N=722)
Univariate OR 
(95% CI)
Adjusted OR 
(95% CI)
Diabetes mellitus^ 38 (22%) 120 (17%) 1.6 (1.1-2.5)* 1.8 (1.1-2.9)*
Diabetes mellitus^
No diabetes
Known diabetes
New diabetes
131 (18%)
27 (23%)
11 (26%)
602 (82%)
88 (77%)
32 (74%)
REF.
1.6 (0.96-2.6)
1.8 (0.9-3.6)
REF.
1.7 (0.98-2.9)
2.0 (0.9-4.4)
HbA1c (%) – median (IQR)^
No diabetes
Diabetes
5.7 (5.4-6.4)
5.6 (5.3-5.8)
10.5 (9.0-11.8)
5.7 (5.4-6.0)
5.6 (5.3-5.8)
11.3 (9.2-13.1)
1.0 (0.97-1.1)
1.1 (0.7-1.7)
0.9 (0.8-1.1)
1.05 (0.97-1.1)
1.4 (0.9-2.3)
0.9 (0.7-1.0)
Age <= 36 years
Age > 36 years
89 (20%)
81 (18%)
353 (80%)
372 (82%)
REF.
0.9 (0.6-1.3)
REF.
0.8 (0.5-1.1)
Male gender 92 (54%) 421 (58%) 0.8 (0.6-1.2) 0.9 (0.6-1.3)
HIV infection 2 (1%) 17 (3%) 0.5 (0.1-2.1) 0.5 (0.1-2.3)
Previous TB treatment 44 (26%) 161 (22%) 1.2 (0.8-1.8) 1.4 (0.9-2.1)
M. tuberculosis lineage
East-Asian
Euro-American
Indo-Oceanic
34 (17%)
135 (20%)
1 (3%)
162 (83%)
535 (80%)
28 (97%)
REF.
1.2 (0.8-1.9)
0.2 (0.02-1.3)
REF.
1.3 (0.8-2.1)
0.2 (0.03-1.6)
The multivariable model was based on 816 patients without missing data (no drug resistance: n = 665; any 
drug resistance: n = 151). The patient with an M. bovis isolate was excluded from the analysis.
* P-value <0.05
^ Diabetes was included in the model as a binary (yes/no) variable, or as a categorical variable distinguishing 
between previously and newly diagnosed disease, or as continuous variable: HbA1c. The adjusted odds 
ratios represent the odds ratios from the model including the binary diabetes variable as the dependent 
variable and age, gender, HIV, previous TB treatment and M. tuberculosis lineage as independent variables.
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Figure 4.2. Forest plot showing the association between diabetes and genotypic drug 
resistance, adjusted for age, gender, site, HIV, previous treatment and M. tuberculosis lineage.
* Odds ratios (ORs) could not be calculated for resistance to amikacin, aminoglycosides and 
acquired multidrug resistance (MDR) for Peru, due to too little resistant isolates. The patient 
with an M. bovis isolate was excluded from the analysis.
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(OR 2.5; 95% CI 1.01-6.4). In Peru, this was 34 out of 49 (69%) compared to 211 out of 
440 (48%) isolates, respectively (OR 2.5; 95% CI 1.3-4.6, Supplementary table S4.1). 
There were no differences in the association between isoniazid or rifampicin resistance 
mutations and potential compensatory mutations between patients with and without 
diabetes, or any interaction between diabetes and the presence of compensatory 
mutations (Supplementary table S4.1).
Table 4.3.  Drug resistance genes with mutation(s) in M. tuberculosis isolates 
from patients with and without diabetes
Indonesia Peru
Drug Gene Diabetes 
(n=115)
No diabetes 
(n=292)
Diabetes
(n=44)
No diabetes 
(n=445)
Isoniazid katG
Rv1482c-fabG1
ahpC
8 (7.0%)
3 (2.6%)
0
19 (6.5%)
10 (3.4%)
0
6 (13.6%)
8 (18.2%)**
1 (2.3%)
48 (10.8%)
23 (5.2%)**
0
Rifampicin rpoB 9 (7.8%) 10 (3.4%) 7 (15.9%) 42 (9.4%)
Ethambutol embB
embC-embA
embR
3 (2.6%)
0
0
6 (2.1%)
0
1 (0.3%)
5 (11.4%)
1 (2.3%)
0
30 (6.7%)
6 (1.3%)
0
Streptomycin rpsL
rrs
4 (3.5%)
1 (0.9%)
5 (1.7%)
2 (0.7%)
1 (2.3%)
0
16 (3.6%)
5 (1.1%)
Pyrazinamide pncA 7 (6.1%) 14 (4.8%) 3 (6.8%) 22 (4.9%)
Ethionamide Rv1482c-fabG1
ethA
3 (2.6%)
0
10 (3.4%)
0
8 (18.2%)**
0
22 (4.9%)**
1 (0.2%)
Fluoroquinolones gyrA
gyrB
3 (2.6%)
0
3 (1.0%)
0
4 (9.1%)*
0
7 (1.6%)*
2 (0.4%)
Amikacin rrs 0 0 0 5 (1.1%)
Capreomycin tlyA
rrs
0
0
1 (0.3%)
0
0
0
7 (1.6%)
5 (1.1%)
Kanamycin eis-Rv2417c
rrs
1 (0.9%)
0
1 (0.3%)
0
1 (2.3%)
0
1 (0.2%)
5 (1.1%)
Para-amino-
salicylic acid
folC
thyA
0
0
2 (0.7%)
0
1 (2.3%)
0
2 (0.4%)
1 (0.2%)
Data represent the number (%) of isolates with at least one mutation in the respective gene. 
* P-value <0.05; ** P-value <0.01 (p-values are Chi-square p-values unless the expected number of resistant 
isolates equalled less than 5, in which case the Fisher’s Exact Test p-value was calculated).
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Sensitivity analysis
In the sensitivity analysis, distinguishing patients with newly and previously diagnosed 
diabetes, we confirmed the association between diabetes and drug resistance, 
although it was no longer significant with smaller numbers (adjusted OR 2.0; 95% CI 
0.9-4.4 for those with newly, compared to OR 1.7; 95% CI 0.98-2.9 for those with 
previously diagnosed diabetes, Table 4.2). HbA1c was not associated with drug 
resistance. In addition, the association between diabetes and individual drug 
resistance differed per drug and per country (Figure 4.2). The association between 
diabetes and drug resistance remained similar after exclusion of the 19 Peruvian 
patients with HIV  (adjusted OR 1.8; 95% CI 1.1-2.9).
Discussion
M. tuberculosis resistance mutations were more common in isolates from TB patients 
with diabetes, compared to those without. The association was evident for resistance 
to rifampicin, with a 2.5 times higher odds of rifampicin resistance in TB patients with 
diabetes, but was also strong for resistance to isoniazid and ethionamide, as well as 
fluoroquinolones, although these only reached statistical significance in the Peruvian 
cohort. The association of diabetes and drug resistance mutations was not explained 
by acquisition of drug resistance as a result of previous TB treatment since it was 
observed for both treatment-naïve, as well as previously treated TB patients.
Previous studies have investigated a possible link between diabetes and drug 
resistance, but most used phenotypic DST and focused on first-line drugs or MDR-TB 
(reviewed in Tegegne et al.6). Whole genome sequencing allowed us not only to 
investigate the association between diabetes and drug resistance at the gene level, 
but also to take the diverse M. tuberculosis genetic background into account. The 
association between drug resistance and diabetes has been confirmed in some2,22, 
but not all23 previous studies. One possible explanation for discrepant results could 
be the different populations that were studied, the size of the studies, the extent to 
which account was taken of factors other than diabetes status, and lack of clarity with 
respect to the time of diabetes testing4. Here, we ascertained the association between 
diabetes and drug resistance, adjusted for possible confounders, and discovered that 
the association holds true regardless of the M. tuberculosis strain’s phylogenetic 
background, and was not explained by clustering of drug-resistant strains among TB 
patients with diabetes, as pairwise distances were not shorter among the isolates 
from TB patients with diabetes (Supplementary figure S4.1). 
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Several factors might account for the observed association between diabetes and 
drug resistance mutations. First, people with diabetes might be at higher risk of 
nosocomial transmission of drug-resistant tuberculosis in low-resource settings24. 
Second, lower rifampicin plasma concentrations among diabetes patients that were 
found in some25 but not all26 studies might lead to acquisition of drug resistance. 
However, all isolates in our study were collected before start of treatment, and only 
26% of patients with a drug-resistant isolate reported an episode of previous TB 
treatment that might have resulted in acquired drug resistance mutations. Third, 
recent papers have found an interaction between drug resistance and cellular immu-
nometabolism27, and this interaction might be altered by diabetes. Fourth, similar to 
HIV28, reduced host defence in people with diabetes might increase the risk of 
developing active TB caused by Mycobacterium tuberculosis strains with drug 
resistance mutations associated with loss of fitness7. Merker et al. have shown that 
the presence of mutations thought to compensate for bacterial fitness deficits was 
associated with transmission success and higher drug resistance rates18. As people 
with diabetes seem more likely to become infected and progress to active TB disease 
following infection, recently transmitted drug-resistant strains with compensatory 
mutations could be overrepresented among TB patients with diabetes. However, larger 
recent studies have challenged the paradigm of loss of fitness associated with drug 
resistance mutations29,30 and we did not find differences in potential resistance-com-
pensating mutations among TB patients with diabetes compared to those without, 
neither did the pairwise distances indicate more recent transmission among TB 
patients with diabetes. The trend towards more fluoroquinolone resistance in TB 
patients with diabetes could be related to the prescription of broad-spectrum 
antibiotics, often fluoroquinolones, in patients with respiratory symptoms who are 
considered at increased risk of infections due to their diabetes31. 
The current study has several limitations. First, the analysis was hindered by a ‘noise’ 
signal related to the different origin and phylogenetic backgrounds. Resistance was 
more common in Peru, and diabetes more common in Indonesia. However, we used 
multilevel regression analysis to account for this and to increase the likelihood of 
finding true associations. Second, we were underpowered for subgroup analyses. For 
instance, it is hard to draw conclusions regarding specific resistance mutations. We 
hope that the findings in this study may serve as a starting point for further, targeted 
research, powered for questions that may have arisen as a result of the presented 
data. Thirdly, we could not prove if diabetes is associated with more transmission of 
drug-resistance as the sampling fraction of M. tuberculosis isolates in the two 
high-endemic settings was likely to be too low, making it difficult to identify 
transmission clusters. Besides higher rates of transmission, diabetes may also lead to 
more TB reactivation caused by drug-resistant strains.
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In summary, for the first time, we used M. tuberculosis whole genome sequencing data 
from two large cohorts of TB patients with and without diabetes to study the association 
between diabetes and genotypic drug resistance in TB patients. Diabetes was associated 
with an increased risk of disease caused by strains with resistance mutations, 
particularly those against rifampicin, but also against isoniazid, ethionamide and 
fluoro quinolones. Higher rates of resistance mutations among TB patients with 
diabetes were not explained by acquisition of drug resistance mutations during 
treatment, but might be related to increased susceptibility to opportunistic infection 
with drug-resistant TB. TB patients with diabetes should be prioritized for DST in 
settings where this is not performed for all patients.
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Supplementary methods
Whole genome sequencing
M. tuberculosis DNA was extracted after subculturing positive cultures on Ogawa 
(Indonesia) or Middlebrook 7H10-7H11 (Peru) solid medium using the cetyl trimethyl-
ammonium bromide (CTAB) method or the UltraClean® Microbial DNA Isolation Kit 
(MO BIO Laboratories, Carlsbad, CA)32.
M. tuberculosis DNA from 148 Indonesian isolates was sequenced on an Illumina 
HiSeq 2000 instrument using 2 x 100 bp paired-end reads at the Beijing Genome 
Institute in Hong Kong, and on an Illumina NextSeq500 instrument using 2 x 150 bp 
paired-end reads at the department of Human Genetics at the Radboudumc, Nijmegen, 
the Netherlands for the remaining 259 Indonesian isolates. M. tuberculosis DNA from 
Peruvian isolates was sequenced on an Illumina HiSeq 4000 instrument using 2 x 150 
bp paired-end reads at the Wellcome Centre for Human Genetics in Oxford, United 
Kingdom. Sequencing coverage was determined using the FastQC quality control tool 
version 0.10.1, and the Genome Analysis Toolkit33. The average coverage depth for the 
896 isolates was 110.7x, and the average percentage of bases covered by at least one 
read was 98.7%. Nine isolates failed the sequencing or mapping quality check and 
were excluded from further analysis. Sequencing quality control statistics are shown 
in Supplementary file 1.
We excluded the rrs C492T mutation from the resistance mutation database, because 
we considered this mutation to be a phylogenetic marker of the LAM3 sublineage 
rather than a resistance mutation34. We used an allele frequency cut-off of ≥ 30%, as 
previously proposed35. In addition, to identify potential compensatory mutations, 
variants were called with Breseq software, version 0.27.136 with a minimum threshold 
of 30x coverage. Mutations with low-quality evidence (i.e. possible mixed read 
alignment) were not included. We reported mutations according to the M. tuberculosis 
complex numbering system, based on the sequence of the reference strain, 
M. tuberculosis H37Rv37.
Phylogeny construction
For phylogeny construction, sequence reads were aligned to reference strain 
M. tuberculosis H37Rv, accession number NC_000962.3, and variants were called 
using Breseq, version 0.27.136. We extracted all 58,041 variable positions across the 
896 M. tuberculosis sequences and concatenated them into a multiple sequence 
alignment. Solely for the purpose of creating the phylogenetic tree, SNPs occurring in 
PE/PPE genes, genes related to mobile elements, as well as genes previously 
associated with drug resistance38 were removed. The remaining 56,654 SNPs were 
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used to construct the phylogenetic tree using PhyML version 3.019 using the HKY85 
model with four gamma-distributed rate-categories, and using a hundred bootstraps.
Statistical analysis
We used the glmer() function from the lme4 library39 to assess the association 
between diabetes and genotypic drug resistance. We used a multilevel regression 
model with robust standard errors to account for clustering within countries40. 
Diabetes, age, gender, HIV-infection, previous TB treatment, and M. tuberculosis 
lineage were included as categorical independent variables in the model. Age was 
included as a binary variable with the median age (36 years) as cut-off value for the 
best fit. The single patient with an M. bovis isolate was excluded from the multilevel 
logistic regression analysis, because it added complexity to the model and did not 
improve model fitness. Data were analysed using complete case analysis.
Significance of possible differences in resistance mutations between diabetes and 
non-diabetes TB patients were determined with the Fisher’s exact test or Chi-square 
test if there were more than two categories per variable. To assess the association 
between isoniazid and rifampicin resistance mutations and the presence of previously 
proposed accompanying compensatory mutations, stratified for diabetes comorbidity, 
for Indonesian and Peruvian isolates separately, we compared crude odds ratios with 
stratum-specific and Mantel-Haenszel odds ratios. The Breslow-Day test was used to 
test the significance of interaction between diabetes and the presence of potential 
compensatory mutations. All analyses were performed in R, version 3.5.2.
 
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 90
90 | Chapter 4
Supplementary figure
Fi
gu
re
 S
4
.1
. H
is
to
gr
am
s 
of
 m
in
im
um
 p
ai
rw
is
e 
ge
ne
tic
 d
is
ta
nc
es
 fo
r M
. t
ub
er
cu
lo
si
s 
is
ol
at
es
 fr
om
 p
at
ie
nt
s 
w
ith
 a
nd
 w
ith
ou
t d
ia
be
te
s.
0510152
0
2
5
3
0
3
5
4
0
<
=
12
13
 t
o
 5
0
5
1 
to
 1
0
0
10
1 
to
15
0
15
1 
to
2
0
0
2
0
1 
to
2
5
0
2
5
1 
to
3
0
0
3
0
1 
to
3
5
0
3
5
1 
to
4
0
0
4
0
1 
to
4
5
0
4
5
1 
to
5
0
0
5
0
1 
to
5
5
0
5
5
1 
to
6
0
0
6
0
1 
to
6
5
0
6
5
1 
to
70
0
70
1 
to
75
0
75
1 
to
8
0
0
>
 8
0
0
M
in
im
u
m
 p
ai
rw
is
e
 g
e
n
e
ti
c
 d
is
ta
n
c
e
 (
n
u
m
b
e
r 
o
f 
S
N
P
s)
0510152
0
2
5
3
0
<
=
12
13
 t
o
 5
0
5
1 
to
 1
0
0
10
1 
to
15
0
15
1 
to
2
0
0
2
0
1 
to
2
5
0
2
5
1 
to
3
0
0
3
0
1 
to
3
5
0
3
5
1 
to
4
0
0
4
0
1 
to
4
5
0
4
5
1 
to
5
0
0
5
0
1 
to
5
5
0
5
5
1 
to
6
0
0
6
0
1 
to
6
5
0
6
5
1 
to
70
0
70
1 
to
75
0
75
1 
to
8
0
0
>
 8
0
0
T
B
-D
M
T
B
-n
o
 D
M
T
B
-D
M
T
B
-n
o
 D
M
In
d
o
n
e
si
a
Percentage isolates within group 
P
e
ru
 
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 91
Diabetes is associated with genotypically drug-resistant tuberculosis | 91
4
Supplementary table
Ta
bl
e 
S
4
.1
.  
 As
so
ci
at
io
n 
be
tw
ee
n 
pu
ta
tiv
e 
co
m
pe
ns
at
or
y 
m
ut
at
io
ns
 a
nd
 is
on
ia
zi
d 
an
d 
rif
am
pi
ci
n 
re
si
st
an
ce
, s
tr
at
ifi
ed
  
by
 d
ia
be
te
s 
co
m
or
bi
di
ty
IN
H
-r
es
is
ta
nt
IN
H
- s
us
ce
pt
ib
le
O
dd
s 
ra
ti
o 
(9
5%
 C
I)
Cr
ud
e 
&
 M
an
te
l-
H
ae
ns
ze
l O
R
Indonesia
N
o 
di
ab
et
es
Co
m
pe
ns
at
or
y 
m
ut
at
io
n(
s)
3
31
0.
9 
(0
.3
-3
.3
)
0.
7 
(0
.2
-2
.6
)
& 0.
7 
(0
.2
-2
.5
)
N
o 
co
m
pe
ns
at
or
y 
m
ut
at
io
n
24
23
4
D
ia
be
te
s
Co
m
pe
ns
at
or
y 
m
ut
at
io
n(
s)
0
8
0.
6 
(0
.0
3-
10
.2
)
N
o 
co
m
pe
ns
at
or
y 
m
ut
at
io
n
10
97
Peru
N
o 
di
ab
et
es
Co
m
pe
ns
at
or
y 
m
ut
at
io
n(
s)
5
8
4.
0 
(1
.3
-1
2.
5)
*
3.
8 
(1
.3
-1
1.
0)
*
& 3.
7 
(1
.2
-1
0.
7)
*
N
o 
co
m
pe
ns
at
or
y 
m
ut
at
io
n
59
37
3
D
ia
be
te
s
Co
m
pe
ns
at
or
y 
m
ut
at
io
n(
s)
1
1
2.
5 
(0
.1-
43
.4
)
N
o 
co
m
pe
ns
at
or
y 
m
ut
at
io
n
12
30
R
IF
-r
es
is
ta
nt
R
IF
-s
us
ce
pt
ib
le
O
dd
s 
ra
ti
o 
(9
5%
 C
I)
Cr
ud
e 
&
 M
an
te
l-
H
ae
ns
ze
l O
R
Indonesia
N
o 
di
ab
et
es
Co
m
pe
ns
at
or
y 
m
ut
at
io
n(
s)
5
91
2.
1 
(0
.6
-7
.4
)
2.
5 
(1
.0
1-
6.
4)
*
& 2.
7 
(1
.1-
6.
8)
*
N
o 
co
m
pe
ns
at
or
y 
m
ut
at
io
n
5
19
1
D
ia
be
te
s
Co
m
pe
ns
at
or
y 
m
ut
at
io
n(
s)
5
27
3.
7 
(0
.9
-1
4.
6)
N
o 
co
m
pe
ns
at
or
y 
m
ut
at
io
n
4
79
Peru
N
o 
di
ab
et
es
Co
m
pe
ns
at
or
y 
m
ut
at
io
n(
s)
29
19
5
2.
4 
(1
.2
-4
.7
)*
2.
5 
(1
.3
-4
.6
)*
& 2.
5 
(1
.3
-4
.7
)*
N
o 
co
m
pe
ns
at
or
y 
m
ut
at
io
n
13
20
8
D
ia
be
te
s
Co
m
pe
ns
at
or
y 
m
ut
at
io
n(
s)
5
16
3.
3 
(0
.6
-1
9.
2)
N
o 
co
m
pe
ns
at
or
y 
m
ut
at
io
n
2
21
Sites  
combined
N
o 
di
ab
et
es
Co
m
pe
ns
at
or
y 
m
ut
at
io
n(
s)
34
28
6
2.
6 
(1
.5
-4
.8
)*
2.
8 
(1
.7
-4
.7
)*
& 2.
9 
(1
.7
-4
.8
)*
N
o 
co
m
pe
ns
at
or
y 
m
ut
at
io
n
18
39
9
D
ia
be
te
s
Co
m
pe
ns
at
or
y 
m
ut
at
io
n(
s)
10
43
3.
9 
(1
.3
-1
1.
3)
*
N
o 
co
m
pe
ns
at
or
y 
m
ut
at
io
n
6
10
0
N
O
TE
. I
so
ni
az
id
 a
nd
 ri
fa
m
pi
ci
n 
re
si
st
an
ce
 w
er
e 
de
fin
ed
 a
s 
an
y 
m
ut
at
io
ns
 in
 g
en
es
 k
no
w
n 
to
 c
on
fe
r r
es
is
ta
nc
e 
to
 is
on
ia
zi
d 
an
d 
rif
am
pi
ci
n 
ac
co
rd
in
g 
to
 T
B 
Pr
of
ile
r 
(1
9)
. F
or
 th
e 
to
p-
ha
lf 
of
 th
e 
ta
bl
e,
 re
la
tin
g 
to
 is
on
ia
zi
d 
re
si
st
an
ce
, c
om
pe
ns
at
or
y 
m
ut
at
io
ns
 c
on
ce
rn
ed
 a
ny
 m
ut
at
io
ns
 in
 u
bi
A 
an
d 
th
e 
ah
pC
 p
ro
m
ot
or
 re
gi
on
; f
or
 
th
e 
bo
tt
om
-h
al
f o
f t
he
 ta
bl
e,
 re
la
tin
g 
to
 ri
fa
m
pi
ci
n 
re
si
st
an
ce
, c
om
pe
ns
at
or
y 
m
ut
at
io
ns
 c
on
ce
rn
ed
 a
ny
 m
ut
at
io
ns
 in
 rp
oA
, r
po
B 
ou
ts
id
e 
th
e 
rif
am
pi
ci
n 
re
si
st
an
ce
-
de
te
rm
in
in
g 
re
gi
on
, a
nd
 rp
oC
. *
 P
-v
al
ue
 <0
.0
5
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 92
92 | Chapter 4
References
1. Pan S-C, Ku C-C, Kao D, Ezzati M, Fang C-T, Lin H-H. Effect of diabetes on tuberculosis control in 13 
countries with high tuberculosis: a modelling study. The Lancet Diabetes & Endocrinology 2015: 3(5): 
323-330.
2. Perez-Navarro LM, Restrepo BI, Fuentes-Dominguez FJ, Duggirala R, Morales-Romero J, Lopez-Alvarenga 
JC, Comas I, Zenteno-Cuevas R. The effect size of type 2 diabetes mellitus on tuberculosis drug resistance 
and adverse treatment outcomes. Tuberculosis (Edinb) 2017: 103: 83-91.
3. Liu Q, Li W, Xue M, Chen Y, Du X, Wang C, Han L, Tang Y, Feng Y, Tao C, He JQ. Diabetes mellitus and the 
risk of multidrug resistant tuberculosis: a meta-analysis. Sci Rep 2017: 7(1): 1090.
4. Huangfu PU-G, C.; Golub, J.; Pearson, F.; Critchley, J. The effects of diabetes on tuberculosis treatment 
outcomes: an updated systematic review and meta-analysis. INTERNATIONAL JOURNAL OF TUBERCULOSIS 
AND LUNG DISEASE 2019.
5. Riza AL, Pearson F, Ugarte-Gil C, Alisjahbana B, van de Vijver S, Panduru NM, Hill PC, Ruslami R, Moore D, 
Aarnoutse R, Critchley JA, van Crevel R. Clinical management of concurrent diabetes and tuberculosis 
and the implications for patient services. The Lancet Diabetes & Endocrinology 2014: 2(9): 740-753.
6. Tegegne BS, Mengesha MM, Teferra AA, Awoke MA, Habtewold TD. Association between diabetes 
mellitus and multi-drug-resistant tuberculosis: evidence from a systematic review and meta-analysis. 
Syst Rev 2018: 7(1): 161.
7. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem 
E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GKH, Pasipanodya JG, Rodrigues 
C, Clark TG, Sirgel FA, Esmail A, Lin H-H, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, 
Horsburgh CR, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, 
Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. The epidemiology, pathogenesis, 
transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and 
incurable tuberculosis. The Lancet Respiratory Medicine 2017: 5(4): 291-360.
8. Walker TM, Merker M, Kohl TA, Crook DW, Niemann S, Peto TE. Whole genome sequencing for M/XDR 
tuberculosis surveillance and for resistance testing. Clin Microbiol Infect 2017: 23(3): 161-166.
9. van Crevel R, Dockrell HM. TANDEM: understanding diabetes and tuberculosis. The Lancet Diabetes & 
Endocrinology 2014: 2(4): 270-272.
10. Grint D, Alisjhabana B, Ugarte-Gil C, Riza AL, Walzl G, Pearson F, Ruslami R, Moore DAJ, Ioana M, McAllister 
S, Ronacher K, Koeseomadinata RC, Kerry-Barnard SR, Coronel J, Malherbe ST, Dockrell HM, Hill PC, Van 
Crevel R, Critchley JA, consortium T. Accuracy of diabetes screening methods used for people with 
tuberculosis, Indonesia, Peru, Romania, South Africa. Bull World Health Organ 2018: 96(11): 738-749.
11. Ugarte-Gil C, Alisjahbana B, Ronacher K, Riza AL, Koesoemadinata RC, Malherbe ST, Cioboata R, Llontop 
JC, Kleynhans L, Lopez S, Santoso P, Marius C, Villaizan K, Ruslami R, Walzl G, Panduru NM, Dockrell HM, 
Hill PC, Mc Allister S, Pearson F, Moore DAJ, Critchley JA, van Crevel R, Consortium T. Diabetes mellitus 
among pulmonary tuberculosis patients from four TB-endemic countries: the TANDEM study. Clin Infect 
Dis 2019.
12. WHO. Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus: abbreviated report of a 
WHO consultation. Geneva, Switzerland: World Health Organization; 2011.
13. Huangfu P, Laurence YV, Alisjahbana B, Ugarte-Gil C, Riza AL, Walzl G, Ruslami R, Moore DAJ, Ioana M, 
McAllister S, Ronacher K, Koesoemadinata RC, Grint D, Kerry S, Coronel J, Malherbe ST, Griffiths U, 
Dockrell HM, Hill PC, van Crevel R, Pearson F, Critchley JA. Point of care HbA1c level for diabetes mellitus 
management and its accuracy among tuberculosis patients: a study in four countries. Int J Tuberc Lung 
Dis 2019: 23(3): 283-292.
14. Critchley JA. Appendices to “Diabetes screening in tuberculosis patients: a diagnostic accuracy analysis 
of risk scores and laboratory methods in Indonesia, Peru, Romania and South Africa”. 2018.
15. Coll F, Preston M, Guerra-Assuncao JA, Hill-Cawthorn G, Harris D, Perdigao J, Viveiros M, Portugal I, 
Drobniewski F, Gagneux S, Glynn JR, Pain A, Parkhill J, McNerney R, Martin N, Clark TG. PolyTB: a genomic 
variation map for Mycobacterium tuberculosis. Tuberculosis (Edinb) 2014: 94(3): 346-354.
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 93
Diabetes is associated with genotypically drug-resistant tuberculosis | 93
4
16. Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, Barry CE, 3rd, Stover CK. Compensatory ahpC gene 
expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996: 272(5268): 1641-1643.
17. Cohen KA, Abeel T, Manson McGuire A, Desjardins CA, Munsamy V, Shea TP, Walker BJ, Bantubani N, 
Almeida DV, Alvarado L, Chapman SB, Mvelase NR, Duffy EY, Fitzgerald MG, Govender P, Gujja S, Hamilton 
S, Howarth C, Larimer JD, Maharaj K, Pearson MD, Priest ME, Zeng Q, Padayatchi N, Grosset J, Young SK, 
Wortman J, Mlisana KP, O’Donnell MR, Birren BW, Bishai WR, Pym AS, Earl AM. Evolution of Extensively 
Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of 
Mycobacterium tuberculosis Isolates from KwaZulu-Natal. PLoS Med 2015: 12(9): e1001880.
18. Merker M, Barbier M, Cox H, Rasigade JP, Feuerriegel S, Kohl TA, Diel R, Borrell S, Gagneux S, Nikolayevskyy 
V, Andres S, Nubel U, Supply P, Wirth T, Niemann S. Compensatory evolution drives multidrug-resistant 
tuberculosis in Central Asia. Elife 2018: 7.
19. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate 
maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 2010: 59(3): 307-321.
20. Ronacher K, van Crevel R, Critchley JA, Bremer AA, Schlesinger LS, Kapur A, Basaraba R, Kornfeld H, 
Restrepo BI. Defining a Research Agenda to Address the  Converging Epidemics of Tuberculosis and 
Diabetes. Chest 2017: 152(1): 174-180.
21. Naidoo CC, Pillay M. Fitness-compensatory mutations facilitate the spread of drug-resistant F15/LAM4/
KZN and F28 Mycobacterium tuberculosis strains in KwaZulu-Natal, South Africa. Journal of Genetics 
2017: 96(4): 599-612.
22. Hsu AH, Lee JJ, Chiang CY, Li YH, Chen LK, Lin CB. Diabetes is associated with drug-resistant tuberculosis 
in Eastern Taiwan. Int J Tuberc Lung Dis 2013: 17(3): 354-356.
23. Leung CC, Yew WW, Mok TYW, Lau KS, Wong CF, Chau CH, Chan CK, Chang KC, Tam G, Tam CM. Effects of 
diabetes mellitus on the clinical presentation and treatment response in tuberculosis. Respirology 2017: 
22(6): 1225-1232.
24. van Crevel R, van de Vijver S, Moore DAJ. The global diabetes epidemic: what does it mean for infectious 
diseases in tropical countries? The Lancet Diabetes & Endocrinology 2017: 5(6): 457-468.
25. Alkabab Y, Keller S, Dodge D, Houpt E, Staley D, Heysell S. Early interventions for diabetes related 
tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. BMC Infect Dis 
2017: 17(1): 125.
26. Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, van Crevel R. Pharmacoki-
netics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob 
Agents Chemother 2010: 54(3): 1068-1074.
27. Howard NC, Marin ND, Ahmed M, Rosa BA, Martin J, Bambouskova M, Sergushichev A, Loginicheva E, 
Kurepina N, Rangel-Moreno J, Chen L, Kreiswirth BN, Klein RS, Balada-Llasat JM, Torrelles JB, Amarasinghe 
GK, Mitreva M, Artyomov MN, Hsu FF, Mathema B, Khader SA. Mycobacterium tuberculosis carrying a 
rifampicin drug resistance mutation reprograms macrophage metabolism through cell wall lipid 
changes. Nat Microbiol 2018: 3(10): 1099-1108.
28. Mesfin YM, Hailemariam D, Biadgilign S, Kibret KT. Association between HIV/AIDS and multi-drug 
resistance tuberculosis: a systematic review and meta-analysis. PLoS One 2014: 9(1): e82235.
29. Becerra MC, Huang C-C, Lecca L, Bayona J, Contreras C, Calderon R, Yataco R, Galea J, Zhang Z, Atwook S, 
Cohen T, Mitnick CD, Farmer P, Murray M. 2018.
30. Liu Q, Zuo T, Xu P, Jiang Q, Wu J, Gan M, Yang C, Prakash R, Zhu G, Takiff HE, Gao Q. Have compensatory 
mutations facilitated the current epidemic of multidrug-resistant tuberculosis? Emerg Microbes Infect 
2018: 7(1): 98.
31. Long R, Chong H, Hoeppner V, Shanmuganathan H, Kowalewska-Grochowska K, Shandro C, Manfreda J, 
Senthilselvan A, Elzainy A, Marrie T. Empirical treatment of community-acquired pneumonia and the 
development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009: 48(10): 1354-1360.
32. Somerville W, Thibert L, Schwartzman K, Behr MA. Extraction of Mycobacterium tuberculosis DNA: a 
question of containment. J Clin Microbiol 2005: 43(6): 2996-2997.
33. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel 
S, Daly M, DePristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next- 
generation DNA sequencing data. Genome Res 2010: 20(9): 1297-1303.
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 94
94 | Chapter 4
34. Tudo G, Rey E, Borrell S, Alcaide F, Codina G, Coll P, Martin-Casabona N, Montemayor M, Moure R, Orcau 
A, Salvado M, Vicente E, Gonzalez-Martin J. Characterization of mutations in streptomycin-resistant 
Mycobacterium tuberculosis clinical isolates in the area of Barcelona. J Antimicrob Chemother 2010: 
65(11): 2341-2346.
35. Black PA, de Vos M, Louw GE, van der Merwe RG, Dippenaar A, Streicher EM, Abdallah AM, Sampson SL, 
Victor TC, Dolby T, Simpson JA, van Helden PD, Warren RM, Pain A. Whole genome sequencing reveals 
genomic heterogeneity and antibiotic purification in Mycobacterium tuberculosis isolates. BMC 
Genomics 2015: 16(1): 857.
36. Barrick JE. Identifying structural variation in haploid microbial genomes from short-read resequencing 
data using breseq. BMC Genomics 2014.
37. Andre E, Goeminne L, Cabibbe A, Beckert P, Kabamba Mukadi B, Mathys V, Gagneux S, Niemann S, Van 
Ingen J, Cambau E. Consensus numbering system for the rifampicin resistance-associated rpoB gene 
mutations in pathogenic mycobacteria. Clin Microbiol Infect 2017: 23(3): 167-172.
38. Coll F, McNerney R, Preston MD, Guerra-Assuncao JA, Warry A, Hill-Cawthorne G, Mallard K, Nair M, 
Miranda A, Alves A, Perdigao J, Viveiros M, Portugal I, Hasan Z, Hasan R, Glynn JR, Martin N, Pain A, Clark 
TG. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome 
Med 2015: 7(1): 51.
39. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Usinglme4. Journal of 
Statistical Software 2015: 67(1).
40. Austin PC, Merlo J. Intermediate and advanced topics in multilevel logistic regression analysis. Stat Med 
2017: 36(20): 3257-3277.
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 95
Diabetes is associated with genotypically drug-resistant tuberculosis | 95
4
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 96
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 97
Tuberculosis disease phenotype
and transmission
PART TWO
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 98
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 99
Large-scale genomic analysis shows 
association between homoplastic genetic 
variation in Mycobacterium tuberculosis 
genes and meningeal or pulmonary 
tuberculosis
Carolien Ruesen, Lidya Chaidir, Arjan van Laarhoven, Sofiati Dian, 
Ahmad Rizal Ganiem, Hanna Nebenzahl-Guimaraes, Martijn A. Huynen, 
Bachti Alisjahbana, Bas E. Dutilh, Reinout van Crevel.
BMC Genomics. 2018; 19:122.
5
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 100
100 | Chapter 5
Abstract
Background
Meningitis is the most severe manifestation of tuberculosis. It is largely unknown why 
some people develop pulmonary TB (PTB) and others TB meningitis (TBM); we 
examined if the genetic background of infecting M. tuberculosis strains may be 
relevant.
Methods
We whole-genome sequenced M. tuberculosis strains isolated from 322 HIV-negative 
tuberculosis patients from Indonesia and compared isolates from patients with TBM (n 
= 106) and PTB (n = 216). Using a phylogeny-adjusted genome-wide association 
method to count homoplasy events we examined phenotype-related changes at 
specific loci or genes in parallel branches of the phylogenetic tree. Enrichment scores 
for the TB phenotype were calculated on single nucleotide polymorphism (SNP), gene, 
and pathway level. Genetic associations were validated in an independent set of 
isolates.
Results
Strains belonged to the East-Asian lineage (36.0%), Euro-American lineage (61.5%), 
and Indo-Oceanic lineage (2.5%). We found no association between lineage and 
phenotype (Chi-square = 4.556; p = 0.207). Large genomic differences were observed 
between isolates; the minimum pairwise genetic distance varied from 17 to 689 SNPs. 
Using the phylogenetic tree, based on 28,544 common variable positions, we selected 
54 TBM and 54 PTB isolates in terminal branch sets with distinct phenotypes. Genetic 
variation in Rv0218, and absence of Rv3343c, and nanK were significantly associated 
with disease phenotype in these terminal branch sets, and confirmed in the validation 
set of 214 unpaired isolates.
Conclusions
Using homoplasy counting we identified genetic variation in three separate genes to 
be associated with the TB phenotype, including one (Rv0218) which encodes a 
secreted protein that could play a role in host-pathogen interaction by altering 
pathogen recognition or acting as virulence effector.
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 101
M. tuberculosis from pulmonary and meningeal tuberculosis patients | 101
5
Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a major global 
health problem1. Active TB mostly affects the lungs but may also spread to other 
organs. TB meningitis (TBM), which represents approximately 1–5% of all TB cases, is 
the most severe manifestation of TB, resulting in death or neurological disability in 
about half of those affected2,3. It is largely unknown why certain people develop 
pulmonary TB (PTB) and others TBM. Host immune-related factors clearly play an 
important role, as shown by the increased risk of TBM for patients with advanced HIV 
infection, and the overrepresentation of young children among TBM patients. Host 
genetic factors may also play a role; single studies have linked susceptibility to TBM 
with variation in candidate genes4–8.
Besides the host, genetic diversity of infecting M. tuberculosis strains may also affect 
disease phenotype. Even though M. tuberculosis is considered a clonal organism, 
there is considerable genetic variation in the genomes of infecting M. tuberculosis 
isolates9,10. Epidemiological studies have reported significant differences among 
M. tuberculosis lineages in terms of virulence11,12, transmission9,13,14, progression to 
active disease after infection15, and response to treatment16,17. In vitro studies have 
supported these findings by showing M. tuberculosis genotype-specific differences in 
the human immune response18–21.
Animal studies have shown that M. tuberculosis strains differ in their ability to invade 
the central nervous system (CNS). Five M. tuberculosis genes (Rv0311 (unknown 
function), Rv0805 (intermediary metabolism and respiration), pknD (protein kinase D), 
Rv0986 (cell wall and cell processes), and MT3280 (unknown function)) have been 
associated with invasion or survival in the CNS but not in lung tissues in mice22. 
Especially M. tuberculosis pknD was associated with invasion of brain, but not lung 
epithelia in guinea pigs23, as was confirmed by another study showing that pknD 
vaccination offered significant protection against bacterial dissemination to the brain 
in guinea pigs24. Similarly, in mice, clinical isolates from TBM patients disseminated 
extensively to cause meningitis, whereas M. tuberculosis H37Rv and clinical isolates 
from PTB patients did not25. In rabbits, production of phenolic glycolipid has been 
linked with the increased propensity of East-Asian/Beijing strains to cause TBM26. 
Finally, four M. tuberculosis genes were crucial for invading an artificial blood brain 
barrier in an in vitro model using primary human brain microvascular endothelial cells: 
PE-PGRS18 (unknown function), Rv0987 (cell wall and cell processes), grcC2 
(intermediary metabolism and respiration), and PPE29 (unknown function)27.
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Much less is known about the role of M. tuberculosis genotype in TBM in humans. 
Most studies have examined associations of M. tuberculosis lineage with disease 
phenotype. Compared to other lineages, strains belonging to the East-Asian lineage 
were associated with extrapulmonary tuberculosis in one study28, but not in another29, 
while other studies found no association of M. tuberculosis lineage and disease 
localisation30,31. Specifically looking at TBM, one study from Vietnam found the 
Euro-American lineage to be associated with PTB rather than TBM32. Only one study 
used whole genome sequencing to compare strains from TBM and PTB patients; 
large-scale and smaller genomic rearrangements, inversions, indels and single 
nucleotide polymorphisms (SNPs) in eight cerebrospinal fluid (CSF)-derived strains 
were not found in 69 comparison respiratory strains isolated from independent 
sputum samples33. In the current study, we used a much larger set of isolates and a 
novel approach to examine the effect of the M. tuberculosis genotype on the 
susceptibility to TBM. We compared M. tuberculosis genomes isolated from 216 PTB 
patients and 106 TBM patients from Indonesia, all HIV-negative, to detect homoplastic 
genetic variants associated with either PTB or TBM.
Results
Lineage distribution and phylogeny construction
M. tuberculosis isolates from established patient cohorts in Bandung, Indonesia were 
selected for whole genome sequencing. All available M. tuberculosis strains isolated 
from HIV-negative TBM patients and randomly selected strains from twice as many 
PTB patients from the same setting were included, one strain was selected per patient. 
Compared to the 216 PTB patients, the 106 TBM patients were from a similar ethnic 
background, but slightly younger, more often male, and more often previously treated 
for TB (Table S5.1). Based on a 62-SNP barcode34 61.5% of the strains belonged to the 
Euro-American lineage (63.4% for PTB; 57.5% for TBM), 36% to the East-Asian lineage 
(33.3% for PTB; 41.5% for TBM), and 2.5% to the Indo-Oceanic lineage (3.2% for PTB; 
0.9% for TBM). The lineage distribution did not differ significantly for strains isolated 
from TBM compared to PTB patients (Chi-square = 3.230; p = 0.199).
A phylogenetic tree was constructed based on 28,544 variable common nucleotide 
positions among the 322 M. tuberculosis isolates. The phylogeny showed that the TBM 
phenotype was not restricted to a certain M. tuberculosis lineage; instead it arose 
many times independently (Figure 5.1). In addition, the tree showed a high degree of 
strain heterogeneity. On average, two strains differed by about 1,000 SNPs, and this 
pairwise distance did not differ among PTB and TBM strains (data not shown), 
indicating that there was equal genetic diversity within PTB and within TBM strains. In 
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addition, the minimum pairwise genetic distance varied from 17 to 689 SNPs (data not 
shown), indicating that there was no clustering of strains (≤12 SNPs distance35). For 
TBM strains the minimum genetic distance ranged from 17 to 1,785, and for PTB strains 
from 31 to 803 SNPs (data not shown).
TB phenotype-associated genetic variations
Genome-wide association approaches for bacteria can broadly be categorised into 
allele counting and homoplasy counting methods36. Allele counting methods are 
based on the overrepresentation of an allele at the same site in cases relative to 
controls, introducing a risk of false-positive findings due to population stratification. 
Homoplasy counting on the other hand, counts repeated and independently emerging 
mutations that occur more often in branches of cases relative to controls. In the current 
study, we used a two-step approach: in the discovery phase, we used homoplasy 
Figure 5.1. Phylogenetic tree of 322 M. tuberculosis strains isolated from TBM (red braches 
and leaves) and PTB (black branches and leaves) patients. The highlighted branches indicate 
the 108 strains in 47 terminal branch sets, together comprising the discovery set. The purple 
stars indicate the origin of the SNP in Rv0218 according to the ancestral reconstruction. 
The grey and black triangles indicate the isolates in which nanK and/or Rv3433c are absent.
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counting by identifying terminal branch sets (TBSs) to maximize power to identify true 
associations with the TB disease phenotype, uncorrected for multiple tests. In the 
validation phase we examined associations identified in the discovery phase using 
allele counting with correction for multiple testing and for phylogenetic bias to distinguish 
true associations from false positives, and performed ancestral reconstruction to 
remove possible phylogenetic bias. To divide the genomes in a discovery and a 
validation set, we identified isolates in terminal branch pairs, trios and quartets (i.e. 
separated at a terminal or near terminal branch in the phylogenetic tree) with distinct 
phenotypes (Figure 5.2). Genetic differences between isolates within a TBS provide 
the strongest, homoplasy-corrected possible association with the phenotype.
The phylogenetic tree revealed a total of 47 TBSs containing 108 paired strains: 54 TBM 
and 54 PTB strains that make up the discovery set. The merged SNP lists consisted 
of 6,488 variable positions with the corresponding nucleotides for the 108 strains 
(Additional file 2). Using the homoplasy-based association analysis, we found individual 
nucleotide positions, genes, or pathways where TB disease phenotype- associated 
mutations repeatedly occur in different branches of the phylogenetic tree. These included 
9 SNPs, 5 genes, and 1 pathway (Table 5.1).
We used the remaining 214 (52 TBM and 162 PTB) isolates not belonging to any of the 
TBSs (validation set) to verify these results. The discovery set showed a total of 6,488 
different non-synonymous SNPs involving 6,483 dimorphic sites and 5 trimorphic sites 
across 2,778 genes; the validation set a total of 12,211 different nonsynonymous SNPs 
involving 12,185 dimorphic sites and 26 trimorphic sites across 3,359 genes (Additional 
file 3). There was an overlap of 2,694 non-synonymous SNPs and 1,564 affected genes. 
Out of 9 SNPs significantly associated with either TBM or PTB in the discovery set, one 
was confirmed in the validation set; the mutation in Rv0218. Similarly, out of 5 genes 
harbouring genetic variation associated with the TB phenotype, Rv0218 was validated 
in the validation set (Table 5.1, Figure S5.1 and Figure S5.2). The pathway (ethylbenzene 
degradation) identified in the discovery set was not confirmed in the validation set.
To correct for potential phylogenetic bias in the validation set, we reconstructed the 
ancestral state for the SNP in Rv0218 and compared the ratio of TBM vs. PTB isolates 
after the occurrence of this particular SNP with the ratio of TBM vs. PTB prior to the 
occurrence of this SNP in the validation set (Figure 5.1 and Figure S5.3). Three branches 
with back mutations (2 TBM, 1 PTB branch) were excluded from the analysis. Among 
the 33 nodes / leaves where the SNP occurred, the average unweighted proportion of 
TBM isolates among the child branches was 44.7%; among 166 isolates in the 
validation set not harbouring this SNP, 29 (17.5%) were from TBM patients (Table S5.2). 
The Z-score for the difference between proportions was −3.83 (p < 0.001).
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 105
M. tuberculosis from pulmonary and meningeal tuberculosis patients | 105
5
Fi
gu
re
 5
.2
. H
om
op
la
sy
-b
as
ed
 a
ss
oc
ia
tio
n 
an
al
ys
is
; d
et
ec
tio
n 
of
 m
ut
at
io
ns
 o
cc
ur
rin
g 
al
on
g 
di
sp
ar
at
e 
lo
ca
tio
ns
 in
 th
e 
ph
yl
og
en
et
ic
 tr
ee
. L
eft
 p
ar
t (
A)
: 
sc
he
m
at
ic
 e
xa
m
pl
e 
of
 a
 tr
ee
 c
on
ta
in
in
g 
tw
o 
te
rm
in
al
 b
ra
nc
h 
se
ts
 (T
BS
s)
 w
ith
 a
 h
om
op
la
st
ic
 S
N
P.
 R
ig
ht
 p
ar
t (
B)
: s
ch
em
at
ic
 o
ve
rv
ie
w
 o
f t
he
 c
om
po
si
tio
n 
of
 th
e 
47
 te
rm
in
al
 b
ra
nc
h 
se
ts
.A
A
A
 
A
A
C
 
A
A
A
 
A
A
A
 
A
A
A
 
A
A
A
 
A
A
A
 
A
A
A
 
A
A
A
 
A
A
C
 
A
A
A
 
A
A
A
 
A
 (
T
B
M
) 
B
 (
P
T
B
) 
C
 
D
 
E
 
F
 
G
 
H
 I 
(T
B
M
) 
J
 (
P
T
B
) 
K
 
L
 
T
B
M
 
P
T
B
 
T
B
M
 
P
T
B
 
P
T
B
 
T
B
M
 
P
T
B
P
T
B
P
T
B
 
3
5
 t
e
rm
in
al
 
b
ra
n
c
h
 p
ai
rs
 
10
 t
e
rm
in
al
 
b
ra
n
c
h
 t
ri
o
s 
2
 t
e
rm
in
al
 b
ra
n
c
h
 
q
u
ar
te
ts
 
A
B
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 106
106 | Chapter 5
De novo genome assembly
Next, we used a reference-free de novo genome assembly approach to examine 
associations between presence/absence of genes and the TB phenotype, and to study 
sequences not present in the reference genome. The list of annotated coding 
sequences for the 108 assembled genomes in the discovery set contained 3,032 
distinct genes that were present in at least one, but not all of the strains (Additional file 
8). The permutation analysis revealed six genes that were significantly associated with 
the TB phenotype. Two of these genes, Rv3433c and nanK, were validated in the 
Table 5.1. Significant SNPs, genes, and pathways identified by homoplasy counting.
SNP-level
Discovery dataset (N=108) Validation dataset (N=214)
Strains with SNP (N) Strains with SNP (N)
Gene  
(Rv-number)
Nucleotide 
change
TBM
(N=54)
PTB
(N=54)
P-value TBM
(N=52)
PTB
(N=162)
P-value^
Unnamed (Rv0218) 261,869CT 25 10 0.002 21 24 0.001
PPE54 (Rv3343c) 3,736,628TG 22 35 0.008 27 87 0.472
PEPGRS19 (Rv1067c) 1,190,093AC 2 11 0.01 5 18 0.487
PEPGRS44 (Rv2591) 2,922,848AT 0 6 0.01 2 7 0.625
PPE3 (Rv0280) 340,372TC 2 10 0.025 4 13 0.589
PEPGRS9 (Rv0746) 836,272AG 7 1 0.029 3 9 0.603
PEPGRS26 (Rv1441c) 16,18,978TC 0 5 0.032 2 3 0.369
Unnamed (Rv0064) 713,36GC 24 34 0.034 29 98 0.355
PEPGRS18 (Rv0980c) 1,095,644CT 0 4 0.044 2 2 0.238
Gene-level SNPs in gene (N) SNPs in gene (N)
Gene (Rv number) TBM PTB P-value TBM PTB P-value
PEPGRS19 (Rv1067c) 2 13 0.004 5 22 0.318
Unnamed (Rv0218) 27 11 0.007 21 32 0.001
PEPGRS26 (Rv1441c) 0 5 0.031 2 4 0.491
glmS (Rv3436c) 0 5 0.031 0 0 n.a.
Unnamed (Rv3740c) 0 4 0.05 3 0 0.011
Pathway-level Genes with mutation (N) Genes with mutation (N)
Pathway name TBM PTB P-value TBM PTB P-value
Ethylbenzene degradation 68 54 0.032 65 224 0.071
NOTE. P-values are based on permutation analysis; bold p-values indicate validated, Bonferroni-corrected 
significant enrichment  ^ P-value thresholds in the validation set were Bonferroni-corrected for multiple 
testing by dividing them by the number of top hits in the discovery set: SNP-level: p < 0.05/9; gene-level: 
p < 0.05/5; pathway-level: p < 0.05/1
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validation set: absence of these genes was associated with TBM (Figure 5.1, Table 5.2, 
Additional file 9). Together with Rv0218 they bring the total number of genes associated 
with the TB phenotype to three.
Effect of detected SNPs on protein function and predicted function  
of phenotype-associated genes
We used published algorithms to predict the effects of identified mutations on protein 
structure and function. The SNP in Rv0218, a protein predicted to have transmembrane 
helices, likely leads to a decrease of stability of the protein (Table S5.3). For Rv3433c, 
and nanK no transmembrane helices or signaling peptides were predicted.
Table 5.2.  Significant genes identified by the de novo genome assembly analysis
Discovery dataset (n=108) Validation dataset (n=214)
Strains with CDS present (N) Strains with CDS present (N)
Coding sequence TBM
(n=54)
PTB
(n=54)
P-value TBM
(n=52)
PTB
(n=162)
P-value^
Bifunctional NAD(P)H-hydrate 
repair enzyme Nnr (Rv3433c)
36 47 0.011 34 144 0.002
TMAO/DMSO reductase 46 53 0.016 49 152 0.592
Antitoxin/MT2731 33 44 0.017 37 130 0.206
NPCBM-associated, NEW3 
domain of alpha-galactosidase
15 6 0.022 14 19 0.063
Oxidoreductase molybdopterin 
binding domain protein
11 3 0.028 7 13 0.197
N-acetylmannosamine kinase 
(nanK)
44 51 0.036 44 157 0.001
NOTE. P-values are based on permutation analysis; bold p-values indicate validated significant enrichment 
^ P-value thresholds in the validation set were Bonferroni-corrected for multiple testing by dividing them by 
the number of top hits in the discovery set: p < 0.05/6
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Discussion
To determine whether M. tuberculosis genetic variation is associated with the TB 
disease phenotype, we compared M. tuberculosis whole genome sequences from 216 
PTB and 106 TBM patients and searched for homoplastic mutations. We identified 
three genes in M. tuberculosis (Rv0218, Rv3433c, and nanK) to be associated with 
either TBM or PTB. Previous experimental studies have assessed the importance 
of Rv0218. This secretome gene encodes for a protein with multiple predicted 
transmembrane regions and a C-terminal molybdopterin binding domain that is often 
found in oxidoreductases and was shown to be essential for M. tuberculosis in vivo 
growth in C57BL/6 J mouse spleen37. The SNP in Rv0218 is predicted to decrease the 
stability of the respective protein. Secretome genes potentially influence pathogen 
recognition and host-pathogen interaction38. If mutations in these genes alter the 
appearance of the M. tuberculosis surface, this could provide a mechanism by which 
M. tuberculosis could evade the immune response and enable dissemination to 
extrapulmonary sites. Secretome genes are more likely to contain false-positive 
associations as they are under selective pressure from the immune system and 
phages39. How Rv3433c and nanK could be related to the TB phenotype is not obvious, 
although functions have been predicted based on homology detection.
To our knowledge, this is only the second attempt to relate M. tuberculosis genetic 
variation to the TB disease phenotype in humans on a genome-wide scale. The other 
study, by Saw et al. showed large-scale rearrangements, short translocations, 
inversions, indels and SNPs in eight strains cultured from CSF33. Non-synonymous 
SNPs in eight genes (embR, lppD, PE-PGRS10, PE-PGRS19, PE-PGRS21, PE-PGRS49, 
PPE58, and Rv0278c) were found in at least four of the eight CSF-derived strains, and 
in none of 69 strains isolated from sputum33. We did not confirm this in our set of 
isolates, although PE-PGRS19 was associated with the TB phenotype in the discovery 
set. Moreover, we used a two-step approach, based on homoplasy counting as well as 
allele counting with a correction for phylogenetic bias to find mutations associated 
with the TB phenotype, and we performed ancestral reconstruction for the most 
discriminative SNP. Unlike a previous study from Vietnam32, we found no association 
between M. tuberculosis lineage and TBM. This is no surprise given the genetic 
diversity even within M. tuberculosis lineages9, and the observed pattern of TBM 
isolates scattered across the phylogenetic tree.
In concordance with previous findings9, we found considerable genetic diversity in M. 
tuberculosis in the current study. Two isolates differed on average by 1,000 SNPs, and 
this did not differ among PTB isolates and among TBM isolates. In addition, we did not 
observe any clustering, defined as two isolates differing by 12 SNPs or less35. The lack 
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of clustering is probably a result of the low sampling fraction in this urban setting with 
thousands of incident TB cases each year.
Theoretically, two scenarios could explain the role of M. tuberculosis genetic variation 
in the development of TBM after infection with M. tuberculosis. First, upon infection 
the M. tuberculosis strain may carry certain mutations associated with dissemination 
and penetration of the blood-brain barrier. Second, a subpopulation of bacteria in the 
lungs of a PTB patient may develop such mutations, though it was recently shown for 
bacterial meningitis caused by S. pneumonia or N. meningitides that there is no 
evidence for differential selection between blood and CSF, and that any mutations 
between these two niches are likely due to mutation hotspots or forms of diversifying 
selection common to both niches40. However, similar to the findings of Saw et al.33, the 
genetic variants that we found to be associated with the TB disease phenotype were 
not exclusive for TBM or PTB, nor were they consistently present in all TBM or PTB 
strains. Therefore it seems that genetic variants may be part of a complex, multifactorial 
process leading to this devastating manifestation of TB, in which the human genotype 
or phenotype equally plays an important role32,41.
This is the second, and by far largest study using whole genome sequencing to link 
M. tuberculosis genotype to TBM. In this large cohort of well-characterised patients we 
studied strains from HIV-negative, adult patients to control for the two most important 
known risk factors for TBM. In addition, both patient groups were similar with regard 
to gender, ethnicity, and previous episodes of TB. The de novo assembly adds to the 
strengths of this study because it enabled us to examine regions of the genome that 
do not map to the reference genome, allowing the investigation of associations 
between genetic variation in these genomic regions and the TB disease phenotype. 
The homoplasy-based association analysis has proven to be a successful method to 
detect M. tuberculosis loci associated with a certain phenotype (e.g. transmissible vs. 
non-transmissible, drug-resistant vs. sensitive)42,43. The major advantage is that 
false-positive associations due to genetic relatedness of strains with the same 
phenotype (i.e. ‘phylogenetic bias’) are filtered out, thereby increasing statistical 
power to find true associations. In addition, the ancestral reconstruction in the 
validation step ruled out the possibility that the significant association for the SNP in 
Rv0218 was due to population structure.
The current study has several limitations. Firstly, we only focused on mutations in 
coding regions of the genome, as they are more likely to have functional consequences, 
but mutations in non-coding regions could also affect function, for instance by tran-
scriptional and translational regulation of protein-coding sequences44. Secondly, 
the large number of genetic variants increases the risk of finding false-positive 
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associations, although homoplasy counting enabled us to filter out many of these 
false-positives. We did not correct for multiple testing in the discovery set, but we 
used a validation set where we did correct for multiple testing for confirmation. Lastly, 
whether bacteria developed TBM-associated mutations before or after infecting a 
patient remains unclear. One way to investigate this is to compare the genomes of 
strains isolated from sputum and CSF from the same patient. Unfortunately we did not 
have the availability of paired isolates. Most TBM patients were too ill to expectorate 
sputum.
Conclusions
We present evidence from a homoplasy-based association analysis that three 
M. tuberculosis genes, including Rv0218, a cell wall-associated and/or secretome gene, 
are associated with the TB disease phenotype. These findings serve as an important 
step forward in the quest for an improved understanding of the mycobacterial 
determinants of TB tissue tropism. Functional validation studies are warranted to 
further explore the effect of mutations in these genes on protein function.
Methods
Patients and isolates
We used M. tuberculosis isolates from two established cohorts of Indonesian patients 
with confirmed TB. The first group consisted of adult patients (≥15 years old) with TBM 
admitted at Hasan Sadikin Hospital between 2006 and 2013, with M. tuberculosis 
cultured from CSF. The second group was randomly selected from a cohort of cul-
ture-positive HIV-negative PTB patients (age ≥ 15 years) from the same setting recruited 
between 2012 and 2015. All patients were tested for HIV, and those who were 
HIV-positive were excluded.
Sequencing, alignment, and variant calling
Mycobacterial DNA was extracted from cultures using cetyl trimethylammonium 
bromide (CTAB) or using UltraClean® Microbial DNA Isolation Kit (MO BIO Laboratories). 
A single isolate from each patient was selected for sequencing. M. tuberculosis DNA 
was sequenced on an Illumina HiSeq 2000 instrument using 2 x 100 bp paired-end 
reads at the Beijing Genome Institute in Hong Kong. After sequencing, the raw FASTQ 
sequence reads were filtered, including removing of adapter sequences, contamination, 
and low quality reads which have more than 10% N base calls, or where more than 
40% of the bases have a quality score ≤ 4. Quality control statistics are shown in Table 
S5.4. Five TBM strains and four PTB strains were contaminated, based on a low 
GC-content, and were excluded from further analyses. Sequencing coverage was 
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determined using the FASTQC quality control tool version 0.10.1. The proportion of 
bases sequenced with a sequencing error rate of 1% or less per base ranged from 93% 
to 97% per genome. The average coverage depth for the remaining 322 sequenced 
strains was 121.1, and the average percentage of bases covered by at least one read 
was 98.9%.
The sequence reads were aligned to reference strain M. tuberculosis H37Rv, accession 
number NC_000962.3, and variants were called using Breseq software, version 
0.27.145 using a minimum threshold of 30x coverage. Mutations with low-quality 
evidence (i.e. possible mixed read alignment) were not included. The Breseq variant 
call output was converted to a tab-separated file for each sequence using customized 
Python and R scripts that are available upon request.
Phylogeny construction
A phylogeny was constructed to determine evolutionary relationships of the isolates. 
We extracted all 29,199 variable positions across the 322 M. tuberculosis sequences 
and concatenated them into a single alignment. Solely for the purpose of creating 
the phylogenetic tree, SNPs occurring in PE/PPE genes and genes related to mobile 
elements (genes listed in Table S5.5) were excluded to avoid any concern about 
inaccuracies in the read alignment in these parts of the genome. In addition, SNPs in 
an additional 40 genes previously associated with drug resistance46 were removed to 
exclude the possibility that homoplasy of drug resistance mutations would significantly 
affect the phylogeny47. After applying these filters to the initial set of 29,199 SNPs, the 
28,544 remaining SNPs were used to construct the phylogenetic tree using PhyML, 
version 3.048 using the HKY85 model with four categories for the gamma distribution, 
and using a hundred bootstraps.
To determine the lineage distribution of the strains and to evaluate whether an 
association exists between M. tuberculosis lineage and TB disease phenotype, 
we determined the lineage for each of the 322 strains using a 62-SNP barcode34. 
The resulting classification in the main M. tuberculosis lineages also served as a 
quality check for the generated Maximum Likelihood (ML)-phylogenetic tree, as it 
enabled us to validate that isolates belonging to the same lineage clustered together 
in the tree. A Chi-square test was used to statistically test the association between 
M. tuberculosis lineage and TB disease phenotype.
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Homoplasy-based association test to identify associations between 
M. tuberculosis genotype and TB disease phenotype
We used a two-step approach: in the discovery step we aimed to maximize power by 
homoplasy counting, without correction for multiple testing. In the subsequent 
validation step, aimed to distinguish true associations from false positives, we used 
allele counting with multiple testing correction, and performed ancestral reconstruction 
to remove possible phylogenetic bias.
To divide the genomes in a discovery and a validation set, we identified isolates in 
terminal branch pairs, trios and quartets (i.e. separated at a terminal or near terminal 
branch in the phylogenetic tree) with distinct phenotypes (Figure 5.2). These terminal 
branch sets (TBSs) together formed the discovery set. These provide the strongest, 
homoplasy-corrected possible association with the phenotype. We used the remaining 
genomes to validate the association. For all isolates in the TBSs, we listed the 
non-synonymous SNPs to create a table with all variable positions in rows, the paired 
isolates in columns, and the corresponding nucleotide in the cells (Additional file 2). 
For every SNP, an enrichment score was calculated using the following formula:
A permutation p-value for each SNP was calculated by randomising the phenotypes 
over the isolates 1,000 times.
In parallel we grouped SNPs per gene, using the same empirical randomisation 
strategy to assess association, adjusted for gene length:
Similarly, we grouped genes with ≥1 SNP per M. tuberculosis pathway according to 
PATRIC49, and calculated association using the aforementioned permutation analysis, 
adjusted for the number of genes in a particular pathway:
Significance of associations was determined by calculating a permutation p-value 
through randomization of the phenotypes over the isolates 1,000 times. All calculations 
were performed with customized Perl scripts that are available upon request.
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We used the set of 214 strains that were not in TBSs to validate candidate SNPs, genes, 
and pathways identified in the discovery set, using the same permutation test as 
described above for the discovery set. We used a p-value threshold of 0.05 for the 
discovery set. The p-value thresholds in the validation set were Bonferroni-corrected 
for multiple testing by dividing them by the number of significant (candidate) hits in the 
discovery set. To correct for potential phylogenetic bias in the validation set, we 
performed ancestral reconstruction for validated TB phenotype-associated SNPs 
using FASTML50 with default parameters, and compared the proportion of TBM vs. PTB 
isolates prior to (i.e. older than) and after (i.e. younger than) the occurrence of the SNP 
in the validation set. For each node / leave where the SNP occurred, we calculated the 
proportion of TBM isolates among the child branches and we calculated the 
(unweighted) average over all of these nodes and leaves to determine the proportion 
of TBM isolates after the SNP (Table S5.2). This way, every independent occurrence of 
the SNP contributes equally to the analysis, regardless of the number of child branches 
after the SNP, thus correcting for phylogenetic bias. The significance of the difference 
in proportion was determined by calculating the Z-score for 2 population proportions 
with accompanying p-value.
PE/PPE genes, a major challenge in the analysis of M. tuberculosis whole genome 
sequences due to the repetitive nature of these sequences, were included in the 
analysis. TB phenotype-associated SNPs in PE/PPE genes were manually examined to 
confirm that they did not fall within a repetitive region (for an example please see 
Figure S5.4).
De novo genome assembly
Sequence reads were de novo assembled using SPAdes, version 3.6.151 with default 
parameters. All assemblies were evaluated, focussing on genome size, N50 length, 
number of contigs and scaffolds, and GC-content. The assembled genomes were 
annotated using Prokka, version 1.1152 with default parameters. Completeness and 
contamination of assemblies were determined with CheckM version 1.0.553. The 
assembly statistics are shown in Additional file 14. Presence or absence of annotated 
genes was determined for the 108 assembled genomes in the discovery set. An 
enrichment score per gene was calculated based on the frequency of occurrence in 
TBM vs. PTB strains using the following formula:
Statistical significance was again determined based on permutation by randomizing 
the phenotypes over the isolates 1,000 times. We repeated this permutation analysis 
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for the 214 genomes comprising the validation set, using Bonferroni-adjusted p-value 
thresholds. For the genes with a validated, significant enrichment for TBM or PTB, we 
confirmed their absence in the respective genomes by mapping the raw sequencing 
reads for these genomes back to the H37Rv reference sequence of the gene (Figure 
S5.5), and visualized this with integrative genomics viewer (IGV), version 2.3.3254.
Prediction of mutation effects
We used two algorithms to predict the effect of the mutations on protein structure and 
function. I-Mutant version 2.0, which predicts the protein stability change upon single 
site mutation (http://folding.biofold.org/imutant/i-mutant2.0.html)55 and PolyPhen-2, 
which predicts the possible impact of an amino acid substitution on the structure and 
function of a protein (http://genetics.bwh.harvard.edu/pph2/)56 to predict the impact 
of the validated SNPs on protein structure and function. In addition, we used TartgetP 
(http://www.cbs.dtu.dk/services/TargetP/)57 to predict the subcellular location of the 
proteins encoded by the validated genes, and TMHMM (http://www.cbs.dtu.dk/
services/TMHMM/)58 to predict transmembrane helices in these proteins.
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Supplementary figures
Figure S5.1. Scatterplot showing the p-values of the SNPs found in the discovery and the 
validation set. P-values in the discovery set are shown on the x-axis; p-values in the validation 
set are shown on the y-axis. Gene names are shown for SNPs significant in both the discovery 
and validation set.
Figure S5.2. Scatterplot showing the p-values of the genes found in the discovery and the 
validation set. P-values in the discovery set are shown on the x-axis; p-values in the validation 
set are shown on the y-axis. Names are shown for genes significant in both the discovery and 
validation set.
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Figure S5.3.
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Figure S5.3. Continued.
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Figure S5.3. Continued.
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Figure S5.3. Phylogenetic tree of 322 M. tuberculosis strains isolated from TBM (red branches 
and leaves) and PTB (black branches and leaves) patients. The highlighted branches indicate 
the 108 strains in 47 terminal branch sets, together comprising the discovery set. The purple 
stars indicate the origin of the SNP in Rv0218 according to the ancestral reconstruction. 
The nucleotide for SNP position 261,869 is indicated next to the leaf labels.
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Figure S5.4. Diagram demonstrating breseq calling a SNP in the PE-PGRS1 gene. Displayed 
are 60 Illumina sequencing reads mapping to the H37Rv reference genome (shown at the top 
and bottom). Visual inspection of the SNP confirms that it does not occur in a region containing 
uniformly lower base quality scores.
 
Predicted mutation
evidence seq id position mutation annotation gene description
RA NC_000962 132,417 C G R346G (CGC GGC) PE_PGRS1 PE PGRS family protein PE_PGRS1
Read alignment evidence...
 seq id position ref new freq score (cons/poly) reads annotation genes product
* NC_000962 132,417 0 C G 100.0% 201.1 / NA 60 R346G (CGC GGC) PE_PGRS1 PE PGRS family protein PE_PGRS1
Reads supporting (aligned to +/- strand):  ref base C (0/0);  new base G (16/44);  total (16/44)
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                                                          tGCCGGTATTGGCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCgggggg                            
                                                          tGCCGGTATTGGCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTgg                            
                                                              ggTATTGGCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCgggtggggtg                        
                                                              ggTATTGGCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATg                        
                                                              ggTATTGGCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATg                        
                                                               gTATTGGCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTggggttg                       
                                                               gTATTGGCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATgg                       
                                                                tATTGGCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATggg                      
                                                                 aTTGGCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGggc                     
                                                                  ttGGCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGGGGGATGggcg                    
                                                                   tGGCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGggcgg                   
                                                                    ggCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGGGGGGGGggcggc                  
                                                                     gCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCa                 
                                                                     gCGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCa                 
                                                                      cGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGGTGGGCGGCaa                
                                                                      cGGTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCaa                
                                                                       ggTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCAAc               
                                                                       ggTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCAAc               
                                                                       ggTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCAAc               
                                                                       ggTAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGGGGGATGGGCGGCAAc               
                                                                         tAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCAACgg             
                                                                         tAACGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGCGGGATGGGCGGCAAAgg             
                                                                          aaCGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGGGGCAACggg            
                                                                           aCGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCAACgggg
                                                                           aCGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGGGGGGAGggcggcgagcggg           
                                                                            cGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCAACggggg
                                                                            cGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCAACggggg
                                                                            cGCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGGGGGATTGGCGGCCACggggg
                                                                             gCCGGGTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCAACGGGGGc
                                                                                 ggTTCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGGGGGATGGGCGGCAACGGGGG
                                                                                   ttCGTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGGGGGGTGGGCGGCAACGGGGG
                                                                                      gTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCAACGGGGG
                                                                                      gTCGGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCAACGGGGG
                                                                                         |                                                                                         
TGTTCGGCGATGGCGGGGCCGGTGGTACCGGCGGTCTGGGTGACGTTAACGGCGGGCTTGCCGGTATTGGCGGTAACGCCGGGTTCGTCCGCAACGGCGGAGCCGGCGGCAATGGCCAGCTCGGCAGCGGCGCAGTCTCCTCGGCGGGTGGGATGGGCGGCAACGGGGG
Alignment Legend
Aligned base mismatch/match (shaded by quality score): ATCG/ATCG < 3  ATCG/ATCG < 20  ATCG/ATCG < 27  ATCG/ATCG < 33  ATCG/ATCG < 41  ATCG/ATCG
Unaligned base: atcg    Masked matching base: atcg    Alignment gap:     Deleted base: 
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Supplementary tables
Table S5.1.  Description of baseline characteristics for PTB and TBM patients
Characteristic TBM patients (N=106) PTB patients (N=216)
Male gender – N (%) 58 (54.7) 111 (51.4)
Age (yrs) – mean (SD) 28.0 (8.9) 39.1 (14.8)
Ethnicity – N (%)
Sundanese
Javanese
Sumatra
Other
45 (93.7)
3 (6.3)
0 (0)
0 (0)
187 (87.4)
21 (9.8)
3 (1.4)
3 (1.4)
Years after admission – median (IQR) 6 (4-8) 1 (1-2)
History of TB treatment - N (%) 13 (13.1) 37 (17.2)
IQR, interquartile range; SD, standard deviation.
* Data were missing for history of TB treatment (TBM, n=7; PTB, n=1); ethnicity (TBM, n=58; PTB = 2).
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Table S5.2.  Ancestral reconstruction of SNP 261869TC in Rv0218
Node/leave where SNP occurred Number 
of child 
branches
Number of 
TBM branches 
among children
Percentage 
TBM branches 
among children
Index12_34_TBM 1 1 100
Index21_109_PTB 1 0 0
Index24_109_PTB 1 0 0
Index18_34_TBM 1 1 100
Index34_34_TBM 1 1 100
Index69_42_PTB 1 0 0
Index6_109_PTB 1 0 0
Index30_88_TBM|Index66_88_TBM 2 2 100
Index24_88_TBM 1 1 100
Index42_42_PTB 1 0 0
Index45_34_PTB 1 0 0
Index15_109_PTB|Index32_34_TBM|Index15_66_TBM|
Index15_34_TBM|Index55_88_TBM
4 3 75
Index6_88_TBM 1 1 100
Index28_106_PTB 1 0 0
Index37_34_PTB|Index61_109_PTB 2 0 0
Index78_109_PTB|Index60_34_PTB|Index34_109_PTB|
Index37_25_PTB|Index45_109_PTB
4 0 0
Index32_109_PTB 1 0 0
Index42_106_PTB 1 0 0
Index55_109_PTB|Index75_109_PTB 2 0 0
Index40_34_TBM|Index60_88_TBM|Index6_34_TBM 2 2 100
Index18_109_PTB 1 0 0
Index42_100_PTB 1 0 0
Index61_34_TBM 1 1 100
Index4_88_TBM 1 1 100
Index55_34_TBM 1 1 100
Index37_109_PTB 1 0 0
Index60_42_PTB 1 0 0
Index69_34_TBM 1 1 100
Index12_21_PTB 1 0 0
Index78_34_TBM 1 1 100
Index12_90_PTB 1 0 0
Index73_34_TBM 1 1 100
Index8_34_TBM|Index69_88_TBM|Index8_88_TBM 3 3 100
Sum 45 21 1475
Average 1,36 0,64 44,70
Listed are the internal nodes and leaves where the SNP in Rv0218 occurred according to the ancestral 
reconstruction of the SNP
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Table S5.4. Description of sequencing quality control parameters and statistics
Study 
number
Clean 
reads
Q20% Total bases Mean 
coverage
Median 
coverage
Percentage 
bases >1
100865 5393826 94,86 496846191 112,60 117 99,00
100866 2806938 95,62 258749297 58,70 61 99,10
100870 3469296 94,54 320142664 72,60 75 99,20
100874 8497168 95,62 783313115 177,60 184 99,70
100876 6903240 95,75 636549074 144,30 150 99,50
100878 8828962 95,59 814420068 184,60 191 99,50
100879 4471336 95,48 412040142 93,40 97 99,00
100883 11819814 95,73 1089505119 247,00 255 99,20
100884 3347584 95,08 309679647 70,20 73 99,50
100886 7686658 95,78 709079468 160,70 167 99,20
100887 4668126 95,28 430856934 97,70 101 99,40
100890 8814420 95,67 814649331 184,70 192 99,20
100891 5695014 95,52 524832508 119,00 123 99,10
100892 2735174 95,89 251826716 57,10 59 99,00
100894 6729510 95,83 620328102 140,60 145 99,50
100895 9433682 95,74 871716597 197,60 205 99,20
100896 8746936 95,72 806976809 182,90 190 99,80
100901 4186882 95,06 386788589 87,70 91 99,20
100904 8058216 95,56 744905643 168,90 175 99,40
100906 5458790 95,47 455994928 103,40 107 99,30
100907 9489138 95,51 876888230 198,80 207 98,70
100912 4186690 94,61 383674366 87,00 89 99,20
100913 6683380 94,67 616012210 139,60 146 98,80
100917 5527220 95,57 508711705 115,30 119 99,90
100918 6806576 94,53 628084709 142,40 148 98,80
100921 3123650 95,05 288755589 65,50 68 99,50
100923 10913652 94,92 1007150244 228,30 238 99,40
100925 8613960 94,75 795469596 180,30 188 98,80
100926 9149536 95,67 832817109 188,80 195 99,30
100927 7666522 95,70 707747568 160,40 165 99,90
100928 5247660 95,03 483371397 109,60 114 98,90
100929 6371238 95,54 587360512 133,10 138 99,00
100930 7564418 95,32 698275127 158,30 163 99,50
100931 9221108 94,85 852549574 193,30 202 99,20
100932 6497346 94,98 599473298 135,90 142 99,20
100933 6973496 94,98 642622186 145,70 152 99,40
100935 2267830 94,46 205539485 46,60 45 99,30
100941 2677256 95,41 244781931 55,50 54 99,10
100943 3170650 94,63 292561071 66,30 69 98,90
100946 5172654 94,71 477425025 108,20 113 98,90
100947 8855840 95,02 816620961 185,10 193 99,20
100951 2767780 95,39 255056580 57,80 57 99,10
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Table S5.4. Continued
Study 
number
Clean 
reads
Q20% Total bases Mean 
coverage
Median 
coverage
Percentage 
bases >1
100960 4637948 95,43 425928568 96,60 99 99,10
100962 4310596 95,63 392051064 88,90 91 99,20
100963 1974408 94,21 182390070 41,30 43 98,80
100964 2262778 94,91 208683478 47,30 48 99,30
100967 2711596 95,22 248967022 56,40 58 99,40
100968 5123952 95,30 471987706 107,00 110 99,00
100972 7477410 95,21 689739641 156,40 161 99,20
100975 7998754 95,34 738615844 167,40 173 99,50
100976 3638594 94,75 335773295 76,10 80 98,80
100983 3669988 94,48 339045575 76,90 80 98,80
100984 6956916 95,35 641494402 145,40 145 99,40
100987 2629362 95,11 243150452 55,10 57 99,10
100989 11563038 95,77 1065686827 241,60 249 99,10
100991 6316160 94,96 582725768 132,10 138 98,90
100992 2859276 94,60 263619555 59,80 62 98,50
100993 8231110 95,79 758381553 171,90 178 99,20
100994 5536364 94,88 510337890 115,70 121 98,80
100996 7075788 95,07 651919072 147,80 153 99,20
100997 2132396 94,05 197331995 44,70 47 98,40
100999 6085482 95,58 556429986 126,10 129 99,60
900077 4657458 95,37 430691102 97,63 103 98,40
900083 6691044 95,56 617998403 140,09 147 98,20
900084 3248492 95,18 299922817 67,99 71 98,30
900089 3523302 95,20 324308817 73,51 76 99,30
900094 3387992 95,47 312171242 70,76 73 99,20
900095 4466868 94,91 411820079 93,40 94 99,10
900104 10781194 95,73 996184664 225,80 234 99,10
900110 6960366 96,63 642971426 145,75 150 99,80
900115 5065176 95,64 466750089 105,80 110 98,80
900126 4039714 95,29 373033196 84,56 89 98,00
900130 8172166 94,80 755611366 171,30 175 99,00
900135 6004426 95,27 555768696 126,00 130 99,30
900138 7583758 95,44 700928339 158,90 165 99,20
900144 4087780 95,28 376924265 85,44 88 99,10
900150 6564174 95,46 604493321 137,03 143 98,50
900157 13620988 95,57 1261781723 286,02 296 99,00
900159 5053700 95,72 465523074 105,50 109 99,00
900160 791534 94,83 72810185 16,50 17 98,90
900161 6767554 95,40 622483695 141,10 146 99,50
900164 5978184 94,93 551296262 125,00 130 99,00
900166 8463916 94,68 783004573 177,50 184 98,70
900169 3531234 95,09 324288155 73,50 73 99,20
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 128
128 | Chapter 5
Table S5.4. Continued
Study 
number
Clean 
reads
Q20% Total bases Mean 
coverage
Median 
coverage
Percentage 
bases >1
900173 4865874 94,96 448459089 101,70 105 99,10
900174 6456632 94,66 596399079 135,20 140 98,80
900176 5891534 94,74 545263881 123,60 129 98,60
900177 8367724 95,47 769016835 174,30 180 99,10
900178 5884278 94,75 544283139 123,40 128 98,80
900179 3757352 94,53 346790136 78,60 82 98,50
900181 3658838 94,80 338192325 76,66 80 98,30
900183 4112656 94,50 379449608 86,00 89 99,50
900190 5386042 95,48 496968260 112,65 117 99,60
900192 4411450 96,52 407585797 92,39 95 99,60
900199 9405206 95,68 869958388 197,20 204 99,30
900201 2187488 95,12 201682848 45,70 47 99,10
900202 8860806 95,83 818983627 185,70 192 99,20
900204 4196972 94,37 387936608 87,90 92 98,50
900206 6629018 94,70 613385999 139,00 145 98,60
900211 8882108 95,37 819024355 185,70 191 99,10
900212 8926712 95,66 822954141 186,60 193 99,00
900215 6848790 95,51 630580535 142,90 147 99,10
900221 2812730 95,25 260233372 58,99 62 98,30
900223 3083040 95,31 284289254 64,44 67 99,10
900225 4983966 95,07 460812198 104,50 108 99,50
900229 6520394 94,75 601645866 136,40 142 98,80
900236 12376840 96,27 1127089142 255,50 261 99,70
900238 9682506 95,50 895230730 202,93 213 98,30
900239 6366596 96,72 587033189 133,07 137 99,30
900241 5696554 96,58 527413573 119,55 123 99,40
900244 7550754 95,37 696142653 157,80 163 99,10
900251 5570528 95,79 513273278 116,40 120 99,30
900319 4327172 95,17 393895196 89,29 88 99,20
900343 4226624 95,62 390290590 88,47 93 97,90
900344 7305994 94,54 673506466 152,70 159 98,80
900365 3633014 95,68 336204924 76,21 80 98,40
900374 7682274 95,54 709433935 160,81 169 98,10
900387 4761330 95,25 438801669 99,50 99 99,30
900394 5895104 95,17 545589186 123,70 128 99,10
900397 6781232 95,65 626276164 141,96 149 98,50
900400 7612354 95,39 703612915 159,49 167 98,20
900406 7457526 95,41 685335643 155,40 159 99,20
900413 8074132 94,82 747137218 169,40 177 98,70
900416 5346728 94,62 494699921 112,10 117 98,70
900417 3282346 94,57 302572231 68,60 72 98,30
900421 6792232 94,41 628043107 142,40 149 98,60
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Table S5.4. Continued
Study 
number
Clean 
reads
Q20% Total bases Mean 
coverage
Median 
coverage
Percentage 
bases >1
900428 6919752 94,64 640814487 145,30 153 98,00
900430 4576412 95,83 421902959 95,60 99 98,80
900437 10100234 94,68 932826377 211,50 220 98,40
900439 1719270 95,22 158735817 35,98 38 97,90
900443 6746410 95,67 622308095 141,10 146 99,30
900446 3568466 95,49 328026972 74,40 76 99,10
900459 3350726 94,33 309370206 70,10 73 98,70
900464 10104002 95,89 931474859 211,20 216 99,10
900469 5572320 95,63 514346967 116,60 120 99,60
900477 10793432 94,58 996500701 225,90 236 98,60
900489 5893196 95,85 543161841 123,10 128 98,80
900490 5546714 95,61 512275952 116,12 122 98,20
900517 5739918 94,60 531133943 120,40 126 98,60
900573 7510088 95,56 693375210 157,17 165 98,60
900574 7482078 95,25 688955525 156,17 162 99,10
900576 9422310 95,75 868555554 196,90 203 98,80
900580 2745100 95,70 232761189 52,80 54 99,00
900586 2581044 95,48 238334139 54,03 57 98,00
900601 9062300 95,53 836943089 189,72 199 98,20
900603 6675866 95,62 616819650 139,80 145 99,20
900609 4064352 94,30 375056975 85,00 89 98,30
900611 6260624 95,40 577124778 130,80 135 99,30
900612 5889964 95,58 542995499 123,10 127 99,00
900618 5136100 95,46 473770925 107,40 110 99,10
900637 2483164 95,21 229386411 52,00 54 99,20
900639 8184572 95,33 757111404 171,60 177 99,30
900654 4897320 95,37 450923632 102,20 105 99,30
900655 3036462 94,58 280487243 63,60 67 98,70
900666 5199786 95,85 478841323 108,50 112 99,00
900677 3880296 94,56 358103680 81,20 85 98,60
900680 5220468 94,67 481344407 109,10 114 98,70
900703 2435754 94,78 225517592 51,10 53 98,60
900706 4981156 95,53 461099564 104,52 109 98,20
900711 4677424 94,92 430474568 97,60 99 99,30
900716 10183442 94,59 938814696 212,80 222 98,80
900731 5091556 95,37 470191118 106,58 112 98,00
900746 6474714 95,36 598086075 135,57 142 98,10
900748 6584354 95,10 607985996 137,82 144 98,40
900751 3003642 95,37 276844453 62,75 65 99,00
900824 6534112 96,35 578749267 131,20 131 99,40
900845 3141548 94,36 290278154 65,80 69 98,60
900849 4992552 95,91 460361996 104,40 108 99,30
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Table S5.4. Continued
Study 
number
Clean 
reads
Q20% Total bases Mean 
coverage
Median 
coverage
Percentage 
bases >1
1001002 8421510 94,85 779007911 176,60 184 99,20
1001003 3107372 95,52 286077988 64,90 67 99,10
1001009 4275054 95,13 394554574 89,40 93 99,30
1001011 5828312 94,85 537712611 121,90 127 99,30
1001012 5244854 95,36 483589099 109,60 113 99,60
1001013 8923730 95,41 822488632 186,40 193 99,70
1100213 4266778 94,92 394750818 89,48 93 98,90
1100217 5838902 95,61 539199148 122,22 125 98,80
1100231 4172814 95,42 384740674 87,21 90 98,90
1100232 6931214 95,41 637630282 144,54 149 99,40
1100233 6438244 96,59 591744287 134,14 136 99,60
1100234 2448826 95,04 226034251 51,24 54 97,90
1100238 5349728 95,45 493746431 111,92 115 99,20
1100246 4241148 94,92 392868330 89,05 92 99,00
1100250 5686092 95,38 525154268 119,04 125 98,10
1100254 691128 95,19 63775796 14,46 15 97,50
1100256 6861744 95,09 635722606 144,10 151 98,50
1100262 1867970 92,89 172516103 39,11 41 98,90
1100264 8528690 95,17 788677462 178,78 185 99,20
1100269 5137284 95,01 474920172 107,65 112 99,10
1100270 6399968 95,37 589507896 133,63 138 99,00
1100273 6762182 95,34 625911758 141,88 149 98,30
1100280 4627628 95,43 427362057 96,87 101 98,40
1100281 6110340 95,50 564048380 127,86 132 99,20
1100283 4638990 95,44 429132510 97,28 102 98,50
1100291 5293572 96,58 488900426 110,82 114 99,70
1100294 7450520 95,38 688696972 156,11 160 99,40
1100300 3092126 95,00 286048335 64,84 68 98,30
1100306 5766562 95,54 532393055 120,68 127 98,30
1100307 5090484 94,61 470152143 106,57 111 98,00
1100315 4590438 95,26 423829736 96,07 101 98,00
1100316 4639218 95,00 429207921 97,29 102 98,20
1100320 4273028 95,14 394124860 89,34 93 98,80
1100331 2893908 95,10 267254684 60,58 63 98,20
1100332 3547096 95,38 327284397 74,19 76 99,10
1100333 7640658 95,53 702530395 159,25 164 99,40
1100335 4719994 95,23 436845013 99,02 104 98,10
1100340 10582420 95,47 977856076 221,66 232 98,60
1100345 5664472 95,22 523635379 118,70 124 98,50
1100348 9478592 96,71 874252406 198,17 204 99,20
1100353 7157040 96,90 662329285 150,14 155 99,60
1100367 4378604 96,73 403022547 91,36 94 99,40
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1100369 3614860 95,09 334572793 75,84 79 98,40
1100373 7817932 96,89 721194175 163,48 169 99,30
1100374 5687648 95,12 524404441 118,87 123 99,30
1100396 4464604 96,87 412472505 93,50 96 99,60
1100397 7952458 95,27 734301221 166,45 172 99,10
1100400 4156544 94,85 384729079 87,21 91 98,50
1100421 8161636 96,93 744477220 168,76 174 99,30
1100607 6876462 95,38 632158432 143,30 148 99,40
1100707 4391668 95,52 405964237 92,02 96 98,90
1100708 5804762 95,37 535042353 121,28 126 98,90
1100716 8686226 95,58 800338659 181,42 188 98,80
1100730 8065486 96,76 746592857 169,24 174 99,70
1100738 5401532 95,40 500478912 113,45 118 98,30
1100746 3480194 95,27 321712017 72,93 75 98,80
1100757 6216226 95,37 572081247 129,68 130 98,90
1100760 3239756 95,38 298617464 67,69 71 98,50
1100763 5502764 95,21 506670287 114,85 117 98,70
1100764 5650758 96,92 521338278 118,18 122 99,30
1100773 5049028 95,31 466844260 105,82 109 99,10
1100774 1121332 95,44 103410546 23,44 25 98,50
1100786 5043614 95,42 463788799 105,13 109 99,10
1100797 6867872 95,63 631656757 143,18 147 99,30
1100903 3940012 95,42 363569155 82,41 85 98,60
1100907 6662502 96,74 616858915 139,83 144 99,40
1100908 4866202 95,41 447414934 101,42 101 99,00
1100909 4321576 95,18 398668836 90,37 94 98,70
1100917 1474708 92,91 136437753 30,93 32 98,40
1100918 8666842 95,55 800281865 181,41 190 98,40
1100921 5637528 96,81 521923240 118,31 122 99,60
1100929 4545226 95,44 419603339 95,12 98 99,20
1100930 3966012 95,49 367144208 83,22 87 98,30
1100931 4305168 95,24 398774103 90,39 94 99,40
1100933 1616234 92,92 149443084 33,88 35 98,40
1100936 4857908 95,07 448087877 101,57 105 98,60
1100937 4023822 95,29 371528087 84,22 86 98,90
1100942 3877632 95,55 357512894 81,04 84 98,70
1100943 4256638 95,07 391629990 88,77 92 99,00
1100945 3707196 95,44 342392133 77,61 81 98,50
1100969 9138662 95,44 843500045 191,20 197 99,20
1100977 5068004 95,36 467957429 106,08 111 98,20
1100981 5409442 95,53 499060319 113,13 117 98,70
1100984 5795768 95,60 535918638 121,48 126 99,00
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1100987 2431690 96,80 392597634 88,99 92 99,00
1100995 4298726 95,24 397765175 90,16 93 99,10
1101003 8605192 95,75 793618170 179,90 186 99,20
1101004 5345552 95,18 493292026 111,82 116 99,20
1101008 6612834 96,66 610379624 138,36 142 99,30
1101011 5311910 95,44 490949034 111,29 115 98,90
1101012 4300000 95,19 397980899 90,21 93 98,90
1101015 8385930 95,79 774182342 175,49 179 98,90
1101018 2563844 95,70 237182128 53,76 56 98,80
1101025 9120244 95,95 843597287 191,23 198 98,90
1101028 1896992 95,80 175609777 39,81 41 98,80
1101037 5087396 95,77 471034289 106,77 111 99,20
1101047 7861958 95,42 727939191 165,01 173 98,30
1101054 7246156 95,44 670754167 152,05 159 98,40
1101061 8923668 96,99 823426144 186,65 193 99,30
1101064 4408312 95,68 406658628 92,18 95 98,50
1101067 8193818 96,70 756937816 171,58 177 99,60
1101074 3883520 95,62 358280741 81,21 85 98,50
1101077 3228516 95,68 298974274 67,77 70 98,70
1101080 4911704 95,80 453246251 102,74 107 98,70
1101084 5692096 95,77 525457900 119,11 124 98,60
1101085 4265798 94,95 394010661 89,31 93 98,80
1101088 3440936 95,98 318639444 72,23 75 98,70
1101089 6002548 96,96 556190844 126,08 130 99,60
1101253 3642584 95,74 336144308 76,20 79 98,80
1101292 6082440 95,86 560795868 127,12 132 98,80
1101303 9312806 95,99 861349125 195,25 202 99,20
1101304 2045310 93,60 188641178 42,76 44 98,50
1101316 10031646 95,64 923436067 209,32 214 99,00
1101317 4281276 94,97 393297145 89,15 92 99,00
1101318 8311646 95,94 767350601 173,94 180 99,10
1101319 5606644 95,88 518165835 117,46 122 99,00
1101321 13908338 95,81 1283563813 290,96 303 99,20
1101322 5388084 95,89 496954407 112,65 117 98,70
1101323 4780336 95,88 441188685 100,01 103 98,80
1101324 10556482 96,05 974353093 220,87 228 99,20
1101329 5265746 95,54 485933498 110,15 114 98,60
1101337 9036512 95,73 834483421 189,16 196 98,90
1101340 5004558 95,76 456531484 103,49 102 99,00
1101342 8516402 95,68 787938504 178,61 185 99,00
1101344 5945098 95,92 548757919 124,39 129 98,90
1101346 5892778 95,82 541723597 122,80 127 98,90
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1101348 7181066 95,79 662390301 150,15 156 98,80
1101350 5585560 95,70 517096265 117,21 122 98,80
1101355 5142926 95,59 475691952 107,83 112 98,70
1101359 8357208 95,68 769440613 174,42 180 99,00
1101360 6005832 95,75 554392328 125,67 130 99,10
1101367 2839034 95,73 262799618 59,57 62 98,80
1101368 5295318 95,94 488701549 110,78 115 98,40
1101382 2494612 95,72 229415793 52,00 54 98,50
1101386 9713036 95,80 896253841 203,16 211 99,10
1101554 8768224 95,99 809038817 183,39 190 99,00
1101556 2695552 93,65 248575069 56,35 58 98,30
1101557 5974612 95,54 552272734 125,19 130 98,80
1101572 9706246 95,94 895520927 203,00 211 98,80
1101576 4786726 95,86 441905771 100,17 104 98,70
1101580 7791782 95,82 718652884 162,90 169 98,90
1101600 3010808 95,87 278389255 63,10 65 98,70
1101602 3259454 95,92 299698944 67,94 71 98,80
1101603 7436708 96,04 686272907 155,56 161 98,90
1101604 6303476 95,18 581855643 131,89 136 98,90
1101610 5124546 96,59 472976032 107,21 111 99,30
1101623 5027232 95,51 463403211 105,04 108 98,70
1101628 5667660 95,74 524058595 118,79 123 99,10
1101652 7220436 96,62 666135610 151,00 156 99,30
1101933 4298652 95,27 397732878 90,16 93 99,10
1101942 4273636 96,65 395475578 89,65 92 99,60
1101947 5441952 96,70 499732433 113,28 115 99,30
1101984 4843912 96,79 446859913 101,29 105 99,20
1101997 5845746 96,62 538540400 122,08 126 99,80
Samples excluded from further analysis
100973 10916526 96,14 1042435 0,12 1 2,40
900089 6737346 96.70 289038979 32,76 34 99,25
900132 3437888 97.96 32333418 7,33 8 96,90
900248 1760232 96.56 NA NA NA NA
900558 1303536 97.11 NA NA NA NA
900625 5877240 95.53 1290461 0,29 1 10,70
1100343 8561266 95.67 6480416 1,47 2 60,60
1100772 1340688 94.87 NA NA NA NA
1101001 8104650 96.05 275263806 62,30 65 98,30
Displayed are various measures of sequencing quality, used for the sequencing quality control check.
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Table S5.5.   PE / PPE genes and drug resistance genes excluded for the phylogeny 
construction.
PE/PPE genes and genes in repetitive regions Rv2107 Rv2741 Rv3381c Known drug 
resistance 
genes
Rv0031 Rv0922 Rv1575 Rv2108 Rv2768c Rv3386
Rv0096 Rv0977 Rv1576c Rv2123 Rv2769c Rv3387
Rv0109 Rv0978c Rv1577c Rv2126c Rv2770c Rv3388 accD6
Rv0124 Rv0980c Rv1578c Rv2162c Rv2791c Rv3425 ahpC
Rv0151c Rv1034c Rv1579c Rv2167c Rv2810c Rv3426 efpA
Rv0152c Rv1035c Rv1580c Rv2168c Rv2812 Rv3427c embA
Rv0159c Rv1036c Rv1581c Rv2177c Rv2814c Rv3428c embB
Rv0160c Rv1039c Rv1582c Rv2278 Rv2815c Rv3429 embC
Rv0256c Rv1040c Rv1583c Rv2279 Rv2853 Rv3430c embR
Rv0278c Rv1041c Rv1584c Rv2328 Rv2885c Rv3474 ethA
Rv0279c Rv1042c Rv1585c Rv2340c Rv2892c Rv3475 fabD
Rv0280 Rv1047 Rv1586c Rv2352c Rv2943 Rv3477 fadE24
Rv0285 Rv1054 Rv1646 Rv2353c Rv2943A Rv3478 fbpC
Rv0286 Rv1067c Rv1651c Rv2354 Rv2944 Rv3507 furA
Rv0297 Rv1068c Rv1705c Rv2355 Rv2961 Rv3508 gid
Rv0304c Rv1087 Rv1706c Rv2356c Rv2978c Rv3511 gyrA
Rv0305c Rv1088 Rv1753c Rv2371 Rv3018A Rv3512 gyrB
Rv0335c Rv1089 Rv1756c Rv2396 Rv3018c Rv3514 inhA
Rv0354c Rv1091 Rv1757c Rv2408 Rv3021c Rv3532 iniA
Rv0355c Rv1135c Rv1763 Rv2424c Rv3022A Rv3533c iniB
Rv0387c Rv1149 Rv1764 Rv2430c Rv3022c Rv3539 iniC
Rv0388c Rv1168c Rv1765A Rv2431c Rv3023c Rv3558 kasA
Rv0442c Rv1169c Rv1768 Rv2479c Rv3115 Rv3590c katG
Rv0453 Rv1172c Rv1787 Rv2480c Rv3125c Rv3595c fabG1
Rv0532 Rv1195 Rv1788 Rv2487c Rv3135 Rv3621c manB
Rv0578c Rv1196 Rv1789 Rv2490c Rv3136 Rv3622c ndh
Rv0741 Rv1199c Rv1790 Rv2512c Rv3144c Rv3636 nat
Rv0742 Rv1214c Rv1791 Rv2519 Rv3159c Rv3637 oxyR
Rv0746 Rv1243c Rv1800 Rv2591 Rv3184 Rv3638 pncA
Rv0747 Rv1313c Rv1801 Rv2608 Rv3185 Rv3640c rmlD
Rv0754 Rv1325c Rv1802 Rv2615c Rv3186 Rv3650 rpoB
Rv0755A Rv1361c Rv1803c Rv2634c Rv3187 Rv3652 rpsL
Rv0755c Rv1369c Rv1806 Rv2646 Rv3191c Rv3653 rrs
Rv0795 Rv1370c Rv1807 Rv2648 Rv3325 Rv3738c Rv0340
Rv0796 Rv1386 Rv1808 Rv2649 Rv3326 Rv3739c Rv1592c
Rv0797 Rv1387 Rv1809 Rv2650c Rv3327 Rv3746c Rv1772
Rv0832 Rv1396c Rv1818c Rv2651c Rv3343c Rv3751 Rv2242
Rv0833 Rv1430 Rv1840c Rv2652c Rv3344c Rv3798 Rv3124
Rv0834c Rv1441c Rv1917c Rv2653c Rv3345c Rv3812 Rv3125c
Rv0850 Rv1450c Rv1918c Rv2654c Rv3347c Rv3827c Rv3126c
Rv0872c Rv1452c Rv1983 Rv2655c Rv3348 Rv3844 thyA
Rv0878c Rv1468c Rv2013 Rv2656c Rv3349c Rv3872 tlyA
Rv0915c Rv1548c Rv2014 Rv2657c Rv3350c Rv3873 accD6
Rv0916c Rv1573 Rv2105 Rv2659c Rv3367 Rv3892c
Rv0920c Rv1574 Rv2106 Rv2666 Rv3380c Rv3893c
Listed are the genes that were excluded from the multiple alignment used to create the phylogenetic tree.
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Abstract
Background
Many studies have examined the host and environmental factors that influence 
tuberculosis transmission and secondary cases of disease, but the M. tuberculosis 
genetic determinants of transmission remain poorly understood.
Methods
Using a household-based case-contact study in Bandung, Indonesia, we determined 
whether the genotype of the M. tuberculosis strain that a contact is exposed to 
influences their risk of infection, measured by interferon gamma release assay 
conversion. Generalised estimating equation for Poisson regression was used to 
investigate whether the M. tuberculosis genotype influences the disease phenotype in 
the contact. We calculated a transmission index reflecting the isolate’s ability to 
transmit to contacts, adjusted for index case characteristics and exposure risk of the 
contact.
Results
M. tuberculosis genotype of 414 index case isolates was linked to IGRA conversion of 
1,201 household contacts. The Beijing genotype was associated with a 39% increased 
risk of uninfected contacts to acquire M. tuberculosis infection compared to non-Beijing 
genotype strains (relative risk 1.39; 95% confidence interval 1.00 – 1.93; p=0.048). This 
was not explained by a higher bacillary load or higher frequency of pulmonary cavities 
in the index cases. In addition, BCG vaccination showed no protection against M. 
tuberculosis infection in contacts exposed to a Beijing genotype strain (RR=1.02; 95% 
CI 0.56 – 1.85; p=0.9), whereas a strong protection was observed against infection 
with non-Beijing genotype strains (RR 0.40; 95% CI 0.27 - 0.61; p<0.001).
Discussion
Beijing genotype strains are associated with increased transmission and BCG 
vaccination showed less protection in contacts exposed to Beijing genotype strains. 
Evading innate immune clearance in the contact, rather than inducing a disease 
phenotype in the index case that favours transmission, may explain the increased 
transmissibility of Beijing genotype strains.
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Introduction
Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), the number 
one cause of death from an infectious disease caused by a single pathogen1. Mounting 
evidence from countries with high TB burdens points to ongoing transmission as the 
driving force maintaining TB incidence2,3. Despite coordinated efforts to control TB 
transmission, an estimated 10 million people developed TB disease in 20171 and 50 
million people worldwide are predicted to become newly infected with M. tuberculosis 
every year4. Transmission of M. tuberculosis occurs through aerosol droplets that are 
produced by coughing pulmonary TB patients and inhaled by exposed contacts. 
Tuberculosis transmission is dependent on the prevalence and infectiousness of 
pulmonary TB cases, the number and susceptibility of TB case contacts, the frequency 
and proximity of interactions between TB cases and contacts, as well as biological 
features of M. tuberculosis5. To date, considerable emphasis has been placed on the 
role of host and environmental factors associated with transmission, but far less effort 
has been put in understanding pathogen factors involved in manipulating and evading 
host immunity6. M. tuberculosis consists of seven human-adapted phylogenetic 
lineages and is subdivided into genetic families defined by genetic traits (single 
nucleotide polymorphisms (SNPs) or deletions)7. The East-Asian lineage (Lineage 2) is 
widespread globally and the Beijing genotype family is its major component8, which 
can be further subdivided into ancient and modern Beijing lineages9. Beijing strains 
have been associated with large outbreaks10-13, suggesting increased transmissibility 
for this genotype family.
M. tuberculosis genotype-specific traits could increase the risk of transmission in two 
ways: first; by inducing a disease phenotype in the index case that favours transmission, 
or second; by evading host immune responses that eradicate M. tuberculosis before 
an adaptive immune response develops14. In the current household case contact 
study, in which contacts are linked to a known index case, we sought to understand 
the influence of host and pathogen factors on M. tuberculosis transmission. Specifically 
we sought to test whether increased Beijing lineage transmission was related to a 
transmission-favourable disease phenotype or to evasion of host responses in the 
contact.
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Methods
Setting and design
The Innate Factors and Early Clearance of M. tuberculosis (INFECT) study was conducted in 
Bandung, Indonesia (estimated TB incidence: 395/100,000)1. The TANDEM project15, 
on the relationship between TB and diabetes mellitus, recruited sputum smear positive 
TB patients over 15 years of age with an abnormal chest x-ray. Patients were eligible for 
the INFECT study if they shared a household with others and had received less than 
two weeks of TB treatment. Their household contacts16 were eligible if they had lived 
with the index case for more than five hours a week and had no previous TB. Children 
under five years were ineligible and were referred to a primary care physician. 
The study was approved by the Health Research Ethics Committee Universitas Padjadjaran 
(14/UN6.C2.1.2/KEPK/PN/2014) and the Southern Health and Disability Ethics Committee 
New Zealand (13/STH/132). All participants gave written informed consent.
Study procedures
Patients with suspected TB disease were referred from primary care. Demographic 
characteristics, sputum smear grade17, and M. tuberculosis culture results were 
recorded18. Their chest x-rays were read by a physician who identified cavities and the 
extent of abnormalities, as previously described19,20. They were treated for TB at no 
cost by the National TB Control Programme. Trained nurses recruited eligible contacts 
at home. They recorded demographic characteristics, smoking status, diabetes, 
history of human immunodeficiency virus (HIV) infection, TB symptoms, and sleep 
proximity to and hours spent with the index case the day before enrolment. Physical 
examination included assessment of the presence of a Bacillus Calmette-Guérin (BCG) 
vaccination scar, height and weight. Household contact M. tuberculosis infection 
status was assessed by QuantiFERON®-TB Gold In-Tube interferon gamma release 
assay (IGRA), interpreted according to the manufacturer’s instructions21. Indeterminate 
tests were repeated, and the repeat value used. A random capillary blood glucose 
(RCBG) was performed, followed by venous glycosylated haemoglobin (HbA1c) for 
those with RCBG > 100 mg/dL (5.5 mmol/L). Contacts who were IGRA negative at 
baseline had a repeat IGRA at 14 weeks. Those with TB symptoms at baseline or follow 
up underwent chest x-ray and sputum examination. 
M. tuberculosis isolates were suspended in liquid media and stored at -80°C until they 
were thawed and re-cultured for DNA extraction. M. tuberculosis DNA was extracted 
after subculturing of positive culture on Ogawa solid medium using the cetyl trimeth-
ylammonium bromide (CTAB) method or the UltraClean® Microbial DNA Isolation Kit 
(MO BIO Laboratories, Carlsbad, CA).
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M. tuberculosis DNA from 137 Indonesian isolates was sequenced on an Illumina HiSeq 
2000 instrument using 2 x 100 bp paired-end reads at the Beijing Genome Institute in 
Hong Kong; the remaining 285 isolates were sequenced on an Illumina NextSeq 500 
instrument using 2 x 150 bp paired-end reads at the department of Human Genetics at 
the Radboudumc, Nijmegen, the Netherlands. After sequencing, the raw FASTQ 
sequence reads were filtered, including removing of adapter sequences. All sequencing 
reads passed the Illumina base caller filter. Sequencing coverage was determined 
using the FastQC quality control tool version 0.10.1, and the Genome Analysis Toolkit22. 
Sequencing coverage statistics are shown in supplementary File 1. The sequence 
reads were aligned to reference strain M. tuberculosis H37Rv, accession number 
NC_000962.3, and variants were called using Breseq, version 0.33.223. We extracted 
all 57,045 variable positions across the 414 M. tuberculosis sequences and 
concatenated them into a multiple sequence alignment. Solely for the purpose of 
creating the phylogenetic tree, SNPs occurring in PE/PPE genes, genes related to 
mobile elements, as well as genes previously associated with drug resistance24 were 
removed. The remaining 55,494 SNPs were used to construct the phylogenetic tree 
using PhyML version 3.3.2018062125 using the HKY85 model with four gamma-distributed 
rate-categories, and using a hundred bootstraps. We used the R package ape26 
(version 5.3) to calculate the distance to the genetically closest other isolate (minimum 
pairwise distance) for all isolates, again excluding SNPs in PE/PPE genes, genes 
related to mobile elements and genes associated with drug resistance. We determined 
M. tuberculosis lineage based on a 62-single nucleotide polymorphisms (SNPs) 
barcode27. To further classify isolates belonging to lineage 2 (East-Asian lineage) into 
non-Beijing, ancient Beijing and modern Beijing sublineages, we categorized isolates 
belonging to lineage 2.1 as non-Beijing (or proto-Beijing), those belonging to lineage 
2.2.2 as ancient Beijing, and those belonging to lineage 2.2.1.1 or 2.2.1.2 as modern 
Beijing. The lineage 2.2.1 isolates, which cannot be unambiguously distinguished into 
ancient or modern Beijing according to the 62-SNP-barcode, were categorized 
according to the M. tuberculosis lineage 2 dendrogram published by Shitikov et al28. 
We used TBProfiler version 2.1.124 to determine genotypic drug resistance. This tool 
uses raw sequence data as input, aligns these to the M. tuberculosis H37Rv reference 
genome, and compares identified SNPs and indels to a curated list of drug resistance 
mutations.
Data management and analysis
All data were double entered into a database (Microsoft Access) and checked for 
errors. IGRA conversion was defined as a change from a negative baseline test to 
positive at 14-week follow-up. Body mass index (BMI) was calculated according to 
the formula BMI = weight/(height2). Diabetes was defined as an HbA1c³6.5% and 
pre-diabetes as HbA1c 5.7-6.4%. To create one summary measure of exposure to 
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facilitate specific analyses described below, exposure risk scores were predicted from 
a logistic regression of M. tuberculosis exposure variables (index case: sputum smear 
grade, drug resistance mutations, cavities, extent of x-ray disease; contacts: hours 
spent with, and sleeping proximity to, the case) against IGRA results, as described 
previously29.
The primary analysis was of risk of IGRA conversion for those with a negative IGRA at 
baseline, as incident conversions are almost certainly due to exposure to the index 
case. A sensitivity analysis of risk of a positive IGRA at baseline or follow up, compared 
to a persistently negative IGRA, was also performed.
Associations between host factors and IGRA were estimated using Poisson regression 
generalised estimating equations, clustering on case, and with robust standard errors 
to account for binomial data. Index case characteristics and exposure risk score were 
included as potential confounders. A modified backwards stepwise regression was 
used, with age and sex retained, and other variables retained if p<0.2. Estimates for 
baseline associations are presented as prevalence ratios (PR) and those for conversion 
are presented as relative risks (RR).
To study pathogen genetic determinates of BCG evasion we calculated a transmission 
index that reflects the isolate’s ability to transmit to contacts, accounting for the 
factors extrinsic to the pathogen such as contact susceptibility and proximity to the 
index case. The transmission index was calculated by subtracting expected instances 
of transmission to BCG-vaccinated contacts from the observed instances of transmission 
to BCG-vaccinated contacts in each household. To score observed transmission events 
we weighted a positive IGRA at baseline at 20% of a conversion, as there is less 
certainty that a positive IGRA at baseline resulted from exposure to the index case. 
The expected risk of transmission was predicted using the multivariable model for the 
primary analysis, but with the lineage term removed. All analyses were carried out 
using Stata version 15.
Results
TB household index cases and contacts
From home visits to 465 index case households, 2,090 contacts were screened and 
1,620 were eligible (Figure 6.1). Of these, 1,347 (83%) contacts of 462 index cases gave 
informed consent for inclusion in the study. The whole genome sequencing was 
available on 414 index case isolates linked to 1,201 contacts. The remaining 48 index 
cases were not included because they did not have a culture submitted (n=13), 
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Figure 6.1. Recruitment and enrolment of participants into the study and outcome of participants 
included in the study.
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the culture was negative (n=14), or contaminated (n=2), failed extraction (n=3) had 
poor sequencing quality (n=6) or were not sequenced (n=10). Contacts were classified 
into three groups as: baseline IGRA positive (n=709), persistently IGRA negative 
(n=277), and IGRA converters (n=108). For the 414 isolates that were whole genome 
sequenced, the median coverage depth was 96x, (range 15-363) and the median 
percentage of bases covered by at least one read was 99.2%. 
The three classified groups of case contacts were similar with respect to median age, 
sex and duration of treatment of their respective index cases and with respect to their 
sex, smoking history and diabetes measurements (Table 6.1). However, persistently 
IGRA negative contacts had relatively lower measures of exposure to M. tuberculosis 
and, along with converters, were younger than those who were initially IGRA positive.
Of the sequenced index case isolates, 260 (62.8%) belonged to the Euro-American 
lineage, 133 (32.1%) were East-Asian (Beijing), seven (1.7%) were East-Asian lineage 
but not from the Beijing lineage and 14 (3.4%) were from the Indo-Oceanic lineage 
(Figure 6.2). Fifty-five (41%) of the East-Asian Beijing genotype isolates were ancient 
Beijing isolates, and 78 (59%) were modern Beijing isolates. Two (Euro-American) 
isolates differed by only ten SNPs, and could have been part of the same transmission 
cluster30.
The clinical or radiological characteristics of index cases were similar for those infected 
with Beijing isolates compared to those infected with non-Beijing isolates (Table 6.2). 
Beijing isolates were more likely to be multi-drug resistant than non-Beijing isolates 
(5.3 vs. 1.8% respectively, P=0.046). Table S6.1 summarizes drug resistance mutations 
according to lineage. Patients infected with Beijing and non-Beijing isolates were similar 
with respect to the smear grade and presence of cavities. There was no difference in 
the dominant abnormality in each lung zone, according to lineage (Table S6.2). 
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Table 6.1.   Characteristics of 1,085 contacts and their index case according to 
the contact’s IGRA result
Characteristic Baseline  
IGRA Positive
Baseline 
IGRA Negative
(N=702) IGRA converter
(N=108)
IGRA Persistently 
Negative (N=275)
Contact’s index casea
Age (years) median (IQR) 37.6 (28.6 - 49.8) 38.4 (28.7 - 50.8) 40.9 (30.5 - 51.9)
Female 323 (46.0) 56 (51.9) 144 (52.4)
Days of treatment
None 574 (81.8) 87 (80.6) 224 (81.5)
<7 115 (16.4) 20 (18.5) 46 (16.7)
7 to 13 13 (1.9) 1 (0.9) 5 (1.8)
Diabetesb 169 (28.8) 36 (37.9) 84 (33.5)
Current smoker b 66 (11.2) 11 (11.6) 31 (12.4)
HIVc 1 (0.2) 2 (2.2) 0 (0.0)
Temperature b (C), 
median (IQR)
36.8 (36.4 - 37.3) 36.8 (36.4 - 37.3) 36.8 (36.4 - 37.4)
X-rayd cavities (present) 404 (59.5) 55 (51.9) 121 (46.7)
Extent of chest x-ray disease,
median (IQR)
50.0 (25.0 - 75.0) 40.0 (25.0 - 55.0) 40.0 (25.0 - 60.0)
Sputum smear grade
3+ 345 (49.1) 60 (55.6) 90 (32.7)
2+ 199 (28.3) 26 (24.1) 76 (27.6)
Scanty/1+ 158 (22.5) 22 (20.4) 109 (39.6)
Any drug resistance 77 (11.0) 17 (15.7) 30 (10.9)
MDR 17 (2.4) 2 (1.9) 10 (3.6)
Beijing lineage 246 (35.0) 39 (36.0) 69 (25.0)
Contacts
Hours with the case 
median (IQR)
5.0 (2.0 - 10.0) 5.0 (3.0 - 8.0) 3.0 (1.0 - 7.0)
Sleep proximity to index case
Same room 482 (68.7) 88 (81.5) 216 (78.5)
Different room 220 (31.3) 20 (18.5) 59 (21.5)
Age (years) median (IQR) 30 (16 - 46) 23 (15 - 35) 23 (13 - 41)
Female 408 (58.1) 57 (52.8) 149 (54.2)
BCG vaccination 539 (76.8) 80 (74.1) 240 (87.3)
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Index isolate and case contact IGRA results at follow-up
In a multivariable model, the relative risk (RR) of IGRA conversion was 1.39 (95% CI 
1.00 – 1.93; p=0.048) for contacts exposed to Beijing versus non-Beijing isolates 
(Table 6.3). Risk of conversion was also increased in contacts exposed to high smear 
grade index cases and those who spent longer with the case, and was decreased in 
those who were BCG vaccinated. The effect of BCG vaccination was modified by the 
lineage of the isolate the contact was exposed to (pinteraction=0.01). BCG showed 
strong protection for contacts exposed to non-Beijing lineages (RR 0.40; 95% CI 0.27 
- 0.61; p<0.001), whereas no protection was observed for contacts exposed to Beijing 
lineage (RR=1.02; 95% CI 0.56 – 1.85; p=0.9) (Table 6.4).
Table 6.1.   Continued.
Characteristic Baseline  
IGRA Positive
Baseline 
IGRA Negative
(N=702) IGRA converter
(N=108)
IGRA Persistently 
Negative (N=275)
Smoking history
Never smoked 458 (65.2) 70 (65.4) 194 (70.5)
Quit >6 months ago 30 (4.3) 3 (2.8) 13 (4.7)
Current smoker 214 (30.5) 34 (31.8) 68 (24.7)
BMI (kg/m2), mean (SD) 21.9 (5.3) 21.6 (5.3) 21.0 (5.0)
Diabetese
No diabetes 637 (90.7) 96 (88.9) 253 (92.0)
Pre-diabetes 44 (6.3) 7 (6.5) 13 (4.7)
Diabetes 21 (3.0) 5 (4.6) 9 (3.3)
Figures are n (%) unless otherwise indicated.
aIndex cases may be represented multiple times if they have more than one contact.
bindex case smoking, diabetes and temperature available for index cases of 1,036 contacts.
cHIV result available for index cases of 1,025 contacts.
dX-ray available for detailed reading in index cases of 1,158 contacts.
eDiabetes defined as follows: No diabetes: RCBG<101 or HbA1c<5.7%; Pre-diabetes: HbA1c 5.7%-6.4%; 
Diabetes: HbA1c³6.5%
Abbreviations: PN: persistently negative; IGRA: interferon-gamma release assay; BMI: body mass index; 
HIV: human immunodeficiency virus; BCG: Bacillus Calmette–Guérin. SD: standard deviation; IQR: interquartile 
range; IGRA: interferon-gamma release assay
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Table 6.2. Clinical and x-ray characteristics of 414 index cases according to lineage.
Characteristic Non-Beijing
(N=282)
Beijing
(N=132)
Total P-value
Age (years) 40.7 (14.6) 38.2 (12.9) 39.9 (14.1) 0.09
Female sex 139 (49.3) 55 (41.7) 194 (46.9) 0.1
Cough 277 (98.2) 131 (99.2) 408 (98.6) 0.4
HIV 0 (0.0) 1 (0.9) 1 (0.3) 0.1
Diabetes 68 (27.8) 34 (30.6) 102 (28.7) 0.5
Current smoker 28 (11.4) 10 (9.0) 38 (10.7) 0.5
Temperature 36.9 (0.8) 36.8 (0.7) 36.9 (0.8) 0.3
Sputum smear grade 0.793
3+ 85 (30.1) 38 (28.8) 123 (29.7)
2+ 76 (27.0) 36 (27.3) 112 (27.1)
Scanty/1+ 121 (42.9) 58 (43.9) 179 (43.2)
Any drug resistance 40 (14.2) 19 (14.4) 59 (14.3) 0.9
MDR 5 (1.8) 7 (5.3) 12 (2.9) 0.046
Cavities 142 (52.4) 70 (53.8) 212 (52.9) 0.8
Temperature 45.0 (25.0-70) 40.0 (25.0-65) 45.0 (25.0-70) 0.3
Hilar adenopathy 50 (18.5) 25 (19.2) 75 (18.7) 0.9
Aorto pulmonary window 42 (15.5) 24 (18.5) 66 (16.5) 0.5
Pleural effusion 23 (8.5) 7 (5.4) 30 (7.5) 0.3
Pleural thickening 14 (5.2) 7 (5.4) 21 (5.2) 0.9
Pleural calcification 3 (1.1) 0 (0.0) 3 (0.7) 0.2
Cardiomegaly 2 (0.7) 0 (0.0) 2 (0.5) 0.3
Tracheal deviation 28 (10.3) 18 (13.8) 46 (11.5) 0.3
Right upper lobe collapse 53 (19.6) 30 (23.1) 83 (20.7) 0.4
Left upper lobe collapse 26 (9.6) 12 (9.2) 38 (9.5) 0.9
Miliary pattern 3 (1.1) 2 (1.5) 5 (1.2) 0.7
Calcified granuloma 233 (86.0) 116 (89.2) 349 (87.0) 0.4
Multiple calcified granuloma 20 (7.4) 8 (6.2) 28 (7.0) 0.7
X-ray available on 401 of 414 index cases. Smoking, diabetes and temperature available for 356 index cases. 
HIV result available for 351 index cases.
Abbreviations: MDR, multidrug-resistant; HIV, human immunodeficiency virus
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Sensitivity analysis
The risk of a positive IGRA at either baseline or follow up was increased for contacts of 
index cases with a Beijing lineage isolate and decreased for BCG-vaccinated contacts 
(Table S6.3). In a multivariable model the effect of BCG vaccination was modified by 
the lineage of the index cases’ isolate (pinteraction=0.03). Contacts of index cases with 
a non-Beijing lineage had a reduced risk of a positive IGRA if BCG-vaccinated (RR 0.82; 
95% CI 0.76 - 0.89; p<0.001), whereas BCG vaccination was not associated with 
protection for contacts of index cases with a Beijing lineage isolate (RR=0.96; 95% CI 
0.86 – 1.06; p=0.4) (Table S6.4).
Exploratory analysis
Of contacts with a negative IGRA at baseline, 25 (9.1%) were exposed to an ancient 
Beijing isolate, 44 (16.0%) to a modern Beijing isolate and 206 (74.9%) to non-Beijing 
isolates. Of contacts who converted, 19 (17.6%) were exposed to an ancient Beijing 
isolate, 20 (18.5%) to a modern Beijing isolate, and 69 (63.9%) to non-Beijing isolates. 
At follow up, the risk of IGRA conversion was 1.72 (95% CI 1.02 – 2.89; P=0.041) 
for contacts exposed to an ancient Beijing isolate versus non-Beijing and 1.25 (95% 
0.77-2.01; P=0.370) for contacts exposed to a modern Beijing isolate versus non-Beijing 
(Table S6.5). Small numbers did not permit analysis of interaction with BCG.
Analysis of M. tuberculosis transmissibility
For the calculation of the M. tuberculosis transmission index, the total number of 
included households was 373; we excluded 41 without BCG-vaccinated contacts. 
We calculated an expected risk of conversion for 880 BCG-vaccinated contacts 
(BP: n=539; converter: n=80; PN: n=240; active TB: n=21). The mean transmission 
score for Beijing isolates was slightly higher but not significantly different from the 
mean transmission score for non-Beijing isolates (0.0037 vs. -0.0323, respectively; 
p=0.251, data not shown). Figure 6.2 shows the transmission indexes along the 
phylogenetic tree.
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Discussion
Here we have shown that both pathogen and host factors affect M. tuberculosis 
transmission. TB household contacts exposed to index cases infected with an M. 
tuberculosis Beijing isolate had a higher risk of becoming infected compared to those 
exposed to non-Beijing isolates. In addition, a history of BCG vaccination among TB 
household contacts was associated with a 60% lower risk of M. tuberculosis infection 
caused by non-Beijing isolates, but not with a lower risk of infection by Beijing family 
isolates. This relationship was independent of the presence of drug resistance 
mutations, or index case cavities or sputum smear grade. Therefore transmission of 
Beijing family isolates most likely arises from its ability to evade BCG-mediated 
protection in contacts, and not by inducing a more infectious disease phenotype in the 
index case31 or through its association with drug resistance.
People have speculated that BCG vaccination beginning in the mid 20th century drove 
the evolution of the virulent modern Beijing lineage32,33. We observed that the isolates’ 
transmissibility varied considerably along the phylogeny and within the Beijing 
lineage, and we did not find evidence of an evolutionary event after which the isolates 
became more transmissible (Figure 6.2). Rather, transmissibility seems to be a 
convergent trait, which has evolved independently multiple times. In addition, we did 
not find evidence to suggest that evasion of BCG protection was specific to modern 
Beijing family isolates. In fact, some studies have suggested that the evolution of 
Table 6.4.   Association between BCG vaccination and IGRA at 14 weeks for those 
negative at baseline, according to index case lineage
Lineage BCG 
vaccination
IGRA PN 
N=275
IGRA positive 
N=108
RRa 95% CI P-value
Non-Beijing No 22 21 1.00 ref
Yes 184 48 0.40 0.27 - 0.61 <0.001
Beijing No 13 7 1.00 ref
Yes 56 32 1.02 0.56 - 1.85 0.946
*Data are presented as N (%) unless indicated otherwise.
aEstimates obtained by multiple regression, adjusted for index case age, sex and smear grade, and contact 
age, sex, hours spent with index case smoking and body mass index.
Abbreviations: PN: persistently negative; IGRA: interferon-gamma release assay; BCG: Bacillus Calmette–
Guérin; IGRA: interferon-gamma release assay; RR: relative risk calculated as risk ratios; 95% CI: 95% 
confidence interval.
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modern lineages predates the widespread use of BCG. Still, evasion of BCG-mediated 
immunity could contribute to the global emergence of the Beijing lineage. It may also 
contribute to the variability in estimates for protective effectiveness of BCG in different 
locations.
Our finding of an increased prevalence of M. tuberculosis infection in Indonesian case 
contacts of index cases with Beijing lineage isolates compared to others, mostly 
Euro-American lineage isolates, is consistent with the global emergence of the Beijing 
lineage over recent decades10-13,34. However, the results of the few case contact 
studies that have assessed the impact of the pathogen on transmission are not 
consistent. In a cohort study of patients with TB and their household contacts in The 
Gambia, no difference in transmission between the MTBC lineages was observed35; 
in addition, the ratio of infected child contacts among those exposed to a Beijing 
strain did not differ from those exposed to a non-Beijing strain in South-Africa36; 
and the Beijing genotype was not associated with a higher number of tuberculin skin 
test (TST)-positive contacts in The Netherlands37. In these countries however, 
the prevalence of the Beijing lineage is low (3 to 5% in Central America, Europe, and 
Africa38) and the estimates for the Beijing lineage may lack precision. A recent study of 
households in Guangxi, China, where the prevalence of Beijing genotype strains is 
higher (as high as 45% in Far East Asia38), showed that exposure to a Beijing strain was 
independently associated with a positive TST39. The discrepancies between results 
from these studies might also result from differences in how and if host-related factors 
were controlled for.
Another method that has been used to study transmission is investigating transmission 
chains, usually by clustering strains based on genotype similarities. Several studies 
have found increased clustering of Beijing lineage isolates, assessed by whole genome 
sequencing10,13,40 or VNTR genotyping41. In contrast, two studies performed in low 
prevalence countries have not found increased clustering associated with the Beijing 
lineage42,43. The Beijing genotype consists of a number of sub-lineages and so the 
discrepant findings could be due to the prevalence of different sub-lineages in the 
different study populations, as suggested previously44. Within the Beijing lineage, 
modern Beijing strains were more often in a cluster than ancient Beijing strains in a 
study of 376 MDR-M. tuberculosis strains in China45, and a study conducted in South 
Africa found significantly more clustering linked to recently evolved sub-lineages of 
the Beijing strain family compared to other sub-lineages46. These studies have inferred 
transmission from the frequency of clustered isolates in surveillance culture collections 
where clinical and exposure data on cases are often limited. Furthermore, clustering in 
such studies may arise from more efficient transmission of a particular isolate but also 
from differences in progression of latent TB infection to active disease. A strength of 
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the present study is the direct measurement of transmission, defined as passing 
infection from index case to contact, and the ability to find detailed data on the index, 
contacts and their exposure to one another, at a level of detail that is not feasible 
for studies of clustered isolates. The prospectively defined groups enabled better 
measurement of confounding factors and accounted for misclassification of baseline 
positive patients, whose source of infection might have been different than the household 
index case47, and whose infection might have happened in the distant past.
A study has found that BCG vaccination and BMI were risk factors for clustering among 
Beijing strains in China48; both factors associated with a persistently negative IGRA in 
the present study. Adaptation of M. tuberculosis Beijing strains to their East-Asian host 
population as a result of host-pathogen co-evolution could have explained their higher 
transmissibility49-51, but is unlikely to have caused the differential protective effect of 
BCG. It is difficult to speculate on the mechanism through which Beijing lineage strains 
evade BCG-mediated protection, when the mechanism of BCG protection itself is 
unknown. Beijing lineage strains could evade host immune response in the contact by 
evading recognition and reducing the pro-inflammatory cytokine production during 
infection, as seen in ex vivo studies52-54. In this cohort we previously showed that a 
persistently negative IGRA was associated with heterologous cytokine responses, 
similar to those activated during induction of trained innate immunity55.
Without a safe human challenge model for tuberculosis, variation in BCG efficacy 
according to M. tuberculosis lineage cannot be assessed in experimental studies. 
Results from observational studies such as this need to be considered in light of their 
potential limitations. We determined BCG vaccination status by assessing the presence 
of a scar, as it is the most reliable method when dealing with a mixed age cohort. 
A minority of BCG vaccine recipients do not form a scar when administered at birth. 
Although this may introduce a bias whereby vaccination status inferred from scar 
formation leads to an underestimate of the effectiveness of BCG56, it is not plausible 
that this misclassification differs according to the M. tuberculosis lineage of the index 
case, which was not determined until after the study concluded. Similarly, the IGRA 
is not a perfect test for M. tuberculosis infection, but there is no evidence that 
its performance differs according to infecting M. tuberculosis genotype. We have 
previously reported that more stringent definitions of conversions did not alter 
estimates of BCG mediated protection29. A sensitivity analysis that included participants 
with a positive IGRA at baseline replicated the main finding, indicating that the 
exclusion of these participants from the primary analysis was not an important source 
of bias. Finally, the distribution of lineages and size of the study meant only an analysis 
of Beijing lineage versus all other lineages was possible.
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In summary, M. tuberculosis Beijing genotype strains are associated with more 
transmission and may evade BCG-induced immunity. Whether this finding is 
generalizable to other ethnic host populations warrants further investigation. The 
impact of BCG vaccination on TB transmission may depend on the M. tuberculosis 
lineage distribution in the setting it is used. Ultimately, understanding the underlying 
mechanism of BCG evasion by Beijing family isolates could advance the knowledge on 
the development of new vaccines.
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Supplementary tables
Table S6.1.   Drug resistance mutations summarized per gene in Beijing and 
non-Beijing M. tuberculosis isolates
Drug
Gene containing 
mutation(s)
Beijing
(N=133)
Non-Beijing
(N=281)
Isoniazid katG
Rv1482c-fabG1
ahpC
10 (8%)
2 (2%)
1 (1%)
14 (5%)
13 (5%)
0
Rifampicin rpoB 9 (7%) 6 (2%)
Ethambutol embB
embC-embA
5 (4%)
0
3 (1%)
1 (0.4%)
Pyrazinamide pncA 4 (3%) 13 (5%)
Streptomycin rpsL
rrs
gid
5 (4%)
2 (2%)
0
1 (0.4%)
0
2 (1%)
Ethionamide Rv1482c-fabG1
ethA
2 (2%)
0
13 (5%)
2 (1%)
Fluoroquinolones gyrA 2 (2%) 1 (0.4%)
Amikacin rrs 1 (1%) 0
Capreomycin rrs
tlyA
1 (1%)
0
0
2 (1%)
Kanamycin eis-Rv2417c
rrs
1 (1%)
1 (1%)
0
0
Para-aminosalicylic acid folC 1 (1%) 1 (0.4%)
Data represent the number (%) of isolates with at least one known drug resistance-conferring mutation in 
the respective gene.
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Table S6.2.   Dominant x-ray abnormality according to lung zone and lineage 
for 401 index cases
Non-Beijing Beijing
Dominant 
x-ray 
 abnormality
Any
N (%)
Upper
N (%)
Mid
N (%)
Lower
N (%)
Any
N (%)
Upper
N (%)
Mid
N (%)
Lower
N (%)
None 2 (0.7) 21 (7.7) 32 (11.8) 89 (32.8) 2 (1.5) 19 (14.6) 26 (20.0) 53 (40.8)
Cavity 142 (52.4) 112 (41.3) 49 (18.1) 6 (2.2) 70 (53.8) 60 (46.2) 18 (13.8) 2 (1.5)
Consolidation 51 (18.8) 42 (15.5) 42 (15.5) 35 (12.9) 25 (19.2) 18 (13.8) 27 (20.8) 19 (14.6)
Patchy Lesion 74 (27.3) 89 (32.8) 137 (50.6) 134 (49.4) 32 (24.6) 32 (24.6) 56 (43.1) 52 (40.0)
Nodules 1 (0.4) 1 (0.4) 2 (0.7) 1 (0.4) 1 (0.8) 1 (0.8) 2 (1.5) 2 (1.5)
Bullae 1 (0.4) 6 (2.2) 9 (3.3) 6 (2.2) 0 (0.0) 0 (0.0) 1 (0.8) 2 (1.5)
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Table S6.4.   Association between BCG vaccination and IGRA at baseline and 
14 weeks, according to index case lineage
Lineage BCG 
vaccination
IGRA-
negative
N=275
IGRA-
positive
N=108
APRa 95% CI P-value
Non-
Beijing
No 22 131 1.00 ref
Yes 185 409 0.82 0.76 - 0.89 <0.001
Beijing No 13 66 1.00 ref
Yes 56 230 0.96 0.86 - 1.06 0.4
aEstimates obtained by multiple regression, adjusted for index case age, sex and smear grade, cavities and 
contact age, sex, sleep proximity to index case, hours spent with index case, smoking and body mass index. 
Abbreviations: BCG: Bacillus Calmette–Guérin; IGRA: interferon-gamma release assay; APR: adjusted prevalence 
ratio; 95% CI: 95% confidence interval.
Table S6.5.   Association between the index cases’ M. tuberculosis lineage  
and IGRA conversion in household contacts who were IGRA negative 
at baseline (N=383)
PN Converter RR 95% CI P-value
Other isolates 206 (74.9) 69 (25.1) 1,00 ref
Ancient Beijing 25 (56.8) 19 (43.2) 1,72 1,02 - 2,89 0,041
Modern Beijing 44 (68.8) 20 (31.3) 1,25 0,77 - 2,01 0,37
*Abbreviations: PN: persistently negative; RR: relative risk; CI: confidence interval.
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General discussion
The two parts of this thesis are discussed separately, followed by an outlook on the 
present and future challenges and opportunities of whole genome sequencing of M. 
tuberculosis.
Part one: drug resistance
The World Health Organization recommends drug-susceptibility testing of M. tuberculosis 
complex (MTBC) isolates for all patients with tuberculosis to guide treatment decisions 
and improve outcomes. Still, it is estimated that only 29% of the 558,000 people 
(range 483,000 – 639,000) who developed multidrug/rifampicin-resistant tuberculosis 
in 2017 were detected and notified to national tuberculosis programmes1. These data 
come from 91 countries that have continuous surveillance systems, and 69 countries 
that rely on epidemiological surveys of bacterial isolates collected from representative 
samples of patients. In resource-limited settings where routine drug-susceptibility 
testing is not accessible to all tuberculosis patients owing to lack of laboratory capacity 
or resources, surveys conducted about every five years represent the most common 
approach to investigate the burden of drug resistance1. In the first part of my thesis 
I have shown that whole genome sequencing is not only a promising alternative to 
phenotypic drug susceptibility testing in the diagnosis of drug-resistant tuberculosis, 
but that it can also guide individualized clinical decision-making, and add to our 
understanding of the epidemiology of drug-resistant tuberculosis.
Performance of genotypic compared to phenotypic drug  
susceptibility testing
Whole genome sequencing is an ideal technique for drug-susceptibility prediction in 
M. tuberculosis, in which drug resistance is largely determined by chromosomal 
mutations, especially now the costs of sequencing have come down substantially and 
tools to facilitate the analysis of whole genome sequencing data are becoming 
increasingly available2,3. In Chapter 2 of this thesis we showed that in a highly endemic 
setting in Indonesia the agreement of whole genome sequencing-based resistance 
prediction and phenotypic testing was high for isoniazid and rifampicin and lower for 
ethambutol and streptomycin. Recently, a large consortium showed, based on the 
analysis of more than 10,000 M. tuberculosis isolates collected from 16 countries 
across six continents and representing all major lineages, that whole genome 
sequencing can characterize susceptibility profiles to first-line antituberculosis drugs 
with high enough accuracy to be used in clinical practice4. The WHO targets of 90% 
sensitivity and 95% specificity for new molecular assays for M. tuberculosis were met 
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for all drugs, except the specificity for ethambutol. This study, like ours and most other 
studies, evaluated the performance of whole genome sequencing for drug susceptibility 
testing compared to phenotypic testing as the gold standard, but phenotyping is an 
imperfect standard5,6, as we also showed in Chapter 3. Currently established 
procedures for M. tuberculosis phenotypic drug susceptibility testing classify clinical 
isolates as either drug-‘resistant’ or drug-‘susceptible’, on the basis of their ability to 
grow in the presence of a (mostly single) ‘critical drug concentration’6, defined as the 
lowest drug concentration that inhibits ≥95% of wild-type strains of bacilli that have 
not been exposed to the drug previously. This definition of drug susceptibility is based 
on laboratory tests, and patients with strains that are flagged resistant in this manner 
do not necessarily fail to respond to treatment7. In addition, breakpoint artefacts, 
where critical concentrations are set too high, have been reported as a major cause 
for systematic phenotypic drug susceptibility testing errors5. Our findings in Chapter 3 
that mutations associated with ethambutol and streptomycin resistance only 
moderately increased the minimum inhibitory concentration and that breakpoints 
were set too high, could explain the discrepant results between genotypic and 
phenotypic drug susceptibility testing for these drugs observed in Chapter 2. 
Therefore, discrepancies between genotypic and phenotypic drug susceptibility 
testing should be studied cautiously and not automatically be judged in favour of the 
phenotypic method.
Precision medicine
Individualization of therapy based on whole genome sequencing for the treatment of 
drug-resistant tuberculosis will require an extensive knowledgebase in which the 
effect of genomic mutations (and their combinations) on all relevant drugs is 
characterized. In addition, a clear understanding of what the molecular-level data are 
predicting is essential. Studies to date have tried to link mutations to minimum 
inhibitory concentrations8,9, or to a probability of one of two outcomes - phenotypic 
resistance or susceptibility10 for certain drugs. In Chapter 3 we linked whole genome 
sequence-determined mutations to minimum inhibitory concentrations for all first- 
and most of the second-line drugs and found that different mutations lead to different 
levels of resistance; knowing the underlying mutations can guide clinical deci-
sion-making and facilitate therapeutic drug monitoring. The ultimate aim would be for 
molecular data to predict treatment outcome directly. The clinical implications of some 
mutations known to lead to high-level isoniazid (katG S315T), rifampicin (rpoB S450L) 
and fluoroquinolone (gyrA 94) resistance and treatment failure have been outlined in 
a consensus statement11, and are in line with our findings. The data we presented in 
Chapter 3 furthermore indicated that particular mutations in rpoB only cause a slight 
increase in the minimum inhibitory concentration for rifampicin and might justify the 
prescription of high-dose rifampicin in patients with these mutations. Similarly, a 
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recent paper by Farhat et al. discovered that promotor mutations have smaller average 
effects on resistance than gene body mutations9 and may be overcome by increased 
dosing. This way, whole genome sequencing can ultimately be used to personalize 
tuberculosis treatment, based on the detailed characterisation of the resistance profile 
of the bacterium12 (Figure 7.1). HIV has already set an example, as nowadays genotypic 
resistance testing in developed countries is performed routinely as companion 
diagnostics in HIV therapy13.
Implementation in routine clinical diagnostics
Sequencing-based drug susceptibility testing offers other benefits for diagnosis and 
therapy besides the prospect of personalizing tuberculosis treatment. First, if all resis-
tance-conferring mutations were known, this would facilitate individualized treatment 
by determining which drugs to give, not only which ones to avoid. Second, as drug 
resistance can be predicted from the genome sequence before phenotypic results 
become available, treatment with an appropriate regimen can be initiated earlier, 
reducing the risk of treatment failure, resistance amplification and transmitting 
drug-resistant tuberculosis. The potential of whole genome sequencing being 
performed directly on clinical samples would reduce the time to appropriate treatment 
initiation even further. Walker and colleagues14 have shown that data from whole 
Figure 7.1. Drug resistance mutations can guide clinical decision-making. “Neutral variant” 
indicates that the mutation has no effect on the minimum inhibitory concentration for a specific 
drug.
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genome sequencing could be used clinically, to predict first-line drug resistance, drug 
susceptibility or to identify drug phenotypes that cannot yet be genetically predicted, 
and that this approach could be integrated into routine diagnostic workflows. Data on 
the routine use of genetic sequencing for antituberculosis drug resistance are scarce 
and only from industrialised countries. However, whole genome sequencing should be 
implemented particularly in low-income, high-burden settings where many still rely on 
empirical treatment regimens and the need is greatest, to actually revolutionize the 
diagnosis of drug-resistant tuberculosis. The studies that are part of this thesis are all 
performed in highly endemic, limited-resource countries, but whole genome sequencing 
was applied retrospectively, for research purposes. Research on the implementation 
of genome sequencing for routine drug-susceptibility testing in resource-limited 
settings has not been performed and is urgently needed.
Further study on possible loss-of-fitness-compensating mutations
Whole genome sequencing has facilitated significant progress in understanding the 
complex biology and epidemiology of drug-resistant tuberculosis, next to the clinical 
benefits of M. tuberculosis sequencing-based drug susceptibility testing. Mutations 
that lead to resistance can be deleterious or produce a fitness cost in the absence of 
the drug. One could therefore hypothesise that resistant strains are less virulent or 
less easily transmitted than drug-sensitive strains15-17. However, recent work has 
shown that additional mutations often follow or coincide with drug resistance mutations, 
and that these mutations can compensate for deleterious effects, restoring their initial 
growth capacity18-20. Based on the data In Chapter 4 one may hypothesize that less fit 
drug-resistant M. tuberculosis strains are more likely to cause active disease among 
people living with diabetes, because of their lower host defence21, and that these 
strains would have less mutations compensating for the resistance-associated loss of 
fitness. Our data did not support this hypothesis: we found no differences in the 
presence of potential rifampicin resistance-compensating mutations between strains 
infecting diabetes and non-diabetes patients.
A large number of putative compensatory mutations have been reported in the rpoA, 
rpoB and rpoC genes encoding the α-, β- and β’-subunits of the RNA polymerase22,23. 
However, except for some notable exceptions24, the evidence that they compensate 
for a loss of fitness caused by the primary resistance mutation has mainly been 
statistical23,25,26. Therefore, in addition to the results presented in Chapter 4, where 
we focused on all non-synonymous mutations in rpoA, rpoB and rpoC, we sought to 
identify which of these mutations co-localized onto the 3D structure of the 
Mycobacterium smegmatis RNA polymerase. To this end, we counted the number of 
rpoA/B/C mutations in M. tuberculosis isolates with a known rifampicin-resistance 
mutation that converged in the 3D structure of the molecule as evidence for their role 
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in compensation for the loss of fitness caused by the resistance mutation. Conceptually 
this takes the approach of counting the number of “convergent” mutations that occur 
a the same location in the sequence a step further by examining it in the 3D structure 
and by putting it on a formal statistical basis (schematically represented in Figure 7.2). 
We projected the mutations that co-occur with the various rifampicin resistance 
mutations (separately for rpoB S450L, V170F and for rpoB mutations at position 435 
and 445) onto the structure of the M. smegmatis RNA polymerase, which is 91% 
identical at the sequence level with M. tuberculosis27. We used the tool mutation3D28 
that uses randomizations of the locations of mutations in the 3D structure to analyse 
whether certain regions are overrepresented, and explicitly includes convergent 
mutations in its analysis. For rpoB S450L we found one, highly significant (E < 1E-5) 
cluster that contains one mutation in rpoA (V183A) and five mutations in rpoC (V483G, 
V483A, W484S, I491V and V517L), distributed over two regions in the sequence 
(Figure 7.3). It should be noted that mutations in this region have been associated 
with resistance mutations before22,29 although not with all specific mutations that 
we found. For the other rifampicin resistance mutations we observed no significant 
clusters of compensating mutations in the 3D structure. The co-localizing mutations in 
the significant cluster occurred in rifampicin-resistant isolates from three tuberculosis 
patients with, and six without diabetes, and there was no difference in the presence of 
these mutations between strains infecting diabetes and non-diabetes patients.
Figure 7.2. Missense mutations in a hypothetical protein. The linear protein model is given 
below the 3D structure to illustrate the importance of studying co-localisation of mutation in 3D 
structures. The mutations in red co-localize in the 3D model, whereas the mutation in green 
seems to cluster with the two red mutations in the linear protein model but falls outside the 
cluster in the 3D structure.
1 308 
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Figure 7.3. Potential rifampicin resistance-compensating mutations in rpoA and rpoC that 
co-localize on the 3D structure of M. smegmatis RNA polymerase. Mutations identified in 
M. tuberculosis isolates with rifampicin resistance mutations were mapped onto the RNA 
polymerase structure of M. smegmatis. The co-localised mutations (residues coloured in red) 
fall at the interface of rpoA (α- subunit, dark blue) and rpoC (β’-subunit, yellow) of the 
M. smegmatis RNA polymerase. RpoB (β-subunit) is coloured in green.
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Although the clustered mutations were not associated with the diabetes phenotype, 
our findings add evidence to the possible compensatory role of these mutations. Their 
interaction with the strain genetic background and the fitness cost of the resistance 
mutations may together influence the spread and maintenance of resistant variants in 
the population, a process called epistasis30 (Figure 7.4).
Figure 7.4. Epistatic interactions: the effect of drug resistance mutations alone or in 
combination as well as the presence of compensatory mutations affects the fitness of 
drug-resistant M. tuberculosis strains as a function of the strain genetic background.
Epistasis
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Based on the findings in this thesis, and those of others, I think that whole genome 
sequencing-based drug susceptibility testing of M. tuberculosis can drastically 
improve the diagnosis of drug-resistant tuberculosis, but that there are important 
challenges to be addressed (Box 7.1).
Part two: tuberculosis disease phenotype and transmission
The second part of this thesis focused on the link between M. tuberculosis genotype 
and tuberculosis disease phenotypes.
Exposure to M. tuberculosis can be followed by early clearance through innate 
immunity, direct development of active disease, or latent infection that may or may not 
reactivate up to several decades after initial exposure. Traditionally, these different 
phenotypes have been attributed to host and environmental variables33. Because of 
the limited genetic diversity within MTBC (99.9% nucleotide identity34) compared to 
other bacteria, the view has been that this “negligible” strain-to-strain genetic variation 
had no phenotypic relevance, i.e. lineage- or strain-specific differences in disease 
Box 7.1.   Conclusions and challenges of using whole genome sequencing 
for drug susceptibility testing
Conclusions
• Whole genome sequencing-based drug susceptibility testing of M. tuberculosis has  
the potential to drastically improve the diagnosis of drug-resistant tuberculosis:
		Faster and more accurate diagnosis
		Possibility to predict drug susceptibility in addition to resistance
• By generating whole genome sequencing data and linking these to relevant clinical 
parameters using state-of-the-art machine learning techniques, we can:
		Increase our understanding of the molecular basis of antibiotic resistance 
			Reach better performance for several drugs while significantly reducing  
the number of candidate mutations to consider31,32
		Design PCR assays that target a small but optimal number of markers
Challenges
• Implementing whole genome sequencing in high-burden countries:
		Need for expensive equipment and highly trained personnel
		Requires complex bioinformatic procedures
• Lack of understanding of the genetic basis of antibiotic resistance complicates  
the interpretation of whole genome sequencing data
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manifestations. However, recent advances in whole genome sequencing of large MTBC 
clinical strain collections from global sources have revealed more genomic diversity 
than previously anticipated. In addition to the genomic diversity across MTBC clinical 
strains, findings from many experimental studies have led to a change in paradigm by 
demonstrating the phenotypic impact of this genetic diversity. For example, studies 
have reported differences between clinical strains with respect to their transcriptomic 
profiles35,36, protein and metabolite levels36,37, methylation profiles37,38, drug susceptibility39 
and cell wall structure40-42. In addition, MTBC genetic diversity has also been shown 
to influence disease severity and human to human transmission, with “modern” 
lineages showing a faster progression to disease and shorter latency periods compared 
to strains from the “ancestral” clades43-46. At the lineage level, the East-Asian lineage 
(Lineage 2) has been linked to increased transmission and extrapulmonary disease47,48 
compared to the other lineages.
Associations beyond M. tuberculosis lineage level
However, associations reported between lineage and disease phenotype are not 
consistent46 and considerable intra-lineage diversity exists. For example, Lineage 2 
strains exhibit a range of inflammatory and virulence phenotypes49,50. This could be 
due to the fact that Lineage 2 consists of a variety of sub-lineages, including various 
variants of “Beijing” strains, which might differ phenotypically42. Beijing strains have 
been proposed to possess selective advantages comprising an increased capacity to 
acquire drug resistance, increased transmissibility, hypervirulence and more rapid 
progression to disease after infection51. Still, also the association of Beijing strain 
infection with disease manifestations is not consistent52. This heterogeneity, together 
with evidence for higher virulence of modern Beijing strains in comparison with 
ancestral sublineage strains53,54, suggests the existence of inter-strain variation within 
sublineages affecting the disease phenotype, or an important role for the interaction 
between the host and pathogen genotypes (co-evolution)55.
In general, the genetic factors that are used to classify M. tuberculosis in phylogenetic 
groups, whether at supra-lineage, lineage, or sub-lineage level, do not necessarily 
provide clear genetic determinants of tuberculosis disease phenotype. For example, 
the genes that have been found to be associated with the invasion or survival of 
M. tuberculosis in the central nervous system56, important for the development 
of tuberculous meningitis, can be found in all lineages of M. tuberculosis. Detecting 
the M. tuberculosis genetic determinants of phenotypic differences requires analytical 
methods that index genomic diversity in a more comprehensive manner. Many 
genotyping schemes have been developed for M. tuberculosis in the past57, but only 
whole genome sequencing provides information about the whole genome, and can 
identify virtually all varieties of markers detected by other genotyping methods. It is 
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therefore highly accurate and precise in detecting variability among strains and 
provides a wealth of information at every level possible. In Chapter 5, we did not find 
an association between M. tuberculosis lineage and the tuberculous meningitis 
phenotype, but using whole genome sequencing we did find evidence for homoplastic 
genetic variation in three genes that were associated with the disease phenotype. The 
one study published on this topic after our study used a similar approach, and also 
identified variants – though different from the ones we found - associated with 
tuberculous meningitis in a lineage-independent fashion58.
Challenges associated with microbial genome-wide association studies
The high resolution of whole genome sequencing also comes with analytical challenges 
in the quest to link genotype to phenotype. Instead of two categories, when linking 
ancient vs. modern lineages to differences in disease phenotype, the number of 
possible variations increases tremendously when examining all possible SNPs, insertions, 
and deletions across the entire genome, even in a clonal organism as M. tuberculosis. 
Whole genome sequencing generates thousands of potentially relevant mutations, 
the large majority of which will be noise that is not related to the phenotype of interest. 
In human genetics, genome-wide association studies (GWAS) have been developed 
and methods advanced significantly in the past fifteen years. The purpose of GWAS 
is to identify statistically significant associations that may indicate the presence of 
a causal relationship between genotype and phenotype while rejecting spurious 
associations arising from confounding factors. Compared to human GWAS, smaller 
genome sizes and the ability to manipulate the genomes in the laboratory may improve 
the power and computational ease of bacterial GWAS and facilitate the confirmation 
of candidate loci59. Bacterial association mapping nonetheless remains a technical 
challenge in search of an optimal methodological approach. Microbial GWAS must 
overcome various confounding factors, such as the stronger population stratification60, 
and the selection force on bacteria-related phenotypes. The problem of population 
stratification is especially critical in highly clonal (rarely recombining) bacteria, and 
in those with separate geographic- or host-associated subpopulations, such as M. 
tuberculosis59.
Phylogenetic approach
Fortunately, population stratification and selection enable the adoption of a 
phylogenetic solution in microbial GWAS. Phylogenetic trees allow for the detailed 
identification of genetic relationships, not only at the level of population clusters, but 
also at the resolution of subpopulations and individual relationships. By combining a 
signal of selection with phenotypic associations, the phylogeny helps to decipher if an 
association is due to genetic relatedness rather than causality for the phenotype of 
interest (e.g. convergent mutations that occur only in cases and not in controls are 
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more likely to be causally related to the phenotype of interest). In Chapter 5, we used 
this ‘homoplasy counting’ method to find M. tuberculosis genetic variations associated 
with the tuberculous meningitis phenotype by focusing on repeated and independently 
emerging mutations occurring more often on branches of isolates from tuberculous 
meningitis patients compared to those from pulmonary tuberculosis patients (Figure 7.5).
The pitfall in using the phylogeny to adjust for associations due to population 
stratification (‘phylogenetic noise’) is the risk of masking causal variants, because 
differences between lineages account for large proportions of both phenotypic and 
genotypic variability. Correcting for lineage-effects will lead to overcorrection when 
these effects are biologically meaningful. In Chapter 6, we discovered that M. 
tuberculosis isolates belonging to the Beijing sublineage were associated with 
increased transmission. Additional analyses, including host-related variables, showed 
that this increased transmissibility was related to evasion of BCG-protection by these 
“Beijing” isolates. In this case, the observed lineage effect could, in a next step, guide 
the identification of loci that contributed to the significant lineage-level association. 
Disentangling the effects of a single variant from those related to lineage is potentially 
challenging, but has been shown to increase the power of microbial GWAS61. This 
strategy provides an alternative to prioritizing variants based solely on locus-specific 
significance, but it carries risks, because lineage-associated effects are more 
Figure 7.5. The homoplastic AC mutation occurs independently in the tree and is associated 
with the tuberculous meningitis (TBM) phenotype.
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susceptible to confounding with population-stratified differences in environment or 
sampling. Hence, dealing with population stratification represents a trade-off between 
the power to detect genuine associations of population-stratified variants and 
robustness to unmeasured, population stratified confounders.
Correction for multiple testing
Apart from the mentioned confounding factors, the other major source of false-positive 
associations is the multiple testing-problem that is intrinsic to GWAS. Various dimen-
sion-reduction approaches can be used to counter this problem. First, well-known 
methods to adjust for the large number of tests are the Bonferroni correction or the 
Benjamini-Hochberg procedure. Second, one can use independent datasets and test 
the most significant associations from the one set in the other. In Chapter 5, we used 
this approach and identified a list of top variants that were most likely associated with 
the tuberculous meningitis phenotype, and tested only these in a validation set of 
independent isolates, reducing the number of tests to correct for. A third method is the 
burden test, to aggregate information across several variant sites within a gene to 
enrich association signals and to reduce the penalty of multiple testing, which we also 
applied in Chapter 5. We also tested variants at pathway-level, an even higher level of 
aggregation. Fourth, a polygenic association test can be employed when one assumes 
that the trait in question is affected by a large number of variants on different genes. 
Fifth, one may choose to filter rare variants occurring in less than 1% of the isolates. 
Due to the highly clonal population structure of M. tuberculosis, many variants are rare 
and only occur in a very small fraction of the isolates (<0.01), increasing the number of 
variants to test for. Recent studies have found that 75% of the variants were found at a 
frequency of less than 0.0028 and 0.00054 in lineages 2 and 4, respectively in 4,408 
sequenced genomes62, and that 83% of the variants had a frequency of ≤0.01 in 1,452 
genomes9. Depending on the underlying assumption whether the cumulative effect of 
these rare variants together could explain a large amount of the variance in risk, they 
can be included in a burden test, a polygenic association test, or filtered-out to reduce 
the multiple testing issues. 
Validation
We know from the experience of human GWAS that some loci found to be associated 
with a trait (after correction for multiple testing), can turn out to have little or no 
functional significance63. Therefore, unless the associated locus has been previously 
shown to affect the phenotype, functional validation is desirable. The strongest 
evidence for the inference of functional associations remains experimental validation 
in the laboratory. The genetic variants we identified in Chapter 5 and 6, associated 
with tuberculous meningitis and transmissibility, respectively, could be validated 
experimentally. For example in a stimulation experiment where human macrophages 
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from tuberculosis patients are infected with M. tuberculosis strains with and without 
the identified mutations, a method that has been applied successfully in our laboratory 
before64. Even stronger proof for a functional role would come from validation by 
genetic disruption and reconstruction of M. tuberculosis strains, coupled with loss and 
regain of the phenotype, using transposon insertion mutagenesis65. With this ‘top 
down’ approach, findings from hypothesis-free GWAS can be used to generate 
hypotheses to be tested either in hypothesis-driven genetic association studies or 
experimentally in the laboratory.
Whole genome sequencing of M. tuberculosis has already, and will continue to improve 
our understanding of the evolutionary and molecular processes involved. Still, truly 
understanding the biological mechanisms underlying particular tuberculosis disease 
phenotypes studied in this thesis and by others remains extremely difficult. I believe 
that one of the major challenges is to define the phenotypic impact of specific 
M. tuberculosis genetic variants in the context of other bacterial determinants, 
the M. tuberculosis strain’s genetic background and other host and environmental 
factors also impacting the phenotype. This requires carefully considered study designs 
with an analytical approach integrating all these factors. 
Future perspectives
Understanding the M. tuberculosis genome biology is a necessary step towards the 
control of tuberculosis. The M. tuberculosis genome was first sequenced in 1998 and 
thanks to progress in high-throughput sequencing and decreasing raw sequencing 
costs many more M. tuberculosis genomes have since been sequenced66-68, including 
the more than 1,000 in this thesis. The community consensus is that M. tuberculosis 
whole genome sequencing is now advanced enough to inform clinical decisions and 
public health policy69. Several challenges associated with the standardization, 
validation and implementation of M. tuberculosis whole genome sequencing remain to 
be addressed (Table 7.1) that will require political commitment and the participation 
of supranational laboratories and regulatory authorities. In addition, the research 
community as a whole should continue to improve the technical and analytical aspects 
of whole genome sequencing. I would encourage health policy makers to commit 
resources to ensure access to standardized and validated whole genome sequencing 
methodologies, especially in high-burden countries, where they will have the largest 
impact on tuberculosis control.
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Implementation in routine clinical diagnostics
Whole genome sequencing has huge potential for applications in diagnostic micro- 
biology including isolate characterization, drug susceptibility testing and establishing 
the source of recurrent infections and between-person transmissions. All of these 
have obvious clinical relevance and could provide additional information or even 
replace the knowledge obtained through standard clinical microbiology techniques. 
However, to date, M. tuberculosis whole genome sequencing has been mostly used 
for research purposes. One major limitation to rapidly obtaining useful information in 
a clinical setting is that analysis pipelines for microbial genomics have generally been 
Table 7.1.   Overview of challenges and opportunities associated with applications 
of M. tuberculosis whole genome sequencing discussed in this thesis
Challenges Opportunities
General
! High costs
! Data storage capacity
! Bioinformatics support & IT infrastructure
! Difficult to sequence regions with repetitive 
elements
! Maintenance of software tools70
+ Information on the entire genome
+ High resolution
+ PacBio sequencing: repetitive regions and 
methylation sites71
+ Can generate hypotheses to be tested 
experimentally
Drug susceptibility testing
! Implementation in low-resource settings
! Relies on quality of mutation database
! Resistance mutation catalogues rely mostly 
on data from lineages 2 & 472,73
! Mixed infections or heteroresistance74
! Incomplete understanding of the genetic 
basis of M. tuberculosis drug resistance
! Standardisation of methodology and 
genotype nomenclature75
! Implementation in routine clinical 
diagnostics
+ Faster than phenotypic DST
+ Personalized medicine
+ Pipeline adaptation for NTM
+ Resistance to many drugs at no extra costs
+ Detection of novel resistance mutations9
+ Sequencing directly on patient samples will 
provide results faster76
+ Mapping transmission routes of drug-
resistant tuberculosis
+ Input for designing PCR-based assays
+ Easy-to-use tools for raw sequencing files
Linking genotype to phenotype
! Confounding by host-related factors
! Strong population stratification77
! Multiple testing problem
! Many rare variants
! Validation
+ Phylogeny-based methods to correct for 
population stratification and selection78
+ Possibilities for dimension reduction  
(e.g. polygenic and burden tests)
+ Genome-to-genome approach79
Abbreviations: DST: drug susceptibility testing; NTM: nontuberculous mycobacteria; PCR: polymerase chain 
reaction.
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 183
 General discussion | 183
7
developed for fundamental research or public health epidemiology80. This usually 
means that the pipeline consists of a very thorough and sophisticated workflow with 
a large number of options and parameters. While this is desirable from a researcher’s 
perspective, it is clearly problematic for real-time analysis in a clinical setting. The user 
requires in-depth knowledge about the purpose each tool serves, the relative strengths 
and weaknesses of each approach, and a functional understanding of the important 
parameters. Furthermore, knowledge of the Linux operating system and command line 
is often essential for most of the advanced bioinformatic analyses; something clinical 
microbiologists are rarely trained for. Hence, there is a need for simpler software tools, 
free of charge, able to analyse data directly from the initial raw sequencing files, 
providing the basic functionalities all in one. Fortunately, online software tools are 
becoming increasingly available to support the clinical microbiologist in the analysis 
of M. tuberculosis whole genome sequencing data2,81 (Table 7.2).
The implementation of whole genome sequencing in routine clinical diagnostics is 
particularly promising for drug susceptibility testing. The prediction of drug 
susceptibility based on drug resistance mutations has been shown reliable for first-line 
drugs4,87, especially in settings with low drug resistance rates, and Public Health 
England has already decided to stop phenotypic drug susceptibility testing of isolates 
that are predicted to be genotypically susceptible to all first-line drugs. Similar 
decisions have been made in the Netherlands (planned for the end of 2019) and New 
York4. Ideally, genetic data should be linked to minimum inhibitory concentrations 
and, preferably, to patient outcomes. The aim would be to have a comprehensive, 
Table 7.2. ‘ Easy-to-use’ non-commercial genome analysis tools using raw 
sequencing data as input
Year of 
introduction
Web-
based
Batch mode Variants 
reported
Number of 
drugs tested 
CASTB82 2015 Yes No None 6
KvarQ83 2014 No Yes Only resistance 
mutations
9
Mykrobe 
Predictor 
TB84
2015 No In command 
line version only
Only resistance 
mutations
12
PhyResSE85 2015 Yes Yes All mutations 12
TBProfiler72 2015 Yes In command 
line version only
All mutations in 
candidate genes
12
TGS-TB86 2015 Yes Yes All core genome 
mutations
8
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standardized and curated resource for clinically relevant genetic mutations and 
associated metadata (geographic location, minimum inhibitory concentration, 
response to treatment)88, similar to the in 2007 established Stanford HIV Drug 
Resistance Database89. Whole genome sequencing on a large number of strains 
collected worldwide, coupled with these metadata can provide the appropriate 
statistical power to identify the subset of mutations predictive of treatment failure to 
any given drug. Furthermore, linking this with therapeutic drug monitoring results 
would enable clinicians to determine if treatment fails because of an increased 
minimum inhibitory concentration or because of a low blood concentration.
Understandably, efforts to develop whole genome sequencing-based microbial 
diagnostics have focussed on high-resource settings. Studies on the impact and cost 
effectiveness of routine whole genome sequencing in high burden settings are needed 
to determine the feasibility of whole genome sequencing in this setting. Currently, 
most hospitals in developing countries do not even benefit from a clinical microbiology 
laboratory. This presents an obvious challenge, but at the same time an outstanding 
opportunity for low- to middle-income countries to get up to speed with whole genome 
sequence-based developments in real-time clinical diagnostics, rather than adopting 
classical microbiological phenotypic drug susceptibility testing that may eventually be 
phased out in high-income countries. The installation of a molecular laboratory based 
around a benchtop sequencer might be an ideal investment, as it is neither far more 
expensive nor more complex than setting up a standard clinical microbiology 
laboratory. The introduction of easy-to-use software tools that predict drug resistance 
profiles based on raw sequence input files has already brought the implementation of 
sequence-based drug susceptibility testing in these settings a step closer. A possible 
alternative or intermediate solution to bridge the gap in drug susceptibility testing 
between high- and low-income countries is by translating the drug resistance markers 
discovered by whole genome sequencing studies into the development of new, 
improved molecular assays that test drug resistance based on these markers and are 
more affordable and easier to use and implement.
A thus far relatively unexplored area is the application of whole genome sequencing in 
routine clinical diagnostics of nontuberculous mycobacteria (NTM), several species of 
which are increasingly recognized as important opportunistic pathogens of humans90. 
Despite the availability of whole genome sequencing technologies, limited effort has 
been put into the genetic characterization of NTM species. This year, we have started 
a project in the medical microbiology department to sequence all clinical NTM isolates 
and develop an automated bioinformatics pipeline for species identification and 
genotypic drug susceptibility testing. Both steps are crucial to guide treatment91; 
using whole genome sequencing can significantly speed up this process, leading to 
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more rapid diagnosis and streamlined treatment. Doing this in parallel with minimum 
inhibitory concentration determination will also enable the identification of novel 
resistance markers. 
Linking genotype to phenotype
Future genetic association studies linking M. tuberculosis genotype to phenotype 
should include the human genotype as a variable of interest, because the global phy-
logeographic structure of M. tuberculosis and the association between M. tuberculosis 
strains and their human host populations provides solid evidence that these are 
closely related92-94. The interaction of the M. tuberculosis and human genotype might 
provide insight in the way the different M. tuberculosis lineages have adapted to 
specific human populations55. Associations between particular human SNPs and 
specific M. tuberculosis genotypes48,95 support the concept of ‘co-evolution’ of M. 
tuberculosis and the human host. Such ‘genome-to-genome’ analyses have a great 
potential to uncover relevant interactions between the pathogen and host genome 
and their joint effects on phenotypes79. For example, M. tuberculosis genetic variation 
X could have a different effect in a patient with genotype Y, than in a patient with 
genotype Z. The success of this approach has recently been shown in pneumococcal 
meningitis96. We would like to use this method in follow-up studies, given that we 
have the availability of DNA samples for many of the patients who were included in the 
studies in this thesis.
The genes we found to be possibly related to the meningeal disease manifestation, 
and the phylogenetic association with a higher transmission rate through ‘BCG-escape’, 
need to be validated in follow-up studies. A genetic association does not prove 
causality, even though we adjusted for host-related factors and confounding by M. 
tuberculosis population stratification. To confirm that the found associations are 
functionally/biologically relevant, the next step would be to test the associations in 
another patient cohort, in a hypothesis-driven genetic association study, or 
experimentally in the laboratory. The advantage of functional validation in the 
laboratory is that conditions can be controlled in a way that other factors affecting the 
phenotype of interest are removed, kept constant, or varied on purpose. For instance 
to validate the genetic variants found to be associated with the tuberculous meningitis 
phenotype, macrophage infection models could be used to measure gene expression 
in vitro by infecting healthy macrophages with various M. tuberculosis strains with and 
without the identified mutations. In addition, macrophages from pulmonary 
tuberculosis and tuberculous meningitis patients could be infected with standard M. 
tuberculosis strains, or pulmonary tuberculosis and tuberculous meningitis patient 
macrophages could be infected with their ‘own’ M. tuberculosis strains to help 
disentangle the effect of M. tuberculosis or host genotype, or their interaction.
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Functional genetics
Genetics does not “say it all”. In the end, the work described in this thesis can be used 
as a basis to work towards ‘functional genetics’ research, linking the M. tuberculosis 
genome to M. tuberculosis transcription, transcriptional regulation (e.g. epigenetics), 
lipidomics, proteomics, and/or metabolomics, in appropriate models (e.g. macrophages 
or blood or cerebrospinal fluid of healthy individuals or tuberculosis patients). 
Integrating multiple types of these quantitative molecular measurements creates a 
more holistic understanding of the functional relevance/consequences of M. tuberculosis 
genetic variation. It could also shed light on the biological role of M. tuberculosis 
genes, as the functions of 27% of the encoded proteins in the annotated version of the 
H37Rv strain have yet to be determined97 while the functions of the remaining proteins 
have been based mostly on sequence comparison98.
M. tuberculosis whole genome sequencing can be applied to the entire spectrum from 
molecule to man to population and will help to find answers to fundamental research 
questions, which can be translated in improved diagnostics and patient care, to 
ultimately be adopted for tuberculosis surveillance and control. I hope the findings in 
this thesis will help to develop better tools and strategies to control a disabling 
disease, for which the burden largely lies in resource-poor countries.
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Summary
The outcome of M. tuberculosis infection and the presentation and course of active 
tuberculosis disease are highly variable. Although many host and environmental 
factors have been identified that contribute to this variation, together they do not 
provide sufficient explanation for this variability. The growing knowledge of the global 
genomic diversity of M. tuberculosis complex (MTBC) affecting different cellular and 
immunological phenotypes supports that bacterial factors also play a role in the 
observed variation in clinical phenotypes of M. tuberculosis infection and active 
tuberculosis disease. Hence, in this thesis, containing whole genome sequencing data 
of more than 1,000 M. tuberculosis isolates and clinical metadata from tuberculosis 
patients from three different continents, I aimed to improve the understanding of 
bacterial factors determining drug resistance, disease presentation and transmission 
by studying genetic differences among M. tuberculosis strains on a genome-wide 
scale (summarized in Table 8.1).
Part one: drug resistance
The first part of this thesis focused on the use of whole genome sequencing to predict 
drug resistance in M. tuberculosis clinical isolates, and on the relation between 
diabetes and drug resistance mutations.
In Chapter 2, we sequenced a selection of 322 M. tuberculosis isolates from Indonesia 
to measure the distribution of drug resistance mutations and the concordance 
between phenotypic and genotypic drug susceptibility testing, which were until then 
unknown in Indonesia. We identified mutations associated with drug resistance to at 
least one tuberculosis drug in almost one sixth of the isolates. Most mutations were 
found in katG, pncA, rpoB, fabG1 and embB. Agreement of whole genome sequence- 
based resistance prediction and phenotypic drug susceptibility testing to first-line 
drugs was high for isoniazid and rifampicin but was lower for ethambutol and 
streptomycin. Our findings support the potential benefit of using whole genome 
sequencing to generate an in silico drug susceptibility profile in Indonesia and show 
that mutations associated with drug resistance are highly predictive for phenotypic 
resistance to rifampicin and isoniazid in the region.
Whole genome sequencing may be a promising alternative to phenotypic drug susceptibility 
testing. However, the degree to which the various drug resistance mutations impact 
drug susceptibility remains to be investigated. Therefore, in Chapter 3, we examined 
drug resistance mutations in 72 phenotypically drug-resistant isolates from Romania 
and linked these to their measured minimum inhibitory concentrations. We observed 
that katG S315T for isoniazid, and rpoB S450L for rifampicin were associated with 
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high-level resistance (8- to 32-fold and 4- to 16-fold increase in MIC, respectively), 
but several mutations such as in rpoB, rrs and rpsL, and embB were associated 
with minimum inhibitory concentration ranges including the critical concentration 
for rifampicin, aminoglycosides and ethambutol, respectively. This could explain 
the discrepant genotypic and phenotypic susceptibility results for streptomycin and 
ethambutol in Chapter 2, and taught us that resistance mutations induce varying 
levels of resistance, some of which may still be overcome by increased dosing. Hence, 
whole genome sequencing can guide clinical decision-making, by informing drug 
selection as well as drug dosing.
Table 8.1.  Summary of the main findings and implications of this thesis
Findings Implications for practice or research
Part one: drug resistance
Agreement of drug resistance mutations and 
phenotypic DST was high for INH and RIF but 
low for EMB and STR (Chapter 2), because low 
DST quality and resolution for these drugs 
(Chapter 3)
Drug resistance mutations lead to varying 
levels of resistance; some may be overcome 
by increased dosing (Chapter 3)
Diabetes is associated with drug-resistant TB, 
especially among patients without prior TB 
treatment (Chapter 4)
Genotypic DST could offer a rapid and 
comprehensive diagnostic solution to 
phenotypic DST in Indonesia; larger studies 
are needed to confirm the clinical relevance of 
several uncommon mutations (Chapter 2)
Whole genome sequencing can aid in the 
timely diagnosis of M. tuberculosis drug 
resistance and guide clinical decision-making 
(Chapter 3)
TB patients with diabetes should be 
prioritized for DST in settings where this is not 
done for all patients (Chapter 4)
Part two: disease phenotype and transmission
Three genes in M. tuberculosis (Rv0218, 
Rv3433c, and nanK) are associated with the 
TB disease phenotype (Chapter 5)
Functional validation studies are warranted 
to further explore the effect of mutations in 
these genes on protein function (Chapter 5)
M. tuberculosis Beijing genotype strains 
may evade BCG vaccine-induced immunity 
(Chapter 6)
The impact of BCG vaccination on 
transmission may depend on the M. 
tuberculosis strain distribution in the setting 
where it is used (Chapter 6)
Abbreviations: DST: drug susceptibility testing; EMB: ethambutol; STR: streptomycin; TB: tuberculosis; BCG: 
Bacillus Calmette-Guérin.
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Diabetes increases the risk of developing active tuberculosis by threefold and the 
increasing prevalence of diabetes poses a great threat to tuberculosis control. 
Increased rates of drug resistance may contribute to poor treatment outcomes among 
tuberculosis patients with diabetes, complicating this even further. Still, little is known 
about the relation of diabetes and genotypic drug resistance. Therefore, in Chapter 4, 
we investigated the mutations underlying drug resistance in M. tuberculosis isolates 
from Indonesian and Peruvian tuberculosis patients with and without diabetes. Taking 
patients’ country of origin into account and after adjusting for age, gender, previous 
tuberculosis treatment and M. tuberculosis lineage, we discovered that diabetes was 
associated with an approximately 1.7-fold increased risk of genotypic drug resistance, 
and to rifampicin in particular (2.5-fold increased risk). This association was especially 
evident for patients not previously treated for tuberculosis (‘primary resistance’), 
and could not be explained by clustering of evolutionarily successful drug-resistant 
strains in patients with diabetes. Mutations in Rv1482c-fabG1, conferring resistance 
to isoniazid and ethionamide, and gyrA, conferring fluoroquinolone resistance, were 
overrepresented in isolates from Peruvian tuberculosis patients with diabetes. These 
results are important for the control of drug-resistant tuberculosis as they highlight 
the need for routine drug-susceptibility testing for tuberculosis patients with diabetes.
Part two: tuberculosis disease phenotype and transmission
The second part of this thesis focused on the role of M. tuberculosis genetic diversity 
in the presentation of disease as pulmonary or meningeal tuberculosis, and on disease 
transmission.
To determine whether M. tuberculosis genetic diversity is associated with the tuberculosis 
disease phenotype, we compared M. tuberculosis genomes from Indonesian pulmonary 
and meningeal tuberculosis patients and searched for homoplastic mutations (Chapter 5). 
We observed that the isolates from meningitis patients were scattered across the 
phylogenetic tree and that there was no association between lineage and disease 
localisation. At a higher level of resolution and using a homoplasy-based association 
analysis, we found that genetic variation in Rv0218 and absence of Rv3343c and nanK 
were significantly associated with disease phenotype, also in an independent 
validation set of isolates. It is unknown how Rv3343c and nanK might affect tuberculosis 
phenotype, but Rv0218 is a predicted secretome gene with multiple transmembrane 
regions, possibly altering M. tuberculosis outer structure. 
Similar to M. tuberculosis tissue tropism and supported by previous findings that M. 
tuberculosis virulence is associated with the isolate’s genetic background, the risk of 
M. tuberculosis transmission could also be influenced by its genotype. Hence, we 
studied the effect of M. tuberculosis lineage on the risk of transmission from index 
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cases to household contacts in Bandung, Indonesia (Chapter 6). We discovered that 
M. tuberculosis Beijing genotype strains are associated with a higher risk of uninfected 
household contacts to acquire M. tuberculosis infection (measured with an interfer-
on-gamma release assay). This was not explained by a higher bacillary load or higher 
frequency of pulmonary cavities in the index cases. In addition, a history of BCG 
vaccination among household contacts was associated with a 60% lower risk of 
M. tuberculosis infection caused by non-Beijing isolates, but no lower risk of infection 
by Beijing family isolates. Evading BCG-mediated protection in the contact, rather 
than inducing a disease phenotype in the index case that favours transmission, 
may increase the transmission rate in Beijing genotype strains.
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Samenvatting
Mycobacterium tuberculosis
Tuberculose is met 1,7 miljoen sterfgevallen in 2017 een van de top-10 doodsoorzaken 
ter wereld en de nummer één doodsoorzaak als gevolg van een infectieziekte. Naar 
schatting tien miljoen mensen wereldwijd kregen de ziekte in 2017. De ziekteverwekker, 
Mycobacterium tuberculosis behoort tot een grotere famile van aan elkaar verwante 
mycobacteriën: het Mycobacterium tuberculosis complex; het DNA van deze bacteriën 
lijkt sterk op elkaar. De bacteriën die tuberculose in de mens veroorzaken, kunnen 
weer onderverdeeld worden in 7 verschillende genotypen met elk specifieke genetische 
kenmerken. Lang dacht men dat er zo weinig genetische variatie binnen de tuberculose-
bacteriën was, dat dit onmogelijk effect kon hebben op de manier waarop de ziekte 
zich uit in de patiënt. Echter, mede door vooruitgang in de techniek waarmee het DNA 
bestudeerd kan worden, is aangetoond dat verschillen in het DNA van de bacterie 
wel degelijk van invloed zijn op het ziekteproces. In dit proefschrift heb ik door middel 
van ‘whole genome sequencing’ het complete DNA van M. tuberculosis onder de loep 
genomen om het effect van genetische variatie op antibioticaresistentie (deel 1), ziekte- 
fenotype (deel 2) en transmissie van tuberculose (deel 2) beter te begrijpen. In dit 
hoofdstuk vat ik de belangrijkste bevindingen van mijn proefschrift samen.
Deel één: antibioticaresistentie
Een van de grootste zorgen met betrekking tot tuberculosebestrijding is resistentie 
van de bacterie tegen een of meerdere geneesmiddelen. Hierdoor is de infectie minder 
goed of in zeldzame gevallen helemaal niet meer te behandelen. Slechts een kwart 
van de naar schatting 558,000 mensen die ziek werden van een multiresistente of ri-
fampicine-resistente bacterie in 2017 werden met tweedelijnsmiddelen behandeld. 
Een belangrijke oorzaak hiervan is het niet, of niet op tijd diagnosticeren van infectie 
met een resistente bacterie. Wanneer ongediagnisticeerde resistente tuberculose niet 
volgens de juiste richtlijn wordt behandeld zal deze niet genezen en kan de resistente 
bacterie bovendien worden overgedragen op andere ongeïnfecteerde personen. 
Omdat antibioticaresistentie in M. tuberculosis veroorzaakt wordt door mutaties in 
bepaalde genen van de bacterie kan resistente tuberculose worden opgespoord door 
te zoeken naar deze mutaties in het DNA van de infecterende bacterie: genotypische 
gevoeligheidsbepaling. Veelal wordt dit echter nog gedaan door middel van de 
zogenaamde fenotypische gevoeligheidbepaling, waarbij in het laboratorium wordt 
vastgesteld of de bacterie groeit bij een bepaalde concentratie antibioticum.
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De fenotypische gevoeligheidsbepaling is complex en bemoeilijkt de diagnose van 
resistente tuberculose. Whole genome sequencing heeft de potentie om betrouwbaar 
antibioticaresistentie te kunnen voorspellen binnen een klinisch relevant tijdsbestek. 
In hoofdstuk 2 hebben we met whole genome sequencing de mutaties in kaart 
gebracht die voor resistentie zorgen bij M. tuberculosis stammen van Indonesische 
patiënten. Daarnaast hebben we onderzocht in hoeverre de genotypische en fenotypische 
gevoeligheidsbepalingen overeen kwamen. We ontdekten bij bijna één op de zes 
 M. tuberculosis stammen mutaties die geassocieerd zijn met antibioticaresistentie, 
vaak bij patiënten die niet eerder behandeld waren voor tuberculose. We vonden veel 
genetische varianten in verschillende genen. Mutaties in de genen katG (aminozuur 
315), in de promotor van fabG1 en in de bekende resistentieregio van rpoB lieten hoge 
overeenstemming zien met fenotypisch vastgestelde resistentie tegen respectievelijk 
isoniazide en rifampicine. Deze overeenkomst was veel lager voor mutaties geassocieerd 
met resistentie tegen ethambutol en streptomycine. We hebben hiermee voor het eerst 
de potentie van whole genome sequencing als voorspeller van resistente tuberculose 
laten zien in Indonesië, waar het fenotypisch bepalen van resistentie vaak niet mogelijk is. 
Met name mutaties geassocieerd met resistentie tegen de eerstelijns middelen isoniazide 
en rifampicine waren zeer voorspellend voor fenotypische resistentie in deze setting. 
Verder onderzoek is nodig om de impact van whole genome sequencing voor routine 
diagnostiek en management van resistente tuberculose in Indonesië te kunnen evalueren.
Whole genome sequencing kan in potentie de huidige, maar tijdrovende en complexe 
fenotypische gevoeligheidsbepaling van M. tuberculosis vervangen. Echter, er is nog 
weinig bekend over de mate van resistentie die de verschillende resistentiemutaties 
veroorzaken en over het effect van combinaties van resistemntiemutaties. Daarom 
hebben we in hoofdstuk 3 de met antibioticaresistentie geassocieerde mutaties in 
fenotypisch resistente M. tuberculosis stammen van Roemeense patiënten vergeleken 
met de mate van verminderde gevoeligheid tegen de verschillende antibiotica. 
We ontdekten dat de mutaties katG S315T en rpoB S450L geassocieerd waren met sterk 
verminderde gevoeligheid voor respectievelijk isoniazide en rifampicine en dat diverse 
mutaties in rpoB, rrs en rpsl, en embB geassocieerd waren met licht verminderde 
gevoeligheid tegen respectievelijk rifampicine, aminoglycosiden en ethambutol. Hierbij 
werden ook waarden gevonden rond het omslagpunt van gevoelig / resistent; dit zou 
mogelijk de lage overeenstemming tussen de fenotypische en genotypische gevoelig-
heidsbepaling voor ethambutol en streptomycine in hoofdstuk 2 kunnen verklaren. 
Verschillende resistentiemutaties kunnen dus verschillende effecten hebben op de mate 
van gevoeligheid van M. tuberculosis voor antibiotica en in sommige gevallen kan de 
patiënt mogelijk nog effectief behandeld worden met een hogere dosis antibiotica. 
Whole genome sequencing kan hiermee richting geven aan de klinische besluitvorming 
met betrekking tot de keuze voor het juiste middel en de hoogte van de dosering.
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Mensen met diabetes mellitus hebben een drie keer verhoogd risisco op het ontwikkelen 
van actieve tuberculose. Het toenemende aantal diabetespatiënten wereldwijd heeft 
dus gevolgen voor de tuberculose-epidemie. Een groter aandeel resistente tuberculose 
onder diabetespatiënten vormt een verdere bedreiging voor de tuberculosebestrijding. 
Toch is er nog weinig bekend over de resistentiemutaties in deze speciefieke patiënten-
populatie. In hoofdstuk 4 hebben we daarom de resistentiemutaties bestudeerd in 
M. tuberculosis stammen van Indonesische en Peruaanse tuberculosepatiënten met 
en zonder diabetes. We vonden dat diabetes geassocieerd was met een 1.7 keer 
verhoogd risisco op genotypisch resistente tuberculose en met name resistentie tegen 
rifampicine. Dit kon niet verklaard worden door andere patiëntegrelelateerde factoren 
zoals leeftijd, geslacht en eerdere behandeling voor tuberculose, of het genotype 
waartoe de M. tuberculosis stam behoorde. Bovendien zagen we geen verband met 
transmissie van evolutionair gezien meer succesvolle resistente stammen in diabetes 
patiënten. Mutaties in met name de genen Rv1482-fabG1, geassocieerd met resistentie 
tegen isoniazide en ethionamide, en gyrA, geassocieerd met fluoroquinolonen-
resistentie, kwamen vaker voor onder Peruaanse tuberculosepatiënten met diabetes. 
Deze resultaten zijn belangrijk omdat ze het belang van de invoering van een routine 
gevoeligheidsbepaling van M. tuberculosis in deze patiëntengroep aantonen.
Deel twee: ziektefenotypen en transmissie van tuberculose
M. tuberculosis wordt vooral verspreid via de lucht wanneer een tuberculosepatiënt 
hoest of niest. Wanneer iemand anders deze bacterie vervolgens inademt, zijn er 
verschillende scenario’s mogelijk: een deel van de blootgestelde individuen ruimt 
M. tuberculosis op, nog voordat het afweersysteem hiertegen geheugen opbouwt. 
Een kleine minderheid wordt direct en vaak ernstig ziek, maar de meerderheid merkt 
niets van de besmetting. De bacterie verkeert dan in een ‘slapende’ staat en de patiënt 
is niet besmettelijk. De patiënt kan later in het leven alsnog ziek worden. De tuber-
culosebacterie kan namelijk tientallen jaren in slapende staat in het lichaam overleven 
en weer actief worden als de afweer van de geïnfecteerde persoon afneemt. Dat gebeurt 
bij omgeveer één op de tien besmette personen. Actieve tuberculose manifesteert 
zich doorgaans in de long, maar M. tuberculosis kan zich in alle organen nestelen en 
daar ziekte veroorzaken. Tuberculose in de hersenen, tuberculeuze meningitis, is de 
meest ernstige vorm van tuberculose. De helft van de patiënten houdt er zware 
neuro logische handicaps aan over of overlijdt aan de aandoening. Uitzonderingen 
daargelaten, kunnen alleen patiënten met actieve longtuberculose de bacterie 
overdragen op anderen.
Verschillende factoren bepalen welk scenario plaatsvindt na blootstelling aan 
M. tuberculosis en hoe de ziekte zich eventueel uit in de patiënt. Veel van deze factoren zijn 
patiënt- of omgevingsgerelateerd. Echter, we komen er steeds meer achter dat ook de 
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bacterie een belangrijke rol speelt. De mate waarin bacteriën ‘ziekmakend’ (virulent) 
zijn verschilt, en genetische variatie binnen M. tuberculosis kan aan deze verschillen 
ten grondslag liggen. In hoofdstuk 5 hebben we bekeken of genetische verschillen 
tussen M. tuberculosis bacteriën geassocieerd zijn met het meningitis of long-
tuberculose fenotype door het DNA van bacteriën uit de hersenen van tuberculeuze 
meningitispatiënten te vergelijken met het DNA van bacteriën uit de longen van long-
tuberculosepatiënten. We vonden dat het M. tuberculosis genotype niet bepalend was, 
maar dat subtielere genetische verschillen geassocieerd waren met het ziektefenotype. 
Mutaties in het gen Rv0218 en de afwezigheid van gen Rv3343c of nanK hielden 
verband met uiting van de ziekte in de longen of in de hersenen. Gebaseerd op 
biologische eigenschappen van het gen Rv0218 zou men kunnen veronderstellen dat 
dit gen invloed heeft op de buitenkant - en daarmee op de herkenning door het 
afweersysteem - van de tuberculosebacterie. Meer onderzoek is nodig naar de manier 
waarop variatie in deze genen invloed heeft op het ziektefenotype.
Naast het ziektefenotype kan genetische variatie binnen M. tuberculosis ook invloed 
hebben op de mate van overdraagbaarheid van tuberculose. Dit kan bijvoorbeeld 
doordat een bacterie meer schade in de longen aanricht waardoor de patiënt meer 
hoest, of doordat de bacterie kan ontsnappen aan het afweersysteem van een 
blootgesteld individu. In hoofdstuk 6 onderzochten we de overdraagbaarheid van 
M. tuberculosis op mensen binnen hetzelfde huishouden in Bandung, Indonesië. 
We kwamen erachter dat ongeïnfecteerde huisgenoten die blootgetseld waren aan 
een patiënt besmet met een M. tuberculosis stam van het Beijing genotype, een hoger 
risico hadden om besmet  te raken. Dit kon niet verklaard worden door een hogere 
concentratie tuberculosebacteriën in, of meer schade aan de longen van de patiënt. 
Bovendien ontdekten we dat huisgenoten die een BCG-vaccinatie hadden gehad, sterk 
beschermd waren tegen besmetting na blootstelling aan M. tuberculosis, maar dat 
BCG-vaccinatie helemaal niet beschermde tegen besmetting bij huisgenoten die 
blootgesteld waren aan M. tuberculosis genotype Beijing. Kortom, het ontsnappen 
aan BCG-gemediëerde bescherming lijkt de verhoogde overdraagbaarheid van 
M. tuberculosis genotype Beijing stammen te verklaren.
Al met al biedt het analyseren van het complete DNA van de tuberculosebacterie 
mogelijkheden, zowel voor de diagnostiek van resistente tuberculose als voor het 
begrijpen van deze complexe ziekte, om haar uiteindelijk beter te kunnen bestrijden. 
Dit vergt het blijvend bijhouden van de correlaties tussen het genotype van de bacterie 
en de verschillende fenotypische aspecten, zoals ik in mijn proefschrift heb gedaan. 
Ik hoop dat de bevindingen in mijn proefschrift bijdragen aan de ontwikkeling van 
betere hulpmiddelen en strategieën om tuberculose te kunnen beheersen. Een van 
de grootste uitdagingen zal liggen in het toegankelijk maken van deze technieken in 
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landen met weinig middelen, waar de ziektelast het hoogst is en de middelen het 
hardst nodig zijn.
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Gageldonk hebben me wegwijs gemaakt in de epidemiologie van tuberculose. Dick, 
ik vind het leuk dat we elkaar af en toe nog tegenkomen en ik hoop dat we elkaar tegen 
blijven komen. Marlies Hulscher was mijn mentor zowel tijdens mijn afstudeerproject 
als tijdens mijn promotieonderzoek. Marlies, ik bewonder je gedrevenheid in het 
verbeteren van de kwaliteit van zorg en ik mag je erg graag als mens.
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The research I did during my PhD was in close collaboration with many inspiring 
colleagues from Bandung, where I worked and lived for seven months, and from many 
other countries. I am grateful for the lessons I learned from you, not only about science, 
but also about hospitality, modesty, and gratefulness. Dr. Bachti Alisjahbana, thank 
you for kindly welcoming me as a member of the TB/HIV research group and for looking 
after me, also outside the office. Professor Rovina Ruslami, thank you for being such a 
welcoming host. Sue McAllister, dear Sue, thank you for generously sharing your house 
with me. I learned a lot from you about doing research and living in a foreign country. 
I cherish the memories of our weekend breakfasts outside and the many motorbike 
rides. Professor Philip Hill, thank you for showing that doing high quality research and 
a good laugh can go hand in hand. Ayesha Verrall, dear Ayesha, you’ve inspired me 
both professionally as well as personally. I enjoyed our epidemiology discussions. 
Anca Riza, dear Anca, your expertise is human genetics but you have been a great help 
with mycobacterial genetics analyses, not to forget the shipments of mycobacterial 
DNA. My gratitude also goes out to ‘the ladies’ from the tuberculosis lab in Craiova for 
all their hard work on culturing and managing isolates. I would like to thank Julia 
Critchley, Cesar Ugarte, David Moore and other colleagues from the TANDEM 
consortium for contributing to Chapter 4 of my thesis. Thomas Kohl and Matthias 
Merker, thank you for introducing me to whole genome sequencing of M. tuberculosis. 
Dr. Ahmad Rizal Ganiem and Dr. Sofiati Dian, you are doing important scientific and 
clinical work on tuberculous meningitis. I learned a lot from you, also about the 
Indonesian cuisine. Dr. Darma Imran, thank you for giving me the opportunity to visit 
the emergency ward at the Cipto Mangunkusumo hospital in Jakarta. I would also like 
to thank my other Indonesian colleagues, Raspati Koesoemadinata, Intan Mauli, Tiara 
Pramaesya, Annisa ‘Itcha’ Rahmalia, Mawar Pohan, Ria Windyani, Bony Wiem Lestari, 
Jessi Annisa, Lika Apriani, my former roommates Ranni Trisnawati, Runi Rahmawati, 
Nopi Susilawati and Alif al Birru, the colleagues from the tuberculosis lab in Bandung 
who took great care of the M. tuberculosis isolates, and all others who contributed to 
the work presented in this thesis but are not mentioned here explicitly.
The time I spent in Bandung was not only an academic learning experience, it was a 
period of personal development. I am grateful for all the people I met and the friends 
I made, also outside the office. Misliani Intan Ardita, dear ‘Dita’, my football buddy. 
I really enjoyed our afternoon practices with the Rumah Cemara team. Thanks for 
welcoming me to your football teams and for introducing me to so many Indonesian 
traditions. Itcha, thank you for taking me by the hand on my quest for a football team 
to join in Bandung. Rizki Kurniawan, the way you use your hobby to do meaningful 
work is inspirational. Our visit to Persib Bandung was memorable! Ferlin Joswara, 
your work spirit is amazing and you create the most wonderful things. It was an honour 
to model for you. I am also grateful for the chance I got to play football with the girls 
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from Rumah Cemara, run with the Indorunners and discover the Bandung mountains 
with the Bandung biking group. You have helped keeping mind and body healthy. 
Arjan van Laarhoven en Suzanne van Dorp, dank jullie wel voor jullie grote dosis 
gastvrijheid tijdens mijn tweede verblijf in Bandung. Met de warmte van jullie persoon-
lijkheden en de verfrissing van koude biertjes en het zwembad voelde jullie huis als 
een tweede thuis.
Een van de leuke dingen aan promoveren is de vrijheid om je helemaal in een 
onderwerp te mogen verdiepen in een omgeving van talentvolle mensen van (en met) 
wie je veel kan leren. Ik heb het geluk gehad dat ik tijdens mijn promotieonderzoek heb 
mogen werken op drie verschillende afdelingen binnen het Radboudumc; de interne 
geneeskunde, het center for molecular and biomolecular informatics (CMBI) en de 
medische microbiologie. Van collega’s met verschillende achtergronden heb ik geleerd 
om vraagstukken vanuit verschillende invalshoeken te benaderen. Met veel plezier 
heb ik samengewerkt met andere (ex-) promovendi aan tuberculose en niet-tuber-
culeuze mycobacteriën. Arjan van Laarhoven, Lidya Chaidir, Sofiati Dian, Lindsey te 
Brake, Valerie Koeken, Edwin Ardiansyah, Ekta Lachmandas, Hinta Meijerink, Anca 
Riza, Hanna Guimaraes, Jodie Schildkraut, Mike Ruth en Jordy Coolen, ik heb ervan 
genoten om met jullie na te denken over ingewikkelde concepten, vragen, scripts en 
analyses en bovenal ook van de gezelligheid. Daarnaast gaat mijn dank uit naar 
ervaren wetenschappers binnen en buiten het Radboudumc van wie ik veel heb 
geleerd, Mihai Netea, Jos van der Meer, Heiman Wertheim, Vinod Kumar, Alexander 
Hoischen, Jelle Goeman, Jan Buitelaar, Taco Kooij, Hester Korthals-Altes, Aldert Zomer, 
Sacha van Hijum, Han de Neeling en Bas Dutilh, zonder wie ik nooit had leren 
programmeren. Mijn nieuwe kamergenoten bij de medische microbiologie, John 
Verbeek, Marion Dinnissen–van Poppel, Nel Gerrits-Hofmans, Paul Rutten, Jordy 
Coolen, Tim Baltussen, Margriet Hokken en Jan Zoll ben ik dankbaar voor het warme 
welkom, net als Ingrid van Weerdenburg, Saskia Kuipers, Ellen Koenraad, Mariëlle 
Rockland, Lian Pennings, Mike Mientjes, Melanie Wattenberg, Nicole Aalders, Jasper 
Sangen, Twan Klaassen en Arjan de Jong. Veel bioinformatica-inzichten heb ik gekregen 
dankzij (oud-) collega’s bij het CMBI; Peter-Bram ’t Hoen, Gert Vriend, John van Dam, 
Wynand Alkema, Rob ter Horst, Jon Black, Wouter Touw, Xiaowen Lu, Selma van Esveld, 
Barbara van Kampen, Josh Gillard, William Leenders, Daniel Garza, Balaji Venkatasu-
bramanian, Laurens van de Wiel, Joeri van Strien, Tom Ederveen, Hanka Venselaar, 
Charlotte Kaffa, Sander Bervoets, Coos Baakman, Jeron Venhuizen, Renee Salz en 
niet te vergeten Arthur Pistorius, die menig serverprobleem voor me heeft opgelost. 
In particular, I’d like to thank Dei Elurbe, Joanna Lange, Robin van der Lee and 
Lisette Meerstein-Kessel. You are not only skilled bioinformaticians, but also close friends. 
I hope we will stay in touch, wherever the wind may take us. Dear Lise, I am verry happy 
to have you as my paranimph.
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Ik wil ook graag mijn dank betuigen aan Barbara van Kampen, Mieke Daalderop en 
Jeanine van der Wijst-Schrauwen, die ontzettend veel werk uit handen nemen van 
artsen en onderzoekers in de dynamische academische ziekenhuisomgeving.
Voor een promovendus is de verleiding groot om je alleen te focussen op de inhoud 
van je onderzoek. Ik ben blij dat ik een groot deel van mijn promotietraject lid ben 
geweest van de PhD Council van het Radboud Institute for Health Sciences. Het heeft 
mijn blik verruimd en me bovendien de mogelijkheid gegeven om iets te kunnen 
betekenen voor medepromovendi. Ik ben Bart Kiemeney, Karin Berens, Marieke de Visser, 
Marie-Louise Roovers en Dagmar Eleveld-Trancikova dankbaar voor het vertrouwen en 
de verantwoordelijkheden die ze ons hebben gegeven. Alle andere leden en oud-leden 
van de Council wil ik graag bedanken voor jullie inzichten, het fijne samenwerken en 
de altijd gezellige sfeer. Ik hoop jullie nog vaak tegen te komen in de toekomst.
Jan en Doreth, dank jullie wel dat jullie deur altijd voor me open staat. Ik heb grote 
bewondering voor jullie positiviteit en levenslust.
Hard werken vraagt ook de nodige ontspanning. Mijn (oud-) teamgenootjes en trainster 
bij Trekvogels wil ik graag bedanken voor de energie die jullie me hebben gegeven 
door jullie enthousiasme en de drive om samen te willen winnen. Voetbal is voor mij 
de ideale uitlaatklep en met jullie heb ik een team gevonden dat prestatiedrang 
koppelt aan teamspirit en gezelligheid. Ik hoop met jullie een mooie herfst van mijn 
voetbalcarrière in te gaan. Ik ben dankbaar voor alle lieve vrienden om me heen met 
wie ik lief en leed kan delen en die me met een gezonde dosis humor helpen relativeren 
en ontspannen. Rozemarijn, Erika, Sander, Jilske, Mirjam, Ieke, Jorie en Sanne, ik ben 
blij met jullie in mijn leven.
Soms moet je de halve wereld over om iemand die dichtbij woont te leren kennen. 
Lieve Rachel, in Bandung ontmoette ik je en intussen ben je een dierbare vriendin 
geworden. Je beseft zelf denk ik maar half hoeveel je me hebt gesteund de afgelopen 
jaren. Dankjewel voor al je positiviteit, lieve attenties en je vermogen om altijd een 
lach op mijn gezicht te kunnen toveren.
En soms moet je iemand anders tegenkomen om jezelf beter te leren kennen. Lieve 
Stéphanie, dankjewel voor je open en verfrissende blik op het leven en voor onze fijne 
vriendschap die ik zeer waardeer.
Lieve Charlotte, Svenja en Marloes, ik vind het zo bijzonder dat wij alle vier aan een 
promotieonderzoek zijn begonnen. Jullie weten als geen ander hoe het is om te 
promoveren en hebben aan een half woord genoeg. Jullie staan altijd voor me klaar, of 
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het nou is om me op te beuren na tegenslag of om een feestje te vieren na goed 
nieuws. Laten we dat ook hierna zo blijven doen. Marloes, je hebt het goede voorbeeld 
gegeven en ik ben trots dat ik jou als paranimf naast me heb staan.
Promoveren betekent soms met oogkleppen op je afsluiten voor de wereld en diep de 
materie induiken. Het is dan heel fijn om daar af en toe even uitgehaald te worden door 
goede vrienden die niets met promoveren te maken hebben. Lieve Sophie, Veronique 
en Marije, de inhoud van mijn proefschrift zegt jullie helemaal niets (“Wat onderzoek 
je ook alweer? Parageen genomische tuberculose?”), maar mede dankzij jullie is deze 
nu wel af. Dank jullie wel voor jullie steun, positivisme, blijheid en gekkigheid. Ik ken 
jullie al meer dan mijn halve leven en ik zou nooit zonder jullie willen.
Ik ben blij en voel me gezegend met mijn lieve, warme familie en iedereen die ik als 
familie beschouw. In het bijzonder wil ik opa en oma Maandag bedanken. Lieve opa, je 
kan er helaas niet meer bij zijn, maar ik weet zeker dat je trots op me geweest zou zijn. 
Lieve oma, ik had me geen lievere oma kunnen wensen. Dankjewel voor jullie liefde en 
steun die ik altijd heb gevoeld en nog steeds voel.
Lieve Tineke, je bent als een moeder voor me en staat altijd voor me klaar. Je bent een 
voorbeeld door wie je bent en hoe je in het leven staat.
Lieve Suzan, mijn wetenschappelijke ontdekkingsreis zit er nu op, maar ons avontuur 
is pas net begonnen. Gelukkig is er nog een hele wereld te ontdekken. Ik kijk ernaar uit 
om samen met jou in het leven te verdwalen.
Ik ben trots op waar ik vandaan kom en dankbaar voor de normen en waarden die ik 
van huis uit heb meegekregen. Een warm en liefdevol thuis met lieve ouders en een 
zusje waar ik altijd op terug kan vallen is met geen titel te verkrijgen. Lieve Isabel, 
hoewel we enorm verschillen zijn we over de jaren heel close geworden. Ik ben je 
dankbaar voor je eindeloze geduld en de leuke momenten die we samen hebben 
beleefd. Ik vind het leuk hoe we elkaar aanvullen en van elkaar leren. De gedeelde 
liefde voor wijn heeft ons al op leuke plekken gebracht en ik ben benieuwd wat er nog 
meer in het vat zit. Lieve papa en mama, jullie geloof in mij is hartverwarmend en alle 
woorden schieten tekort om jullie te bedanken. Het begripvolle, empathische en 
bedachtzame van jou, papa, en het liefdevolle en zorgzame van jou, mama, draag ik 
altijd bij me. Jullie hebben me geleerd om op mijn gevoel te vertrouwen. Met humor en 
relativeringsvermogen hebben jullie me op vele momenten bijgestaan en het plezier 
en de positiviteit waarmee jullie in het leven staan is inspirerend. Bedankt dat jullie 
een omgeving hebben gecreëerd waarin ik me veilig en geliefd voel en kon groeien tot 
wie ik nu ben.
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Curriculum Vitae
Carolien Ruesen was born in Wehl, the Netherlands, on July 26th in 1988, and grew up 
in Duiven with her parents and sister. She graduated from the Stedelijk Gymnasium 
Arnhem, after which she studied Biomedical Sciences at the Radboud University in 
Nijmegen. Carolien went to Southampton, the United Kingdom, for her Bachelor’s 
internship at the Southampton General Hospital where she studied spinal posture in 
chronic stroke patients under supervision of professor Ann Ashburn. She also 
participated in the Honours programme for Medical Sciences. During her Master 
Biomedical Sciences she did a major in Epidemiology, and gained her first experience 
with tuberculosis research during an extracurricular research project on tuberculosis 
together with dr. Rob Aarnoutse and professor Reinout van Crevel. Then, she performed 
an internship on drug-resistant tuberculosis at the Rijksinstituut voor Volksgezonheid 
en Milieu with professor Dick van Soolingen and dr. Rianne van Gageldonk. Carolien 
performed her graduate internship – studying determinants of HIV viral ‘blips’ - at the 
Radboud university medical center department of IQ Healthcare in Nijmegen, under 
supervision of professor Marlies Hulscher and professor Reinout van Crevel, for which 
she was awarded the Radboudumc Masterprijs Biomedische wetenschappen, and the 
Best Student Award Epidemiologie from the department for Health Evidence. After 
graduation, Carolien participated in the Radboud university medical center PhD 
Competition and received a scholarship to start a PhD project designed by herself, 
under supervision of professor Van Crevel. In preparation for her PhD, she worked for 
the TB-HIV research group led by dr. Bachti Alisjahbana at the Padjadjaran University in 
Bandung, Indonesia, and lived there for seven months. Besides her research activities, 
Carolien has been a member of the Radboud Institute for Health Sciences PhD Council. 
She is currently working at the Radboudumc department of medical microbiology, 
in the mycobacteriology lab led by dr. Jakko van Ingen.
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 218
536139-L-bw-Ruesen
Processed on: 27-9-2019 PDF page: 219
 RIHS PhD Portfolio | 219
PhD portfolio
Name PhD candidate: 
C.J. Ruesen, MSc.
Department: 
Internal Medicine / Medical Microbiology
Graduate School: 
Radboud Institute for Health Sciences
PhD period:
01-04-2014 – 01-07-2019
Promotor(s):
Prof. R. van Crevel, Prof. M.A. Huynen
Co-promotor(s): Dr L. Chaidir, Dr J. van Ingen
YEAR(S) ECTS
TRAINING ACTIVITIES
A) COURSES & WORKSHOPS
RIHS Introduction course for PhD students
Introduction to R course, Maastricht University
5E005 Genetic epidemiology
Scientific Integrity
How to write a medical scientific paper
Comparative genomics
BEAST: divergence dating using genomic sequence data,  
Utrecht University
The next step in my career
Introduction to Python for biologists (IPYB05) , Glasgow, UK
Advanced Python for biologists (APYB02), Glasgow, UK
Illustrator Workshop
2014
2014
2014
2015
2015
2016
2016
2017
2018
2018
2019
1.0
1.0
5.5
1.0
0.2
5.5
0.2
0.6
1.5
1.5
0.1
B) SEMINARS & LECTURES
RIHS seminar How to get the most out of your PhD part 1: industry
RIHS seminar How to get the most out of your PhD part 2: a career  
in academia
2015
2015
0.1
0.1
C) SYMPOSIA & CONGRESSES
Science day Internal Medicine
RIHS PhD Retreat (poster)
Radboud Science Day (e-poster)
Center for Molecular and Biomolecular Informatics spring  
conference (poster)
KNAW meeting PhD Students on Science 2.0
Center for Molecular and Biomolecular Informatics autumn  
conference (oral)
RIHS PhD Retreat
TANDEM progress meeting, Craiova, Romania (oral)
European Molecular Biology Organization Conference Tuberculosis 
2016, Paris, France (poster)
Center for Molecular and Biomolecular Informatics spring conference
Radboud Center for Infectious Diseases Science Day (e-poster)
2014
2014
2015
2015
2015
2015
2015
2016
2016
2016
2016
0.25
0.5
0.25
0.2
0.2
0.2
0.5
1.0
1.25
0.1
0.25
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YEAR(S) ECTS
TRAINING ACTIVITIES
C) SYMPOSIA & CONGRESSES
RIHS PhD Retreat
TBNET symposium on drug-resistant tuberculosis in Europe
Vereniging voor Epidemiologie symposium ‘Go your own way’
International Conference on the Pathogenesis of Mycobacterial 
 Infections, Stockholm, Sweden (poster)
RIHS PhD Retreat
European Congress of Clinical Microbiology and Infectious
Diseases, Madrid, Spain (e-poster & poster)
Center for Molecular and Biomolecular Informatics spring  
conference (oral)
Union World Conference on Lung Health, The Hague,  
Netherlands (oral)
Symposium ‘Radboud New Frontiers 2018, Big data,  
better healthcare?’
Science day Infectious Diseases & Global Health (oral)
2016
2016
2017
2017
2017
2017
2018
2018
2018
2018
2018
0.2
0.5
0.25
0.1
1.0
0.5
1.0
0.2
1.0
0.25
0.25
D) OTHER
Journal Club Center for Molecular and Biomolecular Informatics
Journal Club Health Evidence (‘junior refereren’)
Center for Molecular and Biomolecular Informatics comparative 
 genomics lunch meetings
Cytokine meetings Internal Medicine
‘Broodje mycobacteriën’ (tuberculosis / nontuberculous 
 mycobacteria lunch meeting)
2014–2018
2014–2017
2014-2018
2014-2017
2016-2018
1.5
6.0
6.5
2.0
0.5
TEACHING ACTIVITIES
E) LECTURING
BSc course Global Health MED-MIN06
BSc course Infection and Host Defense 5DT05
2014,2016
2015
0.2
0.1
F) SUPERVISION OF INTERNSHIPS / OTHER
Project supervisor BMS Minor Clinical Research, Radboud University
Hilde van Ras, Bo van Santvoort en Marloes Taken
Project supervisor BMS Minor Clinical Research, Radboud University
Monse Wieland, Lieke Vissers, Mariken de Wit en Francine van Wifferen
2015–2016
2016–2017
1.0
1.0
OTHER
RIHS PhD Council member
Co-organizing a 2-day PhD Retreat
College Tour-like interview with Louise Gunning at RIHS PhD Retreat
College Tour-like interview with Ronald Plasterk at RIHS PhD Retreat
2015-2017
2015-2017
2016
2017
2.5
3
0.3
0.3
TOTAL 53.15
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Research data management
The clinical data obtained during my PhD at the Radboud university medical center 
have been captured and stored in REDCap (Research Electronic Data Capture), a 
secure web application for building and managing online surveys and databases, 
which is managed by colleagues at the St George’s University of London. The privacy 
of the participants in this study is warranted by use of encrypted and unique individual 
subject codes. Raw sequencing data described in Chapter 2, 3 and 5 are available 
through the Sequencing Read Archive (SRA) and are accessible via the sample numbers 
described in these chapters. The raw sequencing data used for Chapters 4 and 6 are 
stored on a server belonging to the Center for Molecular and Biomolecular Informatics 
(CMBI) at the Radboud university medical center, and will be made publically available 
through the SRA or the European Nucleotide Archive after publication of the respective 
manuscripts. We are also in the process of archiving these data in the new secured 
Digital Research Environment (DRE) of the Radboud university medical center. The 
scripts used to analyse the data are stored on Evernote, application software designed 
for note taking, organizing, task lists, and archiving. These will also be stored in the 
DRE. Published data generated or analyzed in this thesis are part of published articles 
and their additional files and scripts are available from the associated corresponding 
authors upon reasonable request. 
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List of publications
Ruth MM, van Rossum M, Koeken VACM, Pennings L, Svensson EM, Ruesen C, Bowles 
EC, Wertheim HFL, Hoefsloot W, van Ingen J. Auranofin activity exposes thioredoxin 
reductase as a viable drug target in Mycobacterium abscessus. Antimicrob Agents 
Chemother. 2019 Jul 1.
Zweijpfenning SMH, Schildkraut JA, Coolen JPM, Ruesen C, Koenraad E, Janssen A, 
Ruth MM, de Jong AS, Kuipers S, Aarnoutse RE, Magis-Escurra C, Hoefsloot W, van 
Ingen J. Failure with acquired resistance of an optimised bedaquiline-based treatment 
regimen for pulmonary Mycobacterium avium complex disease. Eur Respir J. 2019 Apr 18.
Ruesen C*, Chaidir L*, Dutilh BE, Ganiem AR, Andryani A, Apriani L, Huynen MA, 
Ruslami R, Hill PC, van Crevel R, Alisjahbana B. Use of whole-genome sequencing to 
predict Mycobacterium tuberculosis drug resistance in Indonesia. J Glob Antimicrob 
Resist. 2019 Mar;16:170-177.
Ruesen C*, Riza AL*, Florescu A, Chaidir L, Editoiu C, Aalders N, Nicolosu D, Grecu V, 
Ioana M, van Crevel R, van Ingen J. Linking minimum inhibitory concentrations to whole 
genome sequence-predicted drug resistance in Mycobacterium tuberculosis strains 
from Romania. Sci Rep. 2018 Jun 26;8(1):9676.
Ruesen C, Chaidir L, van Laarhoven A, Dian S, Ganiem AR, Nebenzahl-Guimaraes H, 
Huynen MA, Alisjahbana B, Dutilh BE, van Crevel R. Large-scale genomic analysis 
shows association between homoplastic genetic variation in Mycobacterium 
tuberculosis genes and meningeal or pulmonary tuberculosis. BMC Genomics. 2018 
Feb 5;19(1):122.
Van Laarhoven A, Dian S, Aguirre-Gamboa R, Avila-Pacheco J, Ricaño-Ponce I, Ruesen 
C, Annisa J, Koeken VACM, Chaidir L, Li Y, Achmad TH, Joosten LAB, Notebaart RA, 
Ruslami R, Netea MG, Verbeek MM, Alisjahbana B, Kumar V, Clish CB, Ganiem AR, van 
Crevel R. Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an 
observational cohort study. Lancet Infect Dis. 2018 May;18(5):526-535.
Van Laarhoven A*, Dian S*, Ruesen C, Hayati E, Damen MSMA, Annisa J, Chaidir L, 
Ruslami R, Achmad TH, Netea MG, Alisjahbana B, Rizal Ganiem A, van Crevel R. Clinical 
Parameters, Routine Inflammatory Markers, and LTA4H Genotype as Predictors of 
Mortality Among 608 Patients With Tuberculous Meningitis in Indonesia. J Infect Dis. 
2017 Apr 1;215(7):1029-1039.
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Te Brake L*, Dian S*, Ganiem AR, Ruesen C, Burger D, Donders R, Ruslami R, van Crevel 
R, Aarnoutse R. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen 
containing rifampicin and moxifloxacin for tuberculous meningitis. Int J Antimicrob 
Agents. 2015 May;45(5):496-503.
Delsing CE, Ruesen C, Boeree MJ, van Damme PA, Kuipers S, van Crevel R. An African 
woman with pulmonary cavities: TB or not TB? Neth J Med. 2014 Oct;72(8):426-8.
Verheyden G, Ruesen C, Gorissen M, Brumby V, Moran R, Burnett M, Ashburn A. 
Postural alignment is altered in people with chronic stroke and related to motor and 
functional performance. J Neurol Phys Ther. 2014 Oct;38(4):239-45.
Ruesen C, van Gageldonk-Lafeber AB, de Vries G, Erkens CG, van Rest J, Korthals Altes 
H, de Neeling H, Kamst M, van Soolingen D. Extent and origin of resistance to anti-
tuberculosis drugs in the Netherlands, 1993 to 2011. Euro Surveill. 2014 Mar 20;19(11).
Ruesen C*, Burhan E*, Ruslami R, Ginanjar A, Mangunnegoro H, Ascobat P, Donders R, 
van Crevel R, Aarnoutse R. Isoniazid, rifampin, and pyrazinamide plasma concentrations 
in relation to treatment response in Indonesian pulmonary tuberculosis patients. 
Antimicrob Agents Chemother. 2013 Aug;57(8):3614-9.
Correspondence
Aarnoutse R, Ruesen C, Burhan E, van Crevel R, Ruslami R. Reply to “strategy to limit 
sampling of antituberculosis drugs instead of determining concentrations at two hours 
postingestion in relation to treatment response”. Antimicrob Agents Chemother. 
2014;58(1):629-30.
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voor het bijwonen van 
de openbare verdediging
van mijn proefschrift
Understanding
tuberculosis drug resistance,
disease phenotype and transmission 
by mycobacterial genome analysis
op dinsdag 5 november 2019
om 10:30 uur in de Aula van
de Radboud Universiteit
Comeniuslaan 2, Nijmegen.
U bent van harte welkom
bij deze plechtigheid
en de aansluitende receptie.
Carolien Ruesen
carolienruesen@gmail.com
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